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Abstract 
Background: Hepatitis C virus infection affects more than 170 million people 
worldwide and is frequently associated with chronic liver disease and 
hepatocellular carcinoma. No protective vaccine is yet available and the current 
standard of care, consisting of pegylated interferon alpha and ribavirin, has 
limited efficacy. Ribavirin is a key component of any effective anti-HCV 
regimen. However, accumulation of ribavirin in the red cell compartment not 
only reduces drug efficacy as a result of diversion to extra-hepatic sites but also 
produces haemolytic anaemia which can lead to dose reduction or 
discontinuation of treatment. Lipid or polymer based nanoparticles can be used 
to deliver therapeutic agents, such as drugs or small interfering RNAs (siRNAs) 
directly to their site of action. We therefore elected to develop new antiviral 
strategies based on the targeted delivery of ribavirin to hepatocytes, coupled 
with the identification of new therapeutic targets. In order to inform the 
rational use of direct intracellular delivery of ribavirin, we enquired whether 
variation in expression of the ribavirin transporter may determine drug uptake 
and permit the identification of individuals who would benefit from these 
alternative approaches to treatment. 
Aims: The aims of this study were to: 
• identify host proteins involved in virus replication 
• demonstrate reduction of viral replication by modulation of host gene 
expression 
• develop and test a nanoparticle based system for the delivery of 
therapeutic molecules, including siRNAs either alone or in combination 
with ribavirin. 
• assess the relationship between ribavirin uptake by primary human 
hepatocytes and expression of ribavirin receptors 
Methods: A subgenomic HCV replicon system was established to study the 
virus-host relationship and identify host proteins supporting viral replication by 
using stealth siRNA. Viral RNAs were in vitro transcribed and transfected into 
Hub7 cells and expression assessed using engineered GFP as a reporter gene. 
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siRNAs were co-transfected with viral RNAs using a nucleofector. Modulation 
of host gene expression was measured by both quantitative RT-PCR and 
protein blotting. Liposomal nanoparticles containing ApoB-l 00 duplexes were 
supplied by Lipoxen. Primary human hepatocytes were isolated by a modified 
two step collagenase perfusion method and cultured on collagen coated plates. 
HPLC and real time PCR conditions were used to measure and correlate drug 
uptake and receptor expression respectively. Equilibrative nucleoside 
transporter (ENTl) gene was analysed by direct sequencing. 
Results: A JFHl (HCV genotype 2a) virus based subgenomic replicon system 
was successfully established. Using this model system, host proteins VAP-A 
and STAT3 were shown to positively regulate virus replication while ACTNl 
had no effect. Liposomes failed to deliver either siRNA targeted at apoB-lOO 
or ribavirin and this was found to be due to structural instability of the delivery 
vehicle. In contrast, fluorescently labelled liposomes were stable and could be 
taken up by human hepatocyte cell lines under optimised conditions. A 
protocol capable of efficient isolation and culture of hepatocytes from human 
donor was validated. Data from primary human hepatocytes show that ENTl 
expression was highly variable in different sets of primary livers and correlated 
strongly with ribavirin uptake. Strikingly, Huh7 cells did not take up ribavirin 
despite expressing wild type ENTl. It was also found that interferon alpha does 
not modulate ENTl expression and therefore ribavirin uptake, suggesting it to 
be a highly unlikely mode of synergism between the two drugs. 
Conclusion: Modulation of host proteins V AP-A and STAT3 inhibited viral 
replication, confirming that host genes can be used as a potential target to 
inhibit viral replication. Liposomes used in this study were, however, found to 
be ineffective vehicles for the delivery of ribavirin or siRNA, as the majority of 
drug leaked before cellular uptake. Polymer based nanoparticles are currently 
being assessed for antiviral drug delivery. Variation in ENTl expression may 
account for differences in response rate in patients receiving anti-HCV therapy. 
Results in the Huh 7 cell line suggest that, while ENTl is necessary, other 
factors are also required to mediate ribavirin uptake. 
3 
Abstracts and scientific communications 
Baby Kanwal Baloch et af: Equilibrative nucleoside transporter 1 (ENTl) 
expression is highly variable in primary human hepatocytes and determines the 
uptake of Ribavirin. Hepatology (Vol 541, Number 4 Supplement October 
2011). Presented at the 62nd Annual meeting of the American Association for 
the study of Liver Diseases, San Francisco, California, 4-8 November, 2011. 
Baby Kanwal Baloch et 01; Ribavirin uptake by Primary human Hepatocytes 
corresponds to Equilibrative Nucleoside Transporter 1 expression. Gut 
(September 2011 Volume 60 Supplement 2). Presented at British Association 
for the Study of the Liver, Annual Meeting, London, United Kingdom, 7-9 
September 2011. 
Baby Kanwal Baloch et af; The use of nanotechnology to deliver intracellular 
therapies for the treatment of Hepatitis C virus infection. Presented at 110th 
Annual meeting of American Society of General Microbiology, San Diego, 
California, 23-27 May 2010. 
B K Baloch et af; Equilibrative nucleoside transporter 1 (ENT 1 ) expression is 
highly variable in primary human hepatocytes and determines the uptake of 
Ribavirin (submitted for publication). 
4 
Acknowledgements 
Firstly, I would like to thank my supervisors Dr Brian Thomson and Prof. 
Mohammad Ilyas for their immense support and guidance over the years. They 
have been inspirational and truly incredible mentors. 
I would like to say special thanks to Dr Liqiong Chen, Dr Rashmi Seth and 
Darryl Jackson who helped me with various laboratory techniques. I also want 
to thank all my colleagues in Pathology Research Group. It has been such a 
great pleasure working with them. I am also thankful to people in FRAME 
group for helping me get the human samples. 
I am truly grateful to the Liaquat University of Medical and Health Sciences, 
Pakistan for providing me funding for this study. 
I am forever indebted to my family especially my parents, Zafarullah Baloch 
and Rashida Baloch, for supporting and loving me and giving me everything 
and more. They have been my greatest motivation and strength for what I am 
today. 
I save my greatest thanks for my husband, Ameer Memon for always believing 
in me and giving me all the emotional support when it was much needed. 
Getting through these tough times would not have been possible without him. 
Lastly, and most importantly, I am thankful to my son, Ahmed for making this 
journey joyful and a memorable one. 
5 
2D 
3D 
Apo 
Ara-C 
C-terminus 
cDNA 
CF 
CLDNl 
bp 
DMSO 
DNA 
dsRNA 
EMCV 
ENTl 
ER 
EVR 
GFP 
HCV 
HCC 
HPA 
HPRT 
HVR 
IC 
IDU 
IFN 
IMPDH 
lRES 
IRF-3 
ISG 
JFHl 
kb 
Abbreviations 
two-dimensional 
three-dimensional 
Apolipoprotein 
Cytarabine 
carboxy terminus 
complementary deoxyribonucleic acid 
carboxyfluorescein 
Claudin-l 
base pair 
dimethy sulfoxide 
deoxyribonucleic acid 
double stranded RNA 
encephalomyocarditis virus 
Equilibrative nucleoside transporter 
endoplasmic reticulum 
Early virological response 
green fluorescent protein 
hepatitis C virus 
hepatocellular carcinoma 
Health Protection Agency 
Hypoxanthine-guanine phosphoribosyltransferase 
Hypervariable region 
internal control 
intravenous drug use 
Interferon 
inosine monophopshate dehydrogenase 
internal ribosome entry site 
interferon regulatory factor 3 
Interferon stimulated gene 
Japanese fulminant hepatitis clone 1 
kiIobase 
6 
kDa 
L 
LDL 
Luc 
ml 
mRNA 
miRNA 
J,ll 
J,lg 
J,lM 
NF-KB 
NP 
N-terminus 
nm 
nM 
NS 
ORF 
PBS 
PC 
peR 
PEG 
pg 
rpm 
RBI 
RdRp 
RIGt 
RNA 
kilo dalton 
litre 
low density lipoprotein 
luciferase 
millilitre 
messenger ribonucleic acid 
microRNA 
micro litre 
microgram 
micromolar 
nuclear factor KB 
nanoparticle 
amino terminus 
nanometre 
nanomolar 
non-structural 
open reading framework 
phosphate buffer saline 
phosphatidyl choline 
polymerase chain reaction 
polyethylene glycol 
plcogram 
revolutions per minutes 
Rhodamine B isothiocyanate 
RNA dependent RNA polymerase 
retinoid-inducible gene t 
ribonucleic acid 
RSD relative standard deviation 
RT reverse trascriptase 
RV ribavirin 
RVR Rapid virological response 
SD standard deviation 
SDS-PAGE sodium dodecyl sulfate- polyacrylamide gel electrophoresis 
7 
SEAP Secreted Alkaline Phosphatase 
SGR subgenomic replicon 
si RNA small interfering RNA 
SVR Sustained virological response 
TLR-3 toll-like receptor 3 
UK United Kingdom 
UTR untranslated region 
UV ultraviolet 
VLDL Very low density lipoprotein 
WHO World Health Organisation 
8 
Table of contents 
Abstract .............................................................................................................. 2 
Abstracts and scientific communications ......................................................... " 
Acknowledgements ............................................................................................. 5 
Abbreviations ..................................................................................................... 6 
Table of contents ................................................................................................ 9 
List of Figures .................................................................................................. 16 
List of Tahles .................................................................................................... 19 
1 General introduction ............................................................................... 21 
1.1 Hepatitis C virus infection ............................................................. 21 
1.1.1 Natural history of hepatitis C virus infection ............................... 21 
1.1.1.1 Epidemiology of hepatitis C virus infection ......................... 21 
1.1.1.2 Course of hepatitis C virus induced liver disease ................. 25 
1.1.1.3 Virus transmission to host and target cell ............................. 28 
1.1.2 Molecular biology of HCV ........................................................... 29 
1.1.2.1 Classification of virus ........................................................... 29 
1.1.2.2 HCV genome ........................................................................ 32 
1.1.2.3 Structure and function ofHCV proteins ............................... 33 
1.1.3 Lifecycle of HCV ......................................................................... 40 
1.1.3.1 HCV receptors ...................................................................... 40 
1.1.3.2 Virus entry, replication and release ...................................... 42 
1.1.3.3 HCV particle assembly and secretion ................................... 45 
1.1.3.4 Model systems to study H CV ............................................... 47 
9 
1.1.4 Host cell response to viral infection ............................................. 50 
1.1.4.1 Pathophysiology of chronic HCV infection ......................... 50 
1.1.4.2 Immune response to HCV infection ..................................... 52 
1.1.4.3 Factors responsible for viral evasion or persistence in host 
cell 54 
1.2 Clinical aspects of H CV infection .................................................. 55 
1.2.1 Clinical features, diagnosis and screening ofHCV infection ....... 55 
1.2.2 Current treatment regimens .......................................................... 57 
1.2.2.1 Pegylated interferon .............................................................. 59 
1.2.2.2 Ribavirin ............................................................................... 61 
1.2.2.3 Side effects of current therapy .............................................. 63 
1.2.3 Anti-HCV drugs in clinical development ..................................... 65 
1.2.3.1 Inhibitors of viral entry ......................................................... 66 
1.2.3.2 Inhibitors of viral translation ................................................ 66 
1.2.3.3 Inhibitors of post-translational polyprotein processing ........ 67 
1.2.3.4 Inhibitors of replication machinery ...................................... 68 
1.2.3.5 Other inhibitors ..................................................................... 69 
1.3 Current status of anti-HCV therapies and strategies proposed to 
improve response rate ................................................................................ 71 
1.4 Research objective .......................................................................... 74 
2 Materials and Methods ............................................................................ 78 
2.1 Cell culture ...................................................................................... 78 
2.2 Preparation of JFHl subgenomic replicon: ................................. 78 
2.3 Transfection of siRNA, plasmid DNA and viral RNA: ••••••••••••••• 80 
10 
2.4 Total RNA (ribonucleic acid) extraction ...................................... 81 
2.5 Reverse transcriptase polymerase chain reaction (RT -PCR) ....• 82 
2.6 Quantitative real time PCR (Q-PCR) ........................................... 82 
2.7 Flow cytometry and GFP expression: ........................................... 84 
2.8 Protein extraction and quantification: .••••••••••••••••••••••••••••...•.•.•••••• 84 
2.9 SDS-PAGE gel and Western blotting: .......................................... 84 
2.10 Isolation and culture of primary human hepatocytes .••••..•••.•••..• 85 
2.11 Ribavirin and interferon alpha treatment .•.••••••••••••.•.•.•••••.•••...••.• 87 
2.12 High performance liquid chromatography (HPLC) ••••..••.•••...•••• 88 
2.12.1 Sample preparation (Cell lysis and enzyme diges tion) ............ 88 
2.12.2 PBA column extraction ............................................................. 88 
2.12.3 Chromatographic conditions: ................................................... 89 
2.13 Analysis of Huh7 ENT1 gene sequence ......................................... 90 
2.13.1 
2.13.2 
2.13.3 
2.13.4 
PCR amplification of ENT 1 coding sequence .......................... 90 
Agarose gel electrophoresis ...................................................... 90 
Cloning of ENT 1 into pCR@2.l-TOPO@ TA cloning vector ... 91 
Analysis of transformants ......................................................... 92 
3 Effect 0/ host gene silencing on replication 0/ HCV sUhgenomic 
rep/icon ............................................................................................................. 94 
3.1 Introduction .................................................................................... 94 
3.1.1 Gene silencing by small interfering RNAs (siRNAs) ................... 94 
3.1.1.1 Mechanism of RNA interference (RNAi) ............................. 94 
3.1.1.2 Advantages and limitations of siRNA based gene silencing 96 
11 
3.1.1.3 Delivery systems for siRNA ................................................. 97 
3.1.2 HCV replicons .............................................................................. 98 
3.1.3 Nucleofector technology ............................................................. 101 
3.1.4 RNAi based therapies for human diseases .................................. 101 
3.1.5 siRNA based therapies for HCV ................................................. 102 
3.1.6 Role of host protein in HCV replication ..................................... 103 
3.1.6.1 Vesicle-associated membrane protein - associated protein A 
(VAP-A) 105 
3.1.6.2 Signal transducer and activator of transcription 3 (STAT-3) 
106 
3.1.6.3 Alphaactinin 1 (ACTN1) ................................................... 107 
3.2 Aims: .............................................................................................. 109 
3.3 Results: ........................................................................................... 110 
3.3.1 Preparation of re pI icon RNA ...................................................... 110 
3.3.2 Nucleofection ofreplicon RNA .................................................. 112 
3.3.3 Validation of siRNA duplexes by Lipofectamine2000 .............. 116 
3.3.4 Optimal nucleofection conditions for duplexes .......................... 120 
3.3.5 Co-transfection of duplexes with the JFHl replicon .................. 122 
3.3.5.1 Analysis ofGFP expression by flow cytometry ................. 122 
3.3.5.2 
3.3.5.3 
3.3.5.4 
Effect ofVAP-A knock down on viral replication ............. 125 
Effect ofSTAT-3 knock down on viral replication ............ 128 
Effect of ACTN 1 knock down on viral replication ............ 130 
3.4 Discussion: ..................................................................................... 132 
4 Liposome for delivery of therapeutic molecules ................................... 142 
12 
4.1 Introduction .................................................................................. 142 
4.1.1 Principle of targeted delivery for anti-HCV therapy .................. 142 
4.1.2 Liposomes as vehicles for targeted drug delivery ...................... 143 
4.1.3 Role of Apolipoprotein B-I00 in HCV replication .................... 147 
4.2 Aims: .............................................................................................. 149 
4.3 Results: ........................................................................................... 150 
4.3.1 Comparisons of ApoB-100 knock down by using naked siRNA vs. 
liposomally entrapped siRNAs ............................................................... 150 
4.3 .1.1 Validation of gene silencing ability of anti"-ApoB 100 siRNA 
150 
4.3.1.2 ApoB-100 knock down by liposomally entrapped siRNAs 155 
4.3.2 Cellular uptake ofliposomes (Fl and F2) containing a GFP 
expression vector .................................................................................... 157 
4.3.3 Analysis ofliposomal uptake by labelled vehicles ..................... 159 
4.3.3.1 Cellular uptake of positive control nanoparticles and carboxy-
fluorescence labelled liposomes ......................................................... 159 
4.3.3.2 Altering physical characteristics ofliposomal formulations to 
improve cellular uptake ...................................................................... 161 
4.3.3.3 Altering serum conditions to enhance liposomal uptake .... 164 
4.3.4 Efficiency ofliposome as a drug delivery vehicle ...................... 166 
4.3.4.1 ApoB-100 gene silencing by liposomal siRNAs ................ 166 
4.3.4.2 Comparison of free and liposomal ribavirin uptake ........... 168 
4.4 Discussion ...................................................................................... 169 
13 
5 Correlation of ribavirin uptake and ENT1 expression by primary human 
hepatocytes ..................................................................................................... 179 
5.1 Introduction .................................................................................. 179 
5.1.1 Treatment for chronic hepatitis C virus infection (HCV) ........... 179 
5.1.1.1 Combination therapy with ribavirin and interferon ............ 179 
5.1.1.2 Limitations of current regimen ........................................... 181 
5.1.1.3 Assay for ribavirin quantification ....................................... 182 
5.1.2 Nucleoside transporters .............................................................. 184 
5.1.2.1 Introduction and classification of nucleoside transporters .184 
5.1.2.2 Functional importance and regulation of human equilibrative 
nucleoside transporters 1 (hENT 1) ..................................................... 185 
5.1.2.3 Ribavirin uptake is mainly mediated by equilibrative 
nucleoside transporters 1 (ENT 1 ) ....................................................... 186 
5.1.3 In vitro model based on primary human hepatocytes ................. 187 
5.1.3.1 
5.1.3.2 
Indication for use of primary human hepatocytes .............. 187 
Culture systems ................................................................... 188 
5.2 Aims: .............................................................................................. 190 
5.3 Results ............................................................................................ 191 
5.3.1 Experimental design and data analysis ....................................... 191 
5.3.2 Human hepatocytes culture ......................................................... 191 
5.3.3 Optimal chromatographic conditions for ribavirin ..................... 194 
5.3.4 Time course for ribavirin uptake and ENTl expression by primary 
human hepatocytes (H ver 1-4) ................................................................ 199 
5.3.5 Correlation ofribavirin uptake and ENTl expression in human 
hepatocytes (Livers 1-6) and Huh7 at 24 hours ...................................... 204 
14 
5.3.6 Analysis of Huh7 ENTl (SLC29Al) gene sequence ................. 206 
5.3.7 Effect of interferon-alpha on ribavirin uptake and ENTl 
Expression ............................................................................................... 208 
5.3.8 Effect of culture conditions on ribavirin uptake and ENTl 
expression ............................................................................................... 208 
5.4 Discussion ...................................................................................... 211 
6 Final discussion ..................................................................................... 217 
6.1 Project summary ........................................................................... 217 
6.2 Cardinal findings and future implications of the present study: 
219 
6.2.1 Role of host protein in viral replication ...................................... 219 
6.2.2 Liposomal nanoparticles as delivery vehicles ............................ 220 
6.2.3 Equilibrative nucleoside transporter 1 expression regulates 
ribavirin uptake by primary human hepatocytes .................................... 222 
6.3 Future work ................................................................................... 224 
6.4 Conclusion ..................................................................................... 225 
7 References .............................................................................................. 217 
8 Appendix ................................................................................................ 257 
15 
List of Figures 
Figure 1.1 Global prevalence of HCV infection ............................................... 23 
Figure 1.2 Laboratory reports of HCVinfectionfrom Englandfrom 1992 to 
2010 .................................................................................. ................................ 24 
Figure 1.3 Natural course of acute HCVinfection .......................................... 27 
Figure 1.4 Evolutionary tree illustrating major HCV genotypes ..................... 31 
Figure 1.5 Structure of HCV genome and viral polyprotein ............................ 35 
Figure 1.6 Life cycle ofHCV ............................................................................ 43 
Figure 1.7 HCV replication cycle ..................................................................... 46 
Figure 1.8 Treatment guidelines for chronic HCV infection ............................ 58 
Figure 2. 1 Plasmid map for subgenomic replicon ........................................... 79 
Figure 3.1 Mechanism of RNA interference by siRNAs ................................... 95 
Figure 3.2 Schematic diagram of the structure of JFH1 (genotype 2a) HCV 
subgenomic replicons ..................................................................................... 100 
Figure 3.3 Example images of JFH1 plasmid DNA or RNA as analysed by 
ethidium bromide gel electrophoresis . ........................................................... III 
Figure 3.4 Work stages for a typical transfection procedure ......................... 113 
Figure 3.5 Optimisation ofnucleofection procedure ..................................... 115 
Figure 3.6 Real time PCRplotsfor STAT3, VAP-A, ACTNl and HPRTprimer 
pairs . ............................................................................................................... 117 
Figure 3.7 Validation of gene knockdown by siRNA (48 hour) ..................... 119 
Figure 3.8 Dose response for gene silencing by nucleofection (72 hours) .... 121 
Figure 3.9 Experimental controlsfor RNAi by nucleofection ........................ 124 
Figure 3.10 Effect of VAP-A knock down on JFH 1 replication at 72 hour .... 126 
Figure 3.11 Effect ofVAP-A knock down onJFHl replication at 48 hour .... 127 
16 
Figure 3.12 Effect ofSTAT-3 knock down on JFH1 replication .................... 129 
Figure 3.13 Effects of A CTN 1 knock down on viral replication .................... 131 
Figure 4.1 Liposomes for drug delivery ...... ................................................... 145 
Figure 4.2 Real time PCRplotsfor ApoB-100 and HPRTprimer ................. 151 
Figure 4.3 Analyses of apoB-1 00 knock down by siRNA delivered by 
Lipofectamine2000 . ........................................................................................ 153 
Figure 4.4 Western blot for ApoB-100 knock down by naked duplexes ......... 154 
Figure 4.5 Comparison of apoB-1 00 knock down by naked vs. liposomally 
entrapped siRNA ............................................................................................. 156 
Figure 4.6 Transfection efficiency ofGFP labelled liposome ........................ 158 
Figure 4.7 Cellular uptake of carboxy-fluorescence labelled liposomes ....... 160 
Figure 4.8 Cellular uptake of DPE and NBD labelled liposomes with variable 
physical characteristics .................................................................................. 163 
Figure 4.9 Influence of serum conditions on liposomal uptake by Huh7 cells 
........................................................................................................................ 165 
Figure 4.10 Analysis of siRNA delivery ability of low sucrose liposomes ..... 167 
Figure 4.11 Possible mechanism ofliposomalfailure ................................... 171 
Figure 5.1 Possible mode of ribavirin anti-HCVactions ............................... 180 
Figure 5.2 Flow schemefor HPLC. ................................................................ 183 
Figure 5.3 Schematic illustration of various liver cells arranged in vivo ..... 189 
Figure 5.4 Human hepatocytes on day 3 of in vitro culture ........................... 193 
Figure 5.5 Calibration curve for ribavirin in cell fraction ............................ 197 
Figure 5.6 Typical chromatogram for ribavirin .. ........................................... 198 
Figure 5.7 Real time PCR plots for ENT1 and HPRT primer pairs ............... 201 
17 
Figure 5.8 Analysis of real time PCR amplified ENTl by agarose gel 
electrophoresis ................................................................................................ 202 
Figure 5.9 Time course for ribavirin uptake and ENT1 expression ............... 203 
Figure 5.10 Correlation ofribavirin uptake and ENT1 expression ............... 205 
Figure 5.11 Agarose gel analysis of peR product.. .. ..................................... 207 
Figure 5.12 Effect of interferon alpha on ribavirin uptake and ENT1 
expression ........................................... ............................................................ 209 
Figure 5.13 Effect of culture condition on transporter expression .... ............ 210 
Figure 6.1 Project overview with principal findings ...................................... 218 
18 
List of Tables 
Table 1.1 Summary of anti-HCV drugs in clinical development ...................... 70 
Table 2.1 Stealth siRNA sequences used in the present study .......................... 81 
Table 2.2 Primers usedfor real time PCR ....................................................... 83 
Table 2.3 Human liver donor information and cell viability ............................ 87 
Table 4.1 Physical properties of /iposomal formulations used in the current 
study ................................................................................................................ 162 
Table 5.1 HP LC assay reproducibility and precision .................................... 196 
19 
Chapter One 
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1 General introduction 
1. 1 Hepatitis C virus infection 
1.1.1 Natural history of hepatitis C virus infection 
Hepatitis C virus (HCV) was first identified in 1989 as a major cause of 
parenterally transmitted non-A, non-B hepatitis (Choo et aI., 1989). Since then, 
it has gained considerable attention because of the high morbidity and 
significant mortality associated with chronic infection. HCV infection 
frequently leads to chronic liver disease, cirrhosis and hepato-cellular 
carcinoma and is now an important cause for liver transplantation worldwide 
(Forman et aI., 2002, Hoofnagle, 2002). 
1.1.1.1 Epidemiology of hepatitis C virus infection 
Estimates show that approximately 170 million people (equalling 3% of 
world's population) are infected with HCV (Hutin et aI., 2004, Shepard et aI., 
2005, Lavanchy, 2009). The figures vary among different regions (Figure 1.1), 
with highest prevalence found in the African and the Eastern Mediterranean 
regions (Lavanchy, 2009). Recently, a systemic review assessing the 
prevalence and risk factors for HCV in different regions of Asia, Australia and 
Egypt (an area containing 40% of the world population) estimated that 49.3 to 
64.0 million adults are HCV positive (Sievert et aI., 2011). Egypt had the 
highest prevalence rate (14%), followed by Pakistan (4.7%) and Taiwan (4.4%) 
whereas it was lowest, yet still significant at 1-1.9 % for countries such as 
China, Japan, India, Saudi Arabia and Syria. In the United States, HCV 
prevalence is estimated to be about 2%, affecting approximately 5.2 million 
21 
people (Chak et aI., 2011). These figures reflect the magnitude of the health 
care burden associated with HCV infection and great need to have effective 
measures to reduce the pool of infected individuals and minimise HCV related 
disease. 
In England, no population based survey of HCV infection has been conducted 
and the prevalence is estimated at around 0.76% of the population (Sweeting et 
aI., 2007). A recent report published by Health Protection Agency (Hpa) shows 
a progressive rise in reported HCV cases between 1992 and 2010 and an 
estimated 0.2 million people chronically infected with HCV in the UK (Figure 
1.2). More than two thirds of these patients (69%) were males and almost half 
(49%) were aged between 25 and 39 years. Of all the reported risk factors, 
intravenous drug use was by far the most common and accounted for the 
acquisition of infection in 89% of all known cases (Hpa, 2011). 
22 
Figure 1.1 Global prevalence of HeV infection 
(Source: Centre of Disease Control) 
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Figure 1.2 Laboratory reports of HeV infection from England from 1992 
to 2010 
The graph hows con istent ri e in newly reported ca es of Hey infection in 
England 0 er a period of - 20 years. Source: the Health Protection agency (Hpa, 
2011 ). 
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1.1.1.2 Course of hepatitis C virus induced liver disease 
Chronic HCV infection is a major cause of liver disease worldwide and a 
potentially huge healthcare burden. No protective vaccine is available as yet. 
Individuals who acquire an acute infection usually remain asymptomatic but a 
majority (50-80%) progresses to chronicity (Marcellin, 1999). The mechanism 
of spontaneous resolution in one fifth of the infected individuals remains 
unknown but is now recognised to have strong host genetic basis. Among those 
with persistent infections, disease severity varies from mild to severe but 
generally progresses over time. A significant proportion will develop fibrotic 
liver disease (cirrhosis) over a period of 20 years with consequent 
decompensation and the development of end stage liver disease (Figure 1.3). 
About one fourth will die as a result of the complications of cirrhosis or 
hepatocellular carcinoma (Pawlotsky, 2004, Qureshi, 2007). Globally, HCV 
infection is responsible for 27% and 25% of cases of cirrhosis and hepato-
cellular carcinoma respectively (Perz et aI., 2006). 
Several factors have been implicated in determining disease outcomes. Female 
sex, perhaps due to protective effect of oestrogen hormone, has been associated 
with higher rate of spontaneous viral clearance i.e. 40% in female subjects vs. 
19% in male subjects (Micallef et aI., 2006). Similarly, a very young age at the 
time of acute infection (Zhang et aI., 2006) and HBV co-infection have also 
been associated with higher rate of spontaneous resolution. The latter may be 
due either to reciprocal inhibition of viral replication in patients infected with 
these two viruses or a more vigorous immune response (Zhang et aI., 2006, 
Shores et aI., 2008). In contrast to HBV, co-infection with human immuno-
25 
deficiency virus (HIV) reduces rates of spontaneous clearance and accelerates 
the development of cirrhosis and its complication (Sulkowski et aI., 2000). This 
is likely to be the result of the underlying immune imbalance seen in HIV 
infected individuals altering response to HeV antigens (Sulkowski, 2003). 
Interestingly, among HIV infected patients, those contracting Hev via sexual 
transmission have greater chance of clearing infection than those who acquire 
it via the intravenous route (21.9 % vs. 11.6% respectively) (Shores et aI., 
2008). 
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Figure 1.3 Natural course of acute HeV infection 
HCY infects liver cells (hepatocytes) and persists in more than half of those 
acutely infected. With the development of chronic hepatitis, virus induced 
changes lead to fibrotic disea e (cirrhosis) in at least one fifth of these livers 
over a period of 20-30 years. A significant number of these patients eventuaJIy 
die due to liver cancer or complications of end stage li ver disea e (HCY = 
hepatitis C virus, H C = hepatocellular carcinoma) 
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1.1.1.3 Virus transmission to host and target cell 
The infectious viral particles circulate in the blood stream of infected 
individuals so transmission is mainly through contact with blood or products 
contaminated with it such as blood transfusion, IV drug abuse or use of non-
sterile equipment during medical and surgical procedures (Alter, 1997, 2002). 
Transfusion mediated transmission has been dramatically reduced by 
implementation of blood screening programmes (Donahue et aI., 1992) but use 
of non-sterile medical equipment and unscreened blood remain an important 
risk factor in many parts of the world. In contrast, intravenous drug abuse has 
emerged as the major risk factor in industrialised countries (Sievert et aI., 2011, 
Sweeting et aI., 2007). Transmission to babies from infected mothers (vertical 
transmission), transplant recipients from infected donors and sexual 
transmission are some other but less frequent modes of virus transmission 
(Albeldawi et aI., 2010). 
Within the infected host, the virus circulates in various forms. It can be found 
in association with plasma lipoproteins like low density lipoproteins (LDL) and 
very low density lipoproteins (VLDL), immunoglobulin or as free virion. The 
first two forms are considered to represent the infectious fraction (Andre et aI., 
2002) (Andre et aI., 2005) and the majority of infectious viral particles are 
found in association with apolipoproteins Band E (Dwen et aI., 2009, Sheridan 
et aI., 2009). 
For HCV, humans are the only natural hosts and liver is the principal organ 
involved in infection. Although the virus is primarily hepatotropic, evidence 
exists for presence of virus or its negative strand intermediates (as occurs 
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during viral replication) in peripheral blood mononuclear cells (Okuda et aI., 
1999), including B lymphocytes (Bare et aI., 2005), T lymphocytes 
(Macparland et aI., 2006), monocytes (Laskus et aI., 2000) and dendritic cells 
(Goutagny et aI., 2003). In vivo studies have suggested a biological 
relationship between HCV infection and cognitive impairments seen in patients 
with HCV infection (Forton et aI., 2005). This has been also shown in vitro 
where the ability of the virus to infect and propagate in certain neuronal cell 
lines has indicated neurotropic involvement of HCV which may account for 
neuropschiatric features like fatigue, weakness, inability to concentrate etc seen 
in a proportion of patients infected with HCV (Fletcher et aI., 2010). 
1.1.2 Molecular biology of HCV 
1.1.2.1 Classification of virus 
HCV belongs to the Flaviviridae family which comprises three genera namely 
Flavivirus, Pestivirus and Hepacivirus (Robertson et aI., 1998). Yellow fever 
virus, dengue fever virus etc are members of the genus Flavivirus while bovine 
viral diarrhea virus, classical swine fever virus etc belong to the Pestivirus 
genus (Pawlotsky, 2006). HCV is a prototype member of genus Hepacivirus as 
a consequence of its tropism for the liver and is structurally closer to the 
Flavivirus than the Pestiviruses genus (Choo et aI., 1991). Flaviruses infect a 
broad range of vertebrates with humans being dead end host (i.e. does not 
participate in virus transmission) while no known Pestivirus infects humans. 
HCV naturally infects only humans but virus can be propagated in a 
Chimpanzee model. 
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Hev comprises at least six major genotypes (1, 2, 3, 4, 5, and 6) and several 
subtypes (a, b, c and d .... ) differing from each other by approximately 30 and 
15-20 percent in their nucleotide sequence respectively (Simmonds et aI., 
2005). Greatest sequence variation is seen in the region designated the 
hypervariable region (HVR-l). The high viral replication rate resulting in 
production of around 1012 virions per day, coupled with the inability of viral 
RdRp to proof read its transcript, accounts for the genetic variability seen 
among HeV isolates and drives formation of quasi-species within an infected 
individual (Holland et aI., 1992). Figure 1.4 illustrates a phylogenetic analysis 
of various Hev genotypes and their epidemiological association (Simmonds et 
aI., 2005). 
Hev genotypes vary in their worldwide distribution and therapeutic 
responsiveness, with some evidence for differences in transmission and disease 
outcome (Gottwein et aI., 2009). With respect to differences in viral 
distribution between different regions, America, Europe and Japan harbour 
genotype la, Ib and 3b followed by 2a and 2b whereas genotype 4 and 5 are 
mainly found in the Middle East and Africa and genotype 6 is the predominant 
type in Southeast Asia (Gottwein et aI., 2009). In Egypt, genotype 4 accounts 
for 90% of all HeV cases as a likely consequence of mass parenteral anti-
schistosomal therapy programmes (Antaki et aI., 2010). In contrast, genotype 1, 
2 and 3 in Europe are uniformly distributed and are thought to have been 
transmitted mainly by intravenous drug abuse. In terms of disease outcome, 
liver steatosis is common and virus specific in genotype 3 infection (Rubbia-
Brandt et aI., 2000). Response rates to treatment with pegylated interferon and 
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ribavirin is much higher (- 70%) for genotype 2 and 3 than for genotype 
(40%) and intermediate for types 4-6 (Manns et aI. , 2006). 
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Figure 1.4 Evolutionary tree illustrating major HCV genotypes 
Major Hey genotypes and their geographical association are shown. Also 
given are the avai lable complete open-reading frame sequences for each HeV 
genotype (Simmonds et al. , 2005) 
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1.1.2.2 HCV genome 
The HCV genome is a 9.6 kilobases (kb) long positive-sense single-stranded 
RNA molecule which serves as template for both replication and translation. It 
consists of a single open reading frame (ORF) flanked on either side by a 341 
and 230 nucleotides long 5' and 3'-UTR respectively (Penin et aI., 2004). The 
ORF encodes for synthesis of - 3000 amino acid long single polyprotein which 
gives rise to HCV structural proteins from N-terminus and non- structural (NS) 
proteins from its C-terminus (Figure 1.5). 
Both UTRs play an important role in protein translation and virus replication. 
The 5'UTR is composed of four highly structured domains (I-IV) of which I 
and II are essential for viral replication (Friebe et aI., 2001). Domains I1, III 
and IV together with the first 12 to 30 nucleotides of the ORF constitute an 
internal ribosome entry site (Madeira et al.) that plays a role in cap-
independent polyprotein translation, a key step in translation initiation 
(Pawlotsky, 2006). The 3' UTR consists of a 40 nucleotide long variable 
region, a poly UIVC tract of 80 nucleotides and a 98 nucleotide long X-tail 
which is highly conserved (Kolykhalov et aI., 1996). There are a number of 
studies showing that the X tail and part of the poly UIVC tract of at least 25 
nucleotides are mandatory for viral replication in in vitro culture models and 
productive infection in vivo. You et al identified a eis-acting replication 
element (CRE) in the 3' end ofNS5B designated as 5BSL3.2 (You et aI., 2004). 
Interaction of the middle stem loop (SL2) of the X tail and 5BSL3.2 seems to 
be indispensable for HCV RNA replication (Friebe et aI., 2005). 
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The lRES facilitates cap-independent translation of viral RNA through binding 
to the 40S ribosome. This complex recruits eukaryotic initiation factor (eIF)-3 
and results in formation of a 48S complex. eIF-3 is later released during joining 
with the 60S ribosomal subunit resulting in production of a translationally 
competent 80S complex which then proceeds with viral protein translation 
(Qureshi, 2007). Translation results into production of a 3000 amino acids 
polyprotein which is then modified by both viral and host enzymes to yield 
structural proteins including core protein (C) and envelope glycoproteins El 
and E2, the p7 ion channel and non- structural (NS) proteins (NS2, NS3, NS4A 
and 4B, NS5A and 5B). Host signal peptidases mediate processing of the 
structural proteins and at the p7INS2 junction, while two virally encoded 
proteases (NS2 and NS3/4A) are essential for maturation of non-structural 
proteins (Penin et aI., 2004). 
1.1.2.3 Structure and function of HCV proteins 
Post translational processing of the HeV polyprotein gives rise to structural 
proteins including core, El and E2 as well as non-structural proteins including 
NS2, NS3, NS4A, NS4B, NS5A and NS5B as illustrated in Figure 1.5. 
CORE PROTEIN: Along with the genomic RNA, the 191 amino acids long or 
21 kDa core protein forms the viral nucleocapsid (Yasui et aI., 1998) and has a 
key role in both viral replication and pathogenesis. It has a highly basic N-
terminal hydrophilic domain (D I) which is thought to be involved in RNA 
binding and nuclear localisation (Suzuki et aI., 2005). The C-terminal D2 
domain is hydrophobic and its association with lipid droplets may lead to the 
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development of steatotic liver disease seen in HeV infection (Asselah et aI., 
2006). Wang et al showed that the core protein is an inhibitor of RNA 
interference suggesting that this could be a possible mechanism of viral escape 
(Wang et aI., 2006). The core protein has also been implicated in modulating 
cellular processes involved in the development of hepatocellular carcinoma 
(Moriya et aI., 1998). Using an HCV cell culture system, a recent study by 
Alsaleh et al identified four basic amino acids at the N-terminal of the core 
protein required for production of infectious viral particles (Alsaleh et aI., 
2010). The F protein or alternate reading frame protein (ARFP) is produced as 
a result of a ribosomal frame shift in the core protein N-terminus. Its role in 
the virallifecycle is unclear but is thought to facilitate persistence of HCV and 
associated induced liver pathogenesis (Baril and Brakier-Gingras, 2005, 
Fiorncci et aI., 2007). 
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Figure 1.5 Structure of HCV genome and viral polyprotein 
The Hey genome is a ingle tranded RNA molecule having an ORF flanked 
on either side by 3 - and 5' -UTR. The ORF encodes for viral structural proteins 
(core El and E2) a well as non-structural protein (p7, NS2-5B). After being 
translated, the Hey polyprotein is cleaved by both host and virus encoded 
enzyme into mature structural and non-structural proteins which perform their 
specific role in virus replication and pathogenesis inside host cells. (ORF = 
open reading fram work, UTR = untranslated region, NS = non-structural , El 
and E2 = envelope proteins). 
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ENVELOPE PROTEINS (El & E2): The two glycoproteins El and E2 are the 
key components of the viral envelope and also play a key role in viral 
attachment and entry into the host cell (Dubuisson et aI., 2002). In general, El 
is fusogenic while E2 serves as a receptor binding subunit. E2 protein has a 
binding site for CD81, a tetraspanin expressed on hepatocytes and B-
lymphocytes and is essential for virus entry (Pileri et aI., 1998). A study by 
Wakita et of demonstrating efficiency of JFHl replication and production of 
infectious viral particles in vitro showed that envelope proteins are required for 
production of infectious viral particles (Wakita et aI., 2005). An in frame 
deletion of envelope proteins coding sequence in HCV clones impaired 
production of infectious viral particles (Wakita et aI., 2005). 
The hypervariable region 1 (HVR-l) ofHCV is near the amino terminus ofE2 
(Kato, 2001) and contains amino acid sequences which can differ up to 80% 
between HCV genotypes and subtypes. This variability may function to 
promote viral evasion of immune response and support persistence (Boulestin 
et aI., 2002). In spite of sequence variability, the physico-chemical properties 
of the residues at each position and overall conformation of the HVR-l region 
are highly conserved among HCV genotypes, underlining the importance of the 
HVR-l region in the viral life cycle (Penin et aI., 2001). This is further 
supported in a chimpanzee model in which Farci and colleagues showed that 
neutralising antibodies can be developed against the first 27 amino acids of 
HVR-l (Farci et aI., 1996). 
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P7: This is a small, 63 amino acid long polypeptide located between E2 and 
NS2. It belongs to the viroporin family and has putative cation channel activity 
(Griffin et aI., 2003, Pavlovic et aI., 2003). Intrahepatic transfection studies in 
Chimpanzees have highlighted its role in viral maturation and release (Sakai et 
aI., 2003). This was confirmed by a later study using a HCV infectious system 
which showed that p7 is required for efficient assembly and release of 
infectious viral particles (Steinmann et al., 2007). 
NON STRUCTURAL PROTEINS (NS): Although NS proteins are not 
involved in virus particle assembly, they are required for polyprotein 
processing and virus replication. NS proteins are cleaved by two viral enzymes, 
a serine and a cysteine protease (Qureshi, 2007, Sharma, 2010). NS2 encodes a 
cysteine protease, also known as auto protease and participates in cleavage at 
the NS2/3 junction (Hijikata et aI., 1993). NS3 is a multi functional protein. At 
its N terminal 1I3rd, the sequence encodes for a viral serine protease which 
along with its co-factor NS4A, mediates cleavage of the NS3/4A, NS4A1B, 
NS4B/5A and NS5AIB junctions (Figure 1.5). Due to its critical role in viral 
protein processing, the NS3 protease is a prime target for development of 
antivirals (Lin, 2010). The remaining C-terminal 2/3rd part of NS3 has 
Helicase-NTPase activity thought to be involved in RNA binding, unwinding 
of RNA, reduction of RNA secondary structures and NTP hydrolysis 
(Kolykbalov et aI., 2000, Tai et aI., 1996, Tomei et aI., 1993). The RNA 
unwinding activity of NS3 is modulated through its interaction with NS5B. 
Through inhibition of RIG-l signalling pathways required for induction of the 
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interferon pathway (Meylan et aI., 2005), NS3-4A also plays a role In 
antagonising the host immune response to viral infection (Li et aI., 2005). 
NS4A acts as a co-factor to the NS3 serine protease (Tomei et aI., 1993) and is 
responsible for membrane association and stabilisation of the NS3/4A complex 
(Wolk et aI., 2000). By interacting with other HCV proteins like NS4B/5A, 
NS4A facilitates formation of the viral replication complex. It also modulates 
viral replication by altering the phosphorylation status of NS5A (Asabe et aI., 
1997, Kaneko et aI., 1994). NS4A has also been shown to localise in 
mitochondria and mediate apoptotic cell damage, thus contributing to viral 
cyto-pathogenesis (Nomura-Takigawa et aI., 2006). 
NS4B has an essential role in viral replication by promoting the assembly of 
membranous structures, which then along with other non-structural proteins, 
serves as sites for RNA replication (Egger et aI., 2002). It has also been 
implicated in HCV induced carcinogenesis (Park et aI., 2000b) and modulation 
of cellular processes involved in virus pathogenesis (Yi Zheng, 2005). 
NS5A belongs to a group of phosphoproteins having a phosphorylated (56kDa) 
and hyper- (58kDa) phosphorylated form and an RNA binding activity (Huang 
et aI., 2005). Its phosphorylation status has been shown to inversely affect its 
function (Appel et aI., 2006, Neddermann et aI., 2004). Subgenomic replicons 
have adaptive mutations (predominantly in NS5A) which enable high 
replication efficiency in the Huh7 cell line (Blight et aI., 2003). Studies using 
an HCV genotype Ib clone subgenomic replicon (ConI) have shown that 
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reduction of the NSSA hyperphosphorylation state by specific kinases 
stimulates RNA replication, producing a non-adapted replicon that replicates 
efficiently in the culture system (Neddennann et al., 2004). Similarly, the 
hyperphosphorylated fonn of NSSA also inhibits its interaction with human 
VAP-A (a host protein supporting virus replication, discussed in detail in 
chapter 3), consequently inhibiting viral replication (Evans et al., 2004). Use of 
specific NS5A inhibitors like BMS-7900S2 (Fridell et al., 2011) has been 
shown to be an effective anti-HCV agent in phase 1 clinical trials (Gao et al., 
2010). In addition to modulating replication ofHCV RNA, variation in amino 
acid sequence between 237-276, the so called interferon sensitivity detennining 
region (lSDR), is shown to modulate the responsiveness of an individual to 
interferon (IFN) treatment in some populations (Pawlotsky and Gennanidis, 
1999, Katze et al., 2002, Ishii et al., 2011). A study using transgenic mice 
showed that NS5A impairs both innate and adaptive immune responses and 
therefore favours chronic hepatitis (Kriegs et al., 2009). All these factors make 
NS5A an attractive target for antiviral intervention. 
NS5B is an RNA dependent RNA polymerase (RdRp) having a three amino 
acid GDD (Glycine-Aspartic acid-Aspartic acid) motif in its active site 
(Lesburg et al., 1999). The GDD is a highly conserved motif in the RdRp in all 
HCV genotypes and is indispensable for polymerase activity (Yamashita et al., 
1998). NSSB catalyzes the replication of HCV and is obligatory for its survival 
(Behrens et al., 1996). Like all other RdRp, it cannot proof read its transcript 
with a consequent mis-incorporation rate of 10-3 per nucleotide per generation. 
Its activity is modulated by viral factors like NS3 and NSSA as well as host 
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factors like Cyclophilin B (Watashi et aI., 2005, Heck et aI., 2009) and human 
V AP-A (Gao et aI., 2004) and V AP-B (Hamamoto et aI., 2005). NS5B is 
therefore, together with NS3, the premier target for antiviral drug development 
(Appel et aI., 2006). During the course of years, several nucleoside (e.g. R-
7128) and non-nucleoside polymerase inhibitors like benzothiadiazine and 
related analogs have been developed and have shown efficacy in in vitro 
studies and in clinical trials (Das et aI., 2011). 
1.1.3 Lifecycle of HeV 
1.1.3.1 HeV receptors 
HCV infection begins by viral attachment to hepatocytes by interaction of 
specific cell surface receptors with viral envelope glycoproteins (V on Hahn 
and Rice, 2008). Pseudo-particles (HCVpp) based on envelope glycoproteins 
Eland E2 on a retroviral or a lentiviral core are a useful system to understand 
processes of virus attachment and entry into host cells (Bartosch et aI., 2003). 
Using this and other systems (section 1.1.3), several receptor molecules for 
HCV have been identified including CD8t, scavenger receptor class B type I 
(SR-BI), claudin 1 (CLDN1), occludin and the low density lipoprotein (LDL) 
receptor. 
The most widely studied of the HCV receptors is the tetraspanin CD81, which 
binds to E2 (Pileri et aI., 1998). This multi-functional protein is expressed on 
the surface of various cells and has diverse functions including cell adhesion 
and activation (Levy et aI., 1998). Various studies have confirmed the essential 
role ofCD81 in HCV based model systems like HCVpp (Bartosch et aI., 2003, 
40 
Hsu et aI., 2003, Mckeating et aI., 2004, Zhang et aI., 2004) and HCV cell 
culture systems (Lindenbach et aI., 2005, Wakita et aI., 2005). Similarly, a 
hepatoma cell line such as HepG2 which is not normally permissive to HCV 
becomes infectable when engineered to express CD81 (Zhang et aI., 2004). 
However, other reports have made clear that, while necessary, CD81 alone is 
not sufficient for viral entry as not all CD81 positive cell lines can be infected 
(Cormier et aI., 2004). This suggested that other factors are also required for 
H CV binding and entry into hepatocytes. 
SR-BI has been identified as a mediator ofHCV entry and, like CD81, has E2 
binding properties (Scarselli et aI., 2002). An SR-BI ligand, high density 
lipoprotein (HDL), has been shown to enhance infectivity in the HCVpp 
system (Voisset et aI., 2005) suggesting the importance of this molecule in 
viral entry. A tight junction protein CLDNl has also been shown to mediate a 
late step in viral entry (Evans et aI., 2007) and its expression was found to be 
higher in infected livers than that of normal tissue (Reynolds et aI., 2008). 
Similarly, CLDNl expression was found to restore HCV infectivity in an 
otherwise resistant cell line (positive for CD81 and SR-BI) while its down 
regulation blocked viral entry in a HCV susceptible hepatoma cell line (Evans 
et aI., 2007). 
Low density lipoprotein receptor (LDL) is another molecule implicated in virus 
entry into hepatocytes (Agnello et aI., 1999). The association of virus particles 
with lipoproteins like LDL and VLDL and discovery that infectivity can be 
reduced by blocking apolipoprotein B and E secretion from infected liver 
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further supports the role of the LDL receptor in viral entry (Andre et aI., 2002, 
Huang et aI., 2007, Owen et aI., 2009) but additional studies are needed to 
confirm its role more precisely. 
The co-location of CD8t, SR-BI and CLDNI on the sinusoidal surface of 
hepatocytes, which is the site of the first encounter with HCV, is consonant 
with their role as the principal receptor molecules (Reynolds et aI., 2008). In 
addition to these receptors other molecules like ocdudin, glysosarninoglycans 
(GAG's), mannose binding lectins like DC-SIGN (dendritic cell-specific 
intercellular adhesion molecule 3-grabbing nonintegrin) and the related L-
SIGN (liver-specific intercellular adhesion molecule 3-grabbing nonintegrin) 
have also been identified as putative entry molecules (Von Hahn and Rice, 
2008). Despite all these findings, some cell lines remain non-permissive for 
HCV suggesting some other factors also affect virus entry. Recently, EWl-
2wint (a CD 81 associated protein) was shown to inhibit HCV entry by 
blocking its interaction with the envelope proteins (Rocha-Perugini et aI., 
2008). 
1.1.3.2 Virus entry, replication and release 
After entering into the target cell by receptor mediated endocytosis, uncoating 
and release of the nucleocapsid into the cytoplasm takes place (Figure 1.6) 
(Lavillette et aI., 2006). The positive sense viral RNA is directly translated into 
HCV proteins in association with ribosomes. With the help of host and mature 
viral proteins, HCV initiates the replicative cycle in which a complex is formed 
consisting of viral non-structural proteins and replicating RNA in association 
with a membranous web alteration derived from endoplasmic reticulum 
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(Bartenschlager et al., 2004, Salonen et aI., 2004). This is known as the HCV 
replication complex (HRC). 
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The viral NS4B protein facilitates fonnation of the membranous web (Egger et 
aI., 2002), which not only provides the physical support and lipid components 
required for replication but also protects double stranded RNA intennediates 
from degradation by the host antiviral defences (Schwartz et aI., 2002). 
Saturated fats promote HCV replication while poly-unsaturated fats are 
inhibitory, demonstrating the influence of fatty acids and cholesterol in viral 
replication (Kapadia and Chi sari, 2005). In light of reports suggesting that 
saturated fatty acids are required for the fonnation of the membranous web 
(Sakamoto et aI., 2005), it has been postulated that altering lipid metabolism by 
drugs may have an effect on down-regulating HCV replication (Torres and 
Harrison, 2008). 
Both untranslated regions (UTRs) and non-structural proteins harbour essential 
elements for RNA replication. NS5B catalyses the fonnation of a full length 
negative strand which then serves as a template for newly synthesised positive 
stranded HeV genomes which can be either directed to polyprotein translation, 
participate as replication intennediate (negative strand) or packaged as virus 
particle. The presence of negative strand serves as an indication of active virus 
replication (Moradpour et al., 2007). The positive strand RNA is enveloped by 
budding into the ER lumen and transported to the Golgi apparatus where newly 
synthesized particles are further matured before being released into the 
pericellular space by exocytosis as virions (Serafino et aI., 2003) as illustrated 
in Figure 1.7. 
44 
1.1.3.3 HCV particle assembly and secretion 
The envelope and core proteins are essential for virus particle assembly, while 
the non-structural proteins (NS3-SB) constitute the minimal viral components 
required for efficient replication (Blight et aI., 2000, Lohmann et aI., I 999a). 
Regardless of their specific roles, the structural proteins, the p7 ion channel and 
the non-structural proteins are essential for the production of infectious viral 
particles. 
Production of virus particles has been linked to lipid droplets and a number of 
studies have shown that infectious virus particle assembly is dependent on 
components of the VLDL biosynthetic machinery (Huang et aI., 2007, 
Gastaminza et aI., 2008, Nahmias et aI., 2008). Using a cell culture system 
supporting full length viral particles secretion, Gastaminza et al showed that 
intracellular HeV particles have higher density than their secreted counterparts 
suggesting that virus may bind low density particles just before its release 
(Gastaminza et aI., 2008). This was further supported by Huang et aI, who 
identified the presence of proteins involved in the lipoprotein synthetic 
pathway, such as microsomal triglyceride protein (MTP) and apoB and E 
within the replication complex, indicating a role for lipoproteins in virus 
release (Huang et aI., 2007). Another study suggested that silencing of apoB-
100 by siRNA leads to 70 percent reduction in virus particle production 
(Nahmias et aI., 2008). Electron microscopic studies of cell culture produced 
Hev particles suggest that HeV virions have spherical shape and a mean 
diameter of approximately 55 nm (Yu et aI., 2007) (Gastaminza et aI., 2010). 
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Infectious viral particles enter into cells and release the single stranded viral 
genome into the host cytoplasm which serves as a template for RNA translation 
and replication. This process takes place in a membranous web derived from 
the ER. Newly synthesised RNA is then enveloped and assembled in the ER 
and matured within the Golgi apparatus before being released as infectious 
virions. (Bartenschlager and Lohmann, 2000) 
46 
1.1.3.4 Model systems to study HCV 
After the HCV discovery in 1989 (Choo et aI., 1989), efforts focused on 
developing infectious systems which would permit the study of the viral 
lifecycle that could facilitate the development of effective anti-viral therapy. 
Such systems, however, proved very difficult to develop and HCV research 
was slowed for many years due to the lack of a reliable and productive in vitro 
model. Humans are the only natural hosts. Chimpanzees can be infected but 
their use is restricted due to ethical issues, limited availability, and high cost. In 
order to create a deeper insight into virus attachment and entry, the replication 
process and host virus interaction, numerous in vitro culture systems have now 
been developed. 
Initial attempts to infect primary human foetal hepatocytes using HCV 
containing patient sera resulted in an encouraging albeit lower replication 
potency and infection was maintained for at least one month (Iacovacci et aI., 
1997). Another study by Lazaro et al demonstrated the infectability of 
untransformed human foetal hepatocytes with genotype 1 a HCV RNA (Lazaro 
et aI., 2007). Considering the short passage life, contamination issues and lack 
of regular availability of primary cells, immortalised/transformed human 
hepatoma cell lines were developed and have been extensively used to study 
cellular processes involved in virus replication. 
Liver cell lines, primarily the human hepatoma Huh7 cell line and its derived 
clones have been used extensively to study HeV pathogenesis. The Huh7 cell 
line was derived in 1982 from a well differentiated hepatocellular carcinoma 
and proliferates efficiently in culture conditions (Nakabayashi et aI., 1982). It is 
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a fairly well differentiated cell line retaining some hepatocyte specific function 
and production of plasma proteins like glucose-6-phosphatase (G6Pase) and 
Fructose 1,6-diphosphatse (FDPase) (Nakabayashi et aI., 1982). However, 
Huh7 cells do not completely reflect primary liver cell characteristics as they 
lack cytochrome P4S0 function and unlike hepatocytes, has high proliferation 
rate. Huh7.S is a subclone of Huh7 and supports higher levels of viral 
replication owing to the loss of retinoid-inducible gene 1 (RIG 1) which helps 
in viral RNA recognition and production of interferon (Blight et aI., 2002). 
Lack of suitable culture systems that efficiently allow viral replication was a 
major hurdle in understanding viral-host relationship, but an important 
breakthrough occurred in 1999 when Lohmann et al developed a bi-cistronic 
subgenomic replicon system based on genotype 1 b (Lohmann et al., 1999a). 
This subgenomic replicon was created by replacing the portion of genome 
encoding core to P7 by the neomycin resistance gene and the lRES of the 
encephalomyocarditis virus (EMCV). Translation of the first cistron was 
mediated by the HCV lRES while translation of the second cistron was 
mediated by the lRES of the EMCV (NS2-SB). These replicons were capable 
of high levels of autonomous replication when transfected into the human 
hepatoma cell line Huh7. With this system, it became possible for the first time 
to study HCV replication in long term cultures based on Huh7 cells in vitro. It 
also enabled researchers to understand the formation of the replication complex, 
host virus interactions, drug targeting and resistance. Some cell culture 
adaptive mutations were found in the replicon system that increased the 
efficiency of virus production by many folds but reduced or almost completely 
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abolished its in vivo infectivity (Bukh et aI., 2002). More recently, replicons of 
genotype 1 a and 2a have also been developed. Genomic replicons consisting of 
full length HCV genome including structural proteins were constructed but 
their replication capacity was lower than that of subgenomic replicons, and 
there was no virus production (Blight et aI., 2003, Ikeda et aI., 2002, 
Pietschmann et aI., 2002). 
The development of HCV cell culture (HCVcc) was a great step forward. A 
specific clone of genotype 2a was isolated from a Japanese patient with 
fulminant hepatitis, known as JFH-I (Kato et aI., 2003). A replicon system 
based on JFH-l was constructed and was used to transfect Huh7 cells without 
the requirement of adaptive mutations (Kato et aI., 2003). Wakita et al 
demonstrated that transfection of full length JFH-l genomes into Huh7 cells 
resulted in production of a virus that can be infectious for naIve Huh7 cells and 
human liver (Wakita et aI., 2005). This system allowed the study of unexplored 
steps in the virus life cycle like the entry process, the replication mechanism, 
host defence and production of virions. Later on Zhong et al established 
another JFHl based culture in Huh7.5, a subclone ofHuh7 (Blight et aI., 2002) 
which allowed the virus to replicate at a higher rate in naIve and serially 
passaged cells (Zhong et aI., 2005). A full length chimeras of JFHl with 
components of other viral genotypes, including J6, have now been developed 
and shown to efficiently replicate and produce infectious viral particles in 
Huh7.5 cells (Lindenbach et aI., 2005). 
Other model systems include HCV like particles and HCV pseudo particles. 
HCV like particles (HCVlp) were first produced in insect cells and include 
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HCV structural proteins El and E2. Based on this model system, it was shown 
that HCV binding to the host cell might induce some changes in gene 
expression facilitating its infection (Fang et aI., 2006b). Another study found 
that humoral and cellular immune responses induced by HCVlp were able to 
downregulate viral infection (Elmowalid et aI., 2007). To understand the virus 
entry process, HCV pseudopartic1es (HCVpp) were developed by replacing the 
natural envelope of other viruses, like vesicular stomatitis virus, with the HCV 
envelope proteins Eland E2. Both of these proteins assemble to form a 
noncovalent heterodimer and the correct folding and orientation of this 
complex is essential for ER retention of virus and interaction with host 
molecules mediating entry (Dubuisson et aI., 2002). 
1.1.4 Host cell response to viral infection 
1.1.4.1 Pathophysiology of chronic HCV infection 
Lack of an obvious relationship between viral load and severity of liver 
damage seen in chronic infection has suggested that the virus itself is not 
cytopathic. The only exception to this is steatosis seen in association of 
genotype 3 infections (Poynard et aI., 2003). Instead, the local immune 
response mediated by T cells appears to be largely responsible for the tissue 
destruction. The lesions characterizing the chronic infection include portal 
lymphoid infiltration, focal and bridging necrosis and degenerative lesions. The 
presence of large numbers of activated CD4+ T cells (producing IFN-garnma) 
and CD8+ T cells in these lesions further validates their role in progression of 
the hepatic inflammatory lesions seen in chronic infection (Bertoletti et al., 
1997, Bertoletti and Ferrari, 2003, Fiore et aI., 1997). 
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The mam complication of chronic HCV infection is liver fibrosis which 
determines the outcome of disease. Fibrosis in HCV disease shares a complex 
set of mechanisms with fibrosis of other aetiologies like alcoholism, HBV 
infection, metabolic disorders, auto immune diseases etc (Henderson and 
Iredale, 2007). Liver injury triggers recruitment of various inflammatory cells, 
production of wide range of cytokines like TGF-p, Platelet derived growth 
factor (PDGF) etc, and results in changes in populations of sinusoidal and 
periportal cells into a myofibroblast phenotype. Hepatic stellate cells (HSC) are 
the most abundant of all the hepatic non-parenchymal cells and chief source of 
myofibroblasts. Once activated, they play a key role in mediating fibrotic 
changes in liver which ultimately progresses to cirrhosis and its attendant 
complications of end stage liver disease and HCC (Reeves and Friedman, 
2002). Activated HSCs not only produce fibrillar collagen but also express 
tissue inhibitors of metalloproteinases (TIMPs) with resultant inhibition of 
matrix degradation. These events favour scar formation and development of 
cirrhosis. In HCV related fibrosis, the virus directly contributes to the 
progression of disease by producing pro-fibrogenic stimuli and activation of 
HSCs (Schulze-Krebs et aI., 2005). Moreover, a direct interaction between 
HCV core protein and non-structural protein may also play a role in stellate 
cell activation (Bataller et aI., 2004). 
Several host related factors like chronic alcoholism, immunocompromised 
states and co-infection with HIV also contribute in this process (Peters and 
Terrault, 2002, Sulkowski et aI., 2000). In the case of HIV, reduced 
CD4+/CD8+ ratio has been held responsible as CD8+ cells act to amplify the 
51 
fibrogenic response, but direct infection of HSC may also contribute to this 
process (Scott L, 2008). 
1.1.4.2 Immune response to HCV infection 
Once inside the body of its host, the virus acutely triggers an immune reaction 
consisting of both an innate (non-specific) and adaptive (specific) immune 
response. The innate or non-specific immune response is the first line of 
defence mechanism. It is mediated by complement, interferon secretion and 
natural killer (NK) cells activation. NK cell cause enzymatic lysis of infected 
cells and produce type II interferon y and tumour necrosis factor alpha (TNF-a). 
Presence of double stranded viral RNA intermediates activate host cell 
interferon genes via toll like receptors (TLR3) (Alexopoulou et aI., 2001), 
which leads to production of type I IFN a and p, that inhibit virus replication 
(Goodbourn et aI., 2000, Randall and Goodbourn, 2008). 
The innate immune response provides an immediate host defence to inhibit 
virus replication (Randall and Goodbourn, 2008) and facilitates the initiation of 
a more specific and effective adaptive immune responses (Fearon and Locksley, 
1996). Studies have shown that this response fails to control the acute infection 
as, in most of the cases, the virus evades these defence mechanisms by various 
means like reducing responsiveness of inflammatory cells to IFN (Jinushi et aI., 
2003) and inhibition of NK cells (Tseng and Klimpel, 2002). Despite the 
importance of the innate immune response in controlling the acute infection, 
the effectiveness of the adaptive immune response largely decides its 
progression to chronic infection (Thimme et aI., 2001). 
52 
Adaptive immune responses are of two types. A humoral response executed by 
production of neutralizing antibodies by B lymphocytes. and a cell mediated 
response elicited by activation of T lymphocytes (both CD4+ or helper T cells 
and CDS+ or cytotoxic T cells). The antibodies are formed within 7 to 31 
weeks after exposure to the virus and are dominantly directed against HVR-l. a 
27 amino acid sequence located in the N terminus of the E2 glycoprotein. The 
role of these antibodies in combating the virus infection is questionable as the 
variability in this region continuously generates new HCV variants capable of 
evading this response and naturally acquired antibodies fail to neutralise viral 
infection. 
The more specific and effective cell mediated immune response is mediated by 
both the CD4+ (helper T) and CDS+ (cytotoxic T ) cells (Thimme et al.. 2001). 
CD4+ T cells are stimulated by MHC class II molecules expressed on the 
surface of antigen presenting cells (APC) and produce cytokines that play a 
role in macrophage (lFN-y). B cell and CDS+ T cell activation. On the other 
hand. they also produce IL-4 and IL-I0 that help in limiting inflammatory 
reaction in order to prevent excessive tissue destruction (Moser and Murphy. 
2000). CD8+ T cells recognise antigens in association with MHC class I 
molecules. and mediate killing of infected cells and secretion of cytokines like 
IFN-y and TNF- a which in turn also inhibit viral replication in bystander cells 
(Kagi and Hengartner. 1996). It has been observed that patients who have 
spontaneous viral clearance have a powerful. sustained and specific CD4+ and 
CDS+ T cell response (Thimme et al.. 2001). By contrast. a weak. transient and 
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non-specific T cell response is associated with progressive infection (Bertoletti 
and Ferrari, 2003). 
1.1.4.3 Factors responsible for viral evasion or persistence in 
host cell 
HCV induces a host response which involves numerous signalling pathways 
and gene products that create a hostile environment for the virus. The presence 
of viral replication products like dsRNA is sensed both in the extra-cellular 
environment during viraemia and intra-cellularly by TLR-3 and RIG-1 
respectively (Qureshi, 2007). These two pathways converge together and 
ultimately lead to activation of interferon response genes via interferon 
regulatory factor (IRF)-3, resulting in secretion of interferon which then exerts 
its antiviral role (detailed in section 1.2.2.1). However, in the majority of cases, 
the virus makes use of various host evasion strategies favouring its survival. 
This is a complex set of functions, including signalling interference, effectors 
modulation and generation of a population of progeny viral variants at a very 
high rate (Gale and Foy, 2005). 
Viral proteins play a major role in its escape from host immune response. 
NS3/4A by blocking phosphorylation and activation ofIRF-3 (Foy et aI., 2003), 
inhibits interferon signalling via attenuation of RIG -1 and TLR-3 signalling 
(Foy et aI., 2005, Meylan et aI., 2005). Similarly, the core protein induces 
expression of suppressor of cytokine signalling-3 (SOCS-3) which inhibits the 
JAK-ST AT pathway downstream of interferon signalling (Bode et aI., 2003). 
HCV E2 inhibits protein kinase R (PKR) and natural killer cell activation 
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(Crotta et aI., 2002). NS5A also contributes to blunting the host interferon 
response by inhibiting PKR (Gale et aI., 1998) and producing IL-8, a 
chemokine which inhibits IFN's antiviral actions (Polyak et aI., 2001). Other 
possible mechanisms of HCV evasion include high mutational frequency due 
to the low fidelity of RNA polymerase (Weiner et aI., 1992) leading to 
mutational inactivation of B- and T- cell epitopes (Mondelli et aI., 2001) 
(Bowen and Walker, 2005) and functionally incompetent CD8+ T cells with 
poor cytotoxity, proliferative ability and cytokine secretion (Spangenberg et aI., 
2005). Similarly, HCV attachment and entry into hepatocytes induces a number 
of host genes that may facilitate viral invasion, entry, replication or persistence 
inside the host cell (Fang et aI., 2006b). 
1.2 Clinical aspects of HCV infection 
1.2.1 Clinical features, diagnosis and screening of HCV 
infection 
Acute HCV infection is often sub-clinical (80-90%) and in the majority of 
cases, it progresses to chronicity. People with chronic hepatitis may present 
with non-specific symptoms of fatigue, abdominal pain, nausea, vomiting, 
malaise, arthlagia, myalgia, or features of end stage liver disease (cirrhosis) 
such as jaundice, ascites, palmar erythema, portal hypertension, upper GI 
bleeding etc (Modi and Liang, 2008). 
Laboratory diagnosis of suspected HCV infection is usually made by 
serological tests, detecting anti-HCV antibodies or molecular techniques for the 
presence of viral RNA (Patel et aI., 2006). Anti-HCV antibody detection 
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(directed against core or non-structural proteins) is mainly performed by 
enzyme-linked immunosorbent assay (Lanford et al.)ELISA) or enzyme 
immune assay (EIA) having 99% specificity. These assays allow for screening 
of large numbers of samples but can produce false negative results due to a 
narrow spectrum, in the event of acute infection (before development or 
antibodies) or immunocompromised states (inadequate immune response). A 
positive immunoassay result does not mean current infection so needs further 
confirmation by other tests like HeV RNA quantification by peR. These 
molecular based techniques have 98-99% specificity and detection limit of 50-
100 copies/ml (viral load usually in range of 0.5-5 million IV/ml), which will 
not only establish current or active infection but can also be used to monitor 
response to therapy. 
Hev genotyping helps in predicting treatment response and deciding treatment 
duration. Liver biopsy determines grade and stage of fibrosis which indicates 
the degree of disease progression and is a key prognostic indicator. HeV 
screening by means of serological tests is usually recommended for patients at 
high risk of acquiring infection including intravenous drug users, recipients of 
blood or blood components before 1992, health care exposure, haemodialysis 
recipients, HIV infected, children or partners of Hev infected individuals 
(Ferguson, 2010). The resultant early diagnosis helps in better control of 
infection and provides the opportunity to prevent or delay disease progression 
to chronicity. In order to quickly screen individuals aged 15 years or more at 
high HeV risk, the V.S. Food and Drug Administration (FDA) in June 2010 
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approved the first rapid blood test for HCV (OraQuick HCV Rapid Antibody 
Test; OraSure Technologies, Bethlehem, PA). 
1.2.2 Current treatment regimens 
The goal of therapy is to eradicate the replicating virus and avert progression of 
chronic liver disease and liver related death. Symptomatic acute HCV infection 
has greater chance of clearing the virus and approximately 50% of these people 
undergo spontaneous viral clearance within 12 weeks of onset of symptoms 
(Gerlach et aI., 2003). Those with persistent HCV infection or asymptomatic 
infected individuals who have an insignificant chance of self resolution, should 
be treated with either standard or pegylated interferon alpha (PEG-IFN a) 
monotherapy in order to prevent progression to chronic infection. In the event 
of chronic infection, combination therapy with PEG-IFN a and ribavirin is 
given and its duration depends on viral genotype. Current EASL guidelines 
applied for the management of chronic HCV are summarised in Figure 1.8. 
Long term response or virologic cure is best measured by sustained virological 
response (SVR), which is defined as un-detectable HCV RNA as measured by 
a sensitive PCR assay 24 weeks after cessation of therapy. SVR is currently 
regarded as indicative of viral eradication and is clearly associated with 
reduction in liver related morbidity and improved outcomes. The best predictor 
ofSVR is rapid virological response (RVR) defined as absence ofHCV RNA 4 
weeks after therapy. Early virological response (Ducat et aJ.) defined as ~ ~ 2 log 
reduction in HCV RNA levels than baseline (partial EVR) or total 
disappearance of viral RNA (complete EVR) within 12 weeks of therapy is 
57 
used as a forecaster of response to ongoi ng treatment. Fai lure to achieve EVR 
suggests non-response and is an indication for stopping therapy. 
Eligible patients 
A n ~ - - C V V positive 
• Confirm RNA presence by Quantitative PCR 
Genotypl ng to deterrnl ne HCV genotype 
~ - - - - - - - ~ ~ ~ r ~ - - - - - - - - ~ ~l Patients with genotype 1 or 4 J I Patients wi th genotype 2 or 3' J 
+ + 
I Pegy1ated Interferon a and Rlbavmn for 48 weeks 1 I Pegy1ated Interferon a and Ribavlrln ,800mglday) for 24 weeks J 
• Peg"yiated alpha-2a = 180 ugM\< s c and nbavirin 
1000 mg/day « 75 kg) 0'12 0 mg >75 kg) 
• Peg"yiated alpha-2b = 1 5 uglkgMl< se and nba .... mn 
800 mglday «65 kg) or 1 000 mglday (66-85 kg) or 1200 
mglday (85-105 kg) and 1400 mglday (> 1 05 kg) 
Co:nplete EVR 
(RN Neg) 
~ ~
PartialEVR 
(Pos> 210g drop) 
Continue treatment Re-assess at 24 weeks 
No EVR 
(Pos<210g drop) 
for 48 weeks / / 
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~ ~
reat for 72 weeks 
Quallta ve CV RNA ar 48 weeks (end of treatment response) 
and at 72 weeks or to establl sh SVR 
1 
Determine HCV RNA at 4 weeks (RVR) I 
• • I RNA Neg I I RNAPos J 
+ 
I Determine HCV RNA at 12 weeks (EVR) 
-'-
NoEVR 
1 Continue therapy 1 (Pos<2Iog drop) 
\ Complete EVR PartlalEVR 
(RNA Neg) (Pos> 210g drop) 
~ ~
Treat for 48 weeks 
Qu alitabve HCV RNA at week 48 
(24 weeks after ending treatment) 
to establish SVR Treatment failed 
• EVR = early Vl rologlcal response 
• SVR = sustained \1fologlcal response 
• Also applies to genotype 5 & 6 
Figure 1.8 Treatment guidelines for chronic HCV infection 
European Association for the Study of the Liver Guidelines (Easl, 201 1) 
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1.2.2.1 Pegylated interferon 
Interferons (IFNs) are a group of naturally occurring cytokines which have 
both antiviral and immuno-regulatory properties. Type I IFNs, including 
interferon alpha (IFN-a) and beta ( I F N - ~ ) , , are produced by many cell types 
such as fibroblasts, hepatocytes and epithelial cells, whereas type II IFNs (IFN-
y) are only produced by certain types of immune cells like natural killer and T 
lymphocytes. The presence of viral replication products, especially double 
stranded (ds) RNA intermediates, acts as a stimulus for the production of 
various factors required for interferon synthesis like IFN regulatory factors 
(IRFs) (Bames et aI., 2002). 
Upon binding to its cell surface receptor, IFNs triggers a complex signalling 
pathway leading to activation of gene transcription (Katze et aI., 2002). 
Hundreds of these interferon stimulated genes (lSGs) have been identified (De 
Veer et aI., 2001). The majority induce an antiviral state within the infected 
cells. A well known type I IFN ISG is protein kinase R, PKR (Meurs et aI., 
1990, Clemens, 1997). PKR inhibits eukaryotic initiation factor 2 (eIF2) which 
in turn down regulates viral protein synthesis (Guo et aI., 2004). Since response 
to interferon varies between HCV genotypes, several viral and host factors 
have been implicated. An interferon sensitivity determining region (ISDR) has 
been identified in viral NS5A and has been suggested to determine response to 
interferon based regimens as patients with treatment response carried mutations 
in this region (Miyamura, 1996). Inhibition ofPKR either by viral NS5A (Gale 
et aI., 1998) or direct phosphorylation (Garaigorta and Chi sari, 2009) may also 
account for interferon resistance. 
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IFN a was initially approved as a monotherapy for Hey but was successful 
only in a small proportion of individuals (Di Bisceglie and Hoofnagle, 2002). 
Standard or conventional IFN is administered subcutaneously three times a 
week and available as Interferon-alpha-2a (Roferon-A, Roche) and Interferon-
alpha-2b (Intron-A, Merck). The limitations of conventional interferon, such as 
short half life and variable peak-trough concentrations requiring frequent 
administration were overcome by surface modification with polyethylene 
glycol (pegylated or PEG) (Lindsay et aI. , 2001). Addition of PEG coating 
creates a srueld around interferon molecules and delays its breakdown and 
clearance from the body. This allows dosing once a week and since the drug 
molecule stays longer in the body, there is even greater suppression of Hey. 
The two currently FDA approved PEG-IFN are Pegasys (pegylated INF-alpha-
2a) from Roche and Peg-Intron (pegylated IFN-alpha-2b) from Merck. 
Albinterferon (Zalibin) is a newer type of interferon genetically fused with 
plasma protein albumin, producing a long acting molecule and thus requiring 
dosing once every two weeks. It was successful in phase III clinical trials and 
is now awaiting FDA approval (http://www.nelm.nhs.uk). Further addition of 
ribavirin to interferon resulted in a significant improvement in response rate, 
especially for genotypes 2 and 3 (Mchutchison, 1999) and transformed the 
treatment paradigm. 
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1.2.2.2 Ribavirin 
Ribavirin ( l - ~ - D - r i b o f u r a n o s y l - l , 2 , 4 - t r i a z o l e - 3 - c a r b o x a m i d e ) ) IS a purine 
nucleoside analogue and was used initially for the treatment of respiratory 
syncytial virus (RSV) infection. A later trial used ribavirin alone for HeV 
infection but was found to have negligible effect on HeV RNA levels (Di 
Bisceglie et aI., 1995). Another trial comparing efficacy of ribavirin 
monotherapy vs. placebo also showed that it had no effect on HeV RNA levels 
despite improved serum aminotransferases (Dusheiko et aI., 1996). Ribavirin 
was, however, found to have dramatic effects on viral clearance and reduction 
of relapse rate when used in combination with interferons. In a study by Fried 
et aI, only 29% of patients receiving IFN monotherapy achieved a SVR 
whereas -56% of those on combination regimen did so, highlighting the 
importance of ribavirin on viral clearance. Ribavirin was subsequently 
approved for use in combination therapy for HeV infection (Mchutchison, 
1999). The exact mechanism by which ribavirin exerts its antiviral action is 
currently unknown. A number of possible modes have been proposed: 
(i) After penetrating the cells, ribavirin is phosphorylated to form ribavirin 
mono- (MIP), di- (DIP) and tri-phosphate (RIP) (Wu et aI., 2005). Maag et al 
showed that RIP is misincorporated into newly produced RNA leading to early 
chain termination and blockage of viral replication (Maag et aI., 2001). 
Although this effect can be produced for all HeV genotypes, it requires a high 
ribavirin concentration. In addition, since ribavirin monotherapy fails to exert a 
direct anti-viral action, this is an unlikely mode of action. 
(ii) Ribavirin monophosphate (RMP) acts as an inhibitor of inosine 
monophopshate dehydrogenase (lMPDH) and leads to depletion of cellular 
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GTP levels required for protein synthesis, hence it down regulates viral 
replication (Feld and Hoofnagle, 2005). However, use of specific IMDPH 
inhibitors failed to produce such inhibition as is seen in the case of ribavirin 
suggesting that other mechanisms are also required (Zhou et aI., 2003). 
(iii) It has been proposed that ribavirin also acts as an immuno-modulator by 
augmenting the CD4+ response and down regulating the CD8+ response (Lau 
et aI., 2002). In support of this, patients receiving combination therapy with 
interferon a and ribavirin possess a strong helper T cell response than those 
receiving interferon monotherapy (Cramp et aI., 2000). 
(iv) HCV has a RNA polymerase that lacks proof reading ability and this 
accounts for the presence of a large number of quasipsecies in infected 
individuals. Using a Poliovirus model, Crotty et al showed that presence of 
ribavirin in the form of RTP leads to mis-incorporation of cytidine and uridine 
bases into RNA, which exert a mutagenic effect leading to replication error 
catastrophe (Crotty et aI., 2000, Cameron, 2001). Some in vitro studies have 
highlighted the importance of this mechanism in HCV infection (Contreras et 
al., 2002) but others have provided evidence to the contrary (Chevaliez et aI., 
2007). 
A limitation of the majority of the above mentioned mechanisms of ribavirin 
was requirement of a very high concentration of ribavirin. A recent study using 
clinically relevant concentrations of ribavirin showed that inhibition of IMPDH 
may be the main mechanism ofribavirin's anti-HCV action (Mori et aI., 2011). 
Clinically available formulations of ribavirin include Rebetol (Merck), 
Copegus (Roche) and Ribasphere (Three Rivers Pharmaceutical, LLC). 
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Ribavirin is administered orally twice a day and dosage is based on body 
weight depending on viral genotype (800-1400 mg/day for genotype 1 and 800 
mg for 2 and 3). Further details are given in Figure 1.8. Taribavirin (formerly 
known as Viramidine), a 3-carboxamidine derivative of ribavirin, is a pro-drug 
which is activated and converted to ribavirin by adenosine deaminase (Wu et 
aI., 2003). Due to favourable properties like its ability to be converted and 
concentrated in liver, and a positive charge with fewer propensities to be 
entrapped by RBCs, Taribravin was in clinical trials for the treatment of 
chronic HCV (Ferguson, 2010). However recent data suggest that at higher 
dosage, anaemia did not differ greatly from ribavirin. 
1.2.2.3 Side effects of current therapy 
Treatment related adverse effects are a common consequence of interferon and 
ribavirin based regimens and often result in dosage reduction or treatment 
discontinuation. Common side effects affecting 20-40% of patients are flu like 
symptoms (fatigue, headache, and fever), gastrointestinal upsets (nausea, 
anorexia and diarrhea), and psychiatric disturbance (depression, insomnia or 
irritability). Interferon based products have the potential to aggravate existing 
neuropsychiatric, autoimmune, ischemic and infectious disorders and are 
contraindicated in patients with hepatic decompensation. 
Ribavirin adds to both the efficacy and side effects of IFN monotherapy. The 
most common adverse reaction is accumulation of ribavirin in red blood cells 
(RBCs) resulting in often severe haemolytic anaemia (Bodenheimer et aI., 
1997). As ribavirin concentration increases, more and more ribavirin enters 
into RBCs and is phosphorylated to its active forms i.e. mono-, di-, and tri 
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phosphates (RMP, RDP and RTP). Once phosphorylated, ribavirin can neither 
be metabolised nor transported out of erythrocytes thus resulting in > 1 00 fold 
higher intracellular concentration than in the plasma (Krishnan and Dixit, 
2011). Presence of high amount of phosphorylated ribavirin causes ATP 
depletion with resultant oxidative stress and cell damage leading to red cell 
death (De Franceschi et aI., 2000). Interferon mediated bone marrow 
suppression also contributes to ribavirin induced haemolytic anaemia through 
impaired cell renewal (Peck-Radosavljevic et aI., 2002). Symptomatic anaemia 
occurs in a substantial number of patients and requires either treatment with 
erythropoietin or blood transfusion or discontinuation of therapy in extreme 
cases (De Franceschi et aI., 2000, Sulkowski, 2003, Sulkowski et aI., 2004). A 
study investigating the effect of ribavirin and IFN combination on hemoglobin 
levels showed that more than 50% of patients suffered a reduction of 2:3g1dl, 
and reducing ribavirin dose improved it by -1 gldl (Sulkowski et aI., 2004). 
However, a reduction in ribavirin dose often compromises its therapeutic 
response (Manns et aI., 2001, Sulkowski, 2003, Reddy et aI., 2007). A report 
by Reddy et al assessing effects of ribavirin dose reduction on SVR in patients 
infected with genotype 1 virus suggested that patients receiving less than 60% 
of planned ribavirin dose had significant (p value = 0.0006) reduction in SVR 
and increase in relapse rate at the end of treatment (Reddy et aI., 2007). 
Ribavirin has the potential to induce birth defects or foetal death and is 
contraindicated in pregnant women or people hypersensitive to it making it 
practically not available to these patients. Despite these limitations, current 
research suggests that ribavirin will remain the cornerstone of any future anti-
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HCV regImen and further approaches are needed to overcome these 
undesirable effects and improve therapeutic responsiveness. 
In addition to the factors like viral genotype, ethnic origin, presence or absence 
of cirrhosis or HIV infection, an important recent advance has been the 
identification of single nucleotide polymorphisms (SNPs) in the interleukin-
28B gene or IL28B which is located on chromosome 19 (rsI2979860), as a 
predictor of spontaneous viral clearance and treatment response (Ge et aI., 
2009). Several studies have confirmed the importance of IL28B 
polymorphisms and response to therapy. In a recent report by Thompson et aI, 
CC type, when compared with CT or TT types, was associated with improved 
early viral kinetics and RVR (28% vs 5% and 5%), EVR (87% vs 38% and 
28%) and SVR (69% vs 33% and 27%) respectively confirming its role as a 
pre-treatment response predictor (Thompson et aI., 2010). Another report by 
Arends et al underlined the association of IL28B and early first phase viral 
decline (Arends et aI., 2011). It is likely that measuring IL28B polymorphisms 
will become an essential part of the pre-treatment assessment of HCV infected 
individuals. 
1.2.3 Anti-HCV drugs in clinical development 
The limited efficacy of current anti-HCV therapy has lead to a search for new 
therapeutic molecules. Distinct stages of the virus lifecycle which present an 
opportunity to target numerous drugs are being investigated. These drugs either 
inhibit viral factors essential for virus entry, RNA replication/protein 
processing or host factors supporting its survival. Unlike HIV, HCV does not 
integrate into the host genome so it can potentially be eradicated with a 
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sustained effect (Monto et aI., 2010). Direct-acting antiviral (DAA) agents or 
Specifically Targeted Antiviral Therapy for hepatitis C (STAT-C) are a class of 
molecules specifically targeting enzymes involved in virus replication. Several 
of these compounds are in different stages of clinical trials (Table 1.1) and are 
of great promise when combined with interferon-a and ribavirin. 
1.2.3.1 Inhibitors of viral entry 
HCV structural proteins (El and E2) interact with host cell receptors (CD81, 
SRB-I, Claudin, occludin etc) to mediate intracellular entry. Interference with 
entry can be accomplished by using molecules which either prevent El and E2 
mediated attachment or fusion to host cell membranes. To achieve this 
monoclonal and polyclonal antibodies are being developed and evaluated in 
early phase clinical trials (Mir et aI., 2009, Zeisel et aI., 2011). The most 
significant of mono clonal antibodies are HCV AB68, HCV AB6865 and 
Bavituximab (Peregrine Pharmaceuticals), together with polyclonal antibodies 
such as HCIg or Civacir (Biotest Pharmaceuticals). 
1.2.3.2 Inhibitors of viral translation 
The IRES located in the 5'UTR controls viral translation by initiating its 
binding to ribosomes and its efficiency is affected by HCV proteins like core, 
NS4A and NS5B. Drug groups which can inhibit IRES can potentially block its 
translation and hinder its persistence and propagation. These include anti sense 
oligonucleotides (DNA or RNA strands capable of binding to an inhibiting 
complementary mRNA and thus inhibiting translation), ribozymes (RNA 
molecules capable of sequence mediated recognition and degradation of target 
RNA) and small molecule inhibitors. An example of each of these categories 
66 
IS gIven In Table 1.1. A VI-4065 is a synthetic phosphorodiamideate 
morpholino oligonucleotide targeting viral 5' UTR. It has shown efficacy in 
phase I trials but was stopped in phase II trial due to limited efficacy in 
reducing viral load (http: //C\inicaltrials. gov/ct// how/NCT00229749). 
Similarly, Heptazyme (a chemically modified ribozyme) was also halted In 
phase II due to evidence of animal toxicity (Pawlotsky et aI. , 2007). 
MicroRNAs (miRNAs) are a class of small molecules involved in gene 
regulation. miRNA122 is specifically and abundantly expressed in liver cells 
and has been shown to positively regulate HCV replication and translation 
(Jopling et aI. , 2005). This may be used as a potential target to inhibit HCV 
replication and drugs based on anti -sense oligonucleotides like SPC3469 
(Santaris Pharma) are in phase J trials (Lares et aI. , 20 I 0). 
1.2.3.3 Inhibitors of post-translational polyprotein processing 
Once the viral protein is translated , it undergoes processing mainly by the 
NS3 /4A serine protease. Numerous studies have shown the efficacy of 
targeting the viral protease. The most advanced protease inhibitors are two 
linear ketonamide compounds called Telaprevir and Boceprevir which have 
been shown in phase III clinical trials to have clear efficacy in both treatment 
naiVe and treatment experienced individuals and are now approved for clinical 
use. Phase 11 trials (pROVE I and 11) have shown that combination of 
Telaprevir with PEG-IFN a and ribavirin improved SVR by 20% but also 
caused more adverse effects like skin rash, gastrointestinal events and anaemia, 
than in patients who were on the standard regimen (Hezode et aI. , 2009, 
Mchutchison et aI. , 2009). Another phase 1I trial (PROVE Ill) demonstrated 
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that non-responders to PEG-IFN a. and ribavirin showed significant 
improvement in response rate to triple therapy (51-52%) than the standard 
regimen (14%) (Mchutchison et aI., 2010). Despite these benefits, addition of 
Telaprevir resulted in higher incidence of adverse effects like anaemia and skin 
rash resulting in the treatment discontinuation in a few patients. Boceprevir has 
also shown similar potency. In a phase 11 trial (SPRINT -1) in genotype 1 
treatment naIve patients, Boceprevir based triple therapy resulted in 67-75% 
SVR compared to only 38% achieved with PEG-IFN a. and ribavirin (Kwo et 
aI., 2010). However, the Boceprevir treated group had a higher incidence of 
anaemia (52-56%) than the control group (35%). One common observation in 
all of these studies was that ribavirin was of integral importance in the 
combination regimen as excluding it not only significantly reduced response 
rate but also increased relapse rate. 
1.2.3.4 Inhibitors of replication machinery 
Hev's positive stranded RNA genome acts as a template for replication and 
with the help of viral and host factors, a replication complex is fonned 
consisting of host derived membranous alterations, a negative stranded RNA 
replicative intennediate and viral proteins. Among the viral factors, the NS5B 
RNA polymerase is central to this process and has been an attractive target for 
drug development (Pawlotsky et aI., 2007). Although the exact mechanism of 
NS5A is not known, it is also involved in replication so inhibitors targeting this 
viral protein are also under development (Table 1.1). 
The NS5B inhibitors can be nucleoside inhibitors (NI) or non-nucleoside based 
inhibitors (NNI) (Jazwinski, 2011). The NI are a natural substrate for the 
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polymerase and therefore become incorporated m growing RNA chains 
resulting in early chain termination and viral inhibition. On the other hand NNI 
directly bind to the viral polymerase and inhibit it. Table 1.1 shows examples 
of some of these compounds in clinical development. 
1.2.3.5 Other inhibitors 
In addition to the above mentioned drugs which are still under development, 
other potential therapeutic targets including RNA interference mediated 
inhibition of the HCV genome (e.g ALN-VSP), cyclophilin inhibitors (Debio 
025), immuno-modulators (Oglufanide disodium), Silibinin (a major 
component of Silymarin with known anti-oxidant activity) etc are also being 
tested in phase 11 clinical trials. Cyclophilins are host proteins involved in 
protein folding and also act as regulators of the NS5B polymerase. Targeting 
host factors like cyclophilin not only complements anti-viral effects but will 
also provide a greater genetic barrier for viral escape mutants (Gaither et aI., 
2010, Heck et aI., 2009, Watashi et aI., 2005). In addition, several other host 
based targets have also been identified using siRNA based screening 
methodology (Ashfaq et al., 2011). 
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Table 1.1 Summa!y_of anti-HeV drugs in clinical development 
Drug Category Drug name General remarks 
Interferon Albinterferon An albumin conjugated longer acting interferon requiring once/2-4 weeks dosing. 
related 
Ribavirin 
Related 
Host based 
Cyclophilin 
inhibitors 
Virus entry 
Taribavirin A ribavirin pro-drug which can be concentrated in liver and can avoid ribavirin induced haemolytic anaemia. 
(Viramidine) H ~ \ \ , ~ v e r , , at higher dose, anaemia rate increased and did not differ greatly from ribavirin. 
DEB025 A synthetic non-immunosuppressive analogue of cyc\osporine A which inhibits effects of cyclophilin on HCV 
(Alisporivir) replication. Efficacious against genotype 1-4. 
Neutralising Bavituximab A monoclonal neutralising antibody that binds to phosphatidyl-serine exposed to surface of virally infected cells, 
antibody thus inhibiting virus entry 
IRES function 
Antisence- AVI-4065 A synthetic phosphorodiamidate morpholino oligomer targeting 5'UTR. Shown efficacy in phase I trials but 
o l i g Q r l I 1 ( ; l Q e t i d ~ _ _ _ _ phase 11 trial was halted due to limited reduction in viral load. 
Ribozyme Heptazyme Chemically modified ribozyme with improved stability. Shown efficacy in early phase clinical studies but halted 
because of animal toxicity. 
Small molecule 
inhibitors 
DAA/STAT-C 
VGX-4IOC Orally active small molecule anti-lRES inhibitor which blocks its association with elF3 and therefore blocks 
translation initiation. 
Current status 
Awaiting 
approval 
Phase III 
Phase 11 
Phase 11 
Phase 11 
Phase II 
Phase II 
NS3A/4A BMS-850032 Interferes with viral poly-protein processing and activation into mature form after being translated. These are --=-P_ha"-s'-'e....:I ___ _ 
Protease inhibitors Vaniprevir, most extensively studied and successful DAA therapies. Two of these, Bocepravir (SCH-503034) and Telaprevir Phase II 
Danoprevir (VX-950) have successfully completed phase III trial and are awaiting approval for clinical use. These _____ _ 
NS5A inhibitor 
NS5B NI 
NS5B NNI 
Telaprevir, compounds have been found to be most effective for genotype 1 than other HCV genotypes. 
Boceprevir 
PPI-461 
R7128 
VX-222 
Inhibits NS5A of all HCV genotypes and has shown to improve efficacy of current drugs. 
An oral cytidine nucleoside analog polymerase inhibitor. In phase I trial, -60% achieved RVR when combined 
with standard regimen and appear to be safe and well tolerated in early trial. 
An oral non-nucleoside analog shown potency in early clinical trial and is being evaluated as a combination with 
Telaprevir as an adjuvant to standard regimen. 
(NI = Nucleoside inhibitors, NNI = Non-nucleoside inhibitors) 
Approved 
Phase I 
Phase II 
Phase II 
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1.3 Current status of anti-HCV therapies and strategies 
proposed to improve response rate 
Current anti-viral regimens based on pegylated IFN alpha and ribavirin, are not 
only toxic but have lower efficacy for certain genotypes (Manns et aI., 2001). 
Sustained virological response (SVR), although is achievable in 76-82% of 
those with genotype 2/3 infection, is very low i.e. 42-52% in patients infected 
with the most abundant genotype 1 (Manns et aI., 2001, Fried et aI., 2002, 
Hadziyannis et aI., 2004, Zeuzem et aI., 2004). Despite the fact that DAAs 
have shown great promise in clinical trials, the majority of them still require 
ribavirin. These are also commonly associated with development of clinical 
resistance due to appearance of mutants resulting in viral rebound. One of the 
most advanced of DAAs is Telaprevir. In phase 11 clinical trials with genotype 
1 virus, the Telaprevir receiving group achieved SVR of 67-69% (Prove 112) 
and 24-53% (Prove 3) when compared to 41-46% (Prove 112) and 14% (Prove 
3) in patients on the standard regimen. Removing ribavirin not only lowered 
anti-viral efficacy but also caused higher relapse rate indicating that ribavirin 
remains important for achieving SVR. Also Telaprevir appeared to be less 
efficacious for genotytpe 2 and minimally effective for genotype 3 and 4. 
Compliance with therapy and the dose of RV appear to be vital determinants of 
therapeutic efficacy (Feld and Hoofnagle, 2005). In a comparative study 
assessing the efficacy of lower dose of ribavirin (800mg daily) vs. standard 
dose (1000 or 1200mg daily), clearance rates were higher (52%) in patients 
receiving standard dose, suggesting that lower dose ribavirin will compromise 
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efficacy (Hadziyannis et aI., 2004). Conversely, Lindahl et al showed that 
using a higher daily dose of ribavirin, sufficient to achieve plasma 
concentration of 15uMIL (mean dose 2540mg/day, range 1600-3600), achieved 
a response rate of 90% even in genotype 1 infection. The majority of these 
patients developed severe haemolytic anaemia and required treatment with 
either erythropoietin or blood transfusion, implying that the improved response 
rates associated with higher doses of ribavirin are only achievable at the 
expense of greater side effects (Lindahl et aI., 2005) The sequestration of 
ribavirin into the red cell compartment also reduces its availability in liver, and 
is a crucial factor in limiting the efficacy of ribavirin for the treatment of HCV 
infection (Takaki et aI., 2004). All of these features point towards the need for 
an effective delivery method for the currently available drugs, which will not 
only reduce associated side effects but will direct high concentrations of the 
drug to hepatocytes. The principle of targeted therapy for ribavirin is also 
applicable to novel therapeutic agents that may be used in combination with 
ribavirin based regimens (Jazwinski, 2011). This is particularly relevant to 
small molecule inhibitors like Telapevir and Boceprevir, which have now been 
approved for clinical use but still require ribavirin and also cause additional 
side effects (Hezode et aI., 2009). 
Although next generation anti-viral agents have improved in efficacy in 
comparison to standard regimens, there remains a need to identify new 
therapeutic drugs for HCV with higher efficacy and fewer side effects. Many 
such agents will be used in combination with other drugs, so minimal side 
effects and lacks of cross resistance are important considerations. A specific 
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delivery vehicle for transport of multiple drugs to their site of action in 
hepatocytes could therefore enhance the efficacy of next generation anti-viral 
therapy. Small interfering RNAs are therapeutic molecules which can be 
utilised to silence viral or host gene expression and are ideal candidates for 
development as novel anti-viral agents. The process of viral replication 
presents a number of highly specific targets for siRNA action. A number of 
such siRNA based targets have been identified but are associated with 
development of resistance to siRNAs due to the intrinsic error prone nature of 
HCV replication (Ashfaq et aI., 2011). Host derived genes, which are involved 
in virus replication provide relatively invariant targets which may have 
therapeutic potential. Once validated, these can be combined with current 
therapy to improve response rate of existing drugs. Two of these host proteins 
(VAP-A and STAT-3) have been tested and validated in this study (chapter 3). 
Such small molecules will, however, require a suitable delivery vehicle. 
Taken together, current evidence indicates that ribavirin and interferon will 
remain the cornerstone of HCV therapy for the foreseeable future. New 
therapeutic targets based on either the viral genome or siRNA targeting of host 
proteins are an attractive therapeutic option. A key requirement for realising 
the value of this approach is the development of an efficient, targeted drug 
delivery system. Such a system may improve viral clearance and minimise the 
systemic toxicity of anti-viral drugs. Additionally, it will also enable delivery 
of more the one therapeutic molecule as is the case of DAAs, either alone or in 
combination with current drugs. 
73 
1.4 Research objective 
In light of the inadequacies in the current therapeutic options available at the 
time of planning this thesis, we aimed to improve therapy for HeV through 
identification of new targets and improving efficacy of current treatments. 
Thus, the aims of this thesis were: 
A) Identification of new targets: In this part of the project we aimed to test 
whether specific host molecules could be targeted to inhibit viral replication. 
This firstly required the establishment of a sub genomic replicon system in 
which subgenomic viral replication could be quantified. This was then used to 
assess the effect of inhibition of a number of cellular proteins (by siRNA) on 
viral replication. 
B) Improved delivery of therapies: Ribavirin is an effective therapy but it can 
become sequestered in red blood cells resulting in haemolysis. siRNAs can also 
be degraded by RNAses present in the blood. We hypothesised that it would be 
useful to exploit the potential of nanopartic1es (NPs), either liposomal or 
polymer based for drug delivery. These molecules can potentially deliver anti-
viral drugs to the liver in a manner which may have many advantages over 
conventional systematically administered drugs. Since the majority of a drug 
reaches its target site, this potentially powerful approach will increase drug 
responsiveness at a lower dosage. We aimed to test whether ribavirin and 
siRNAs to ApoB-IOO could be targeted accurately to cells using liposomal 
nanopartic1es. 
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C) Improved targeting in patients: Ribavirin is a key component of anti-HCV 
therapy and being a nucleoside analogue requires a nucleoside transporter to 
gain intracellular entry. Addition of ribavirin substantially improves response 
rates and reduces relapse rate when added to interferon alpha. It is therefore 
also important to recognize the factors responsible for variation in response 
rate in different individuals exposed to ribavirin based regimen. Earlier studies 
have highlighted the importance of intracellular ribavirin concentration and 
response to therapy but the primary reasons remain obscure. In this part of the 
project, we aimed to understand the mechanism of ribavirin entry in primary 
human hepatocytes. It was hypothesised that the nucleoside transporter 
mediated ribavirin uptake in human hepatocytes is responsible for variation in 
response rate in treated individuals. This also involved validation of an 
effective method to isolate and culture primary human hepatocytes. 
Figure 1.10 summarises the outline of this study and the specific aims to 
address these research questions. 
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Project overview 
Current HCV treatment regimen 
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Chapter Two 
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2 Materials and Methods 
2.1 Cell culture 
Tissue culture treated flasks (75 cm2) and 6 well tissue culture plates were 
obtained from Coming, UK. Collagen coated 6 well plates were purchased 
from BD Biosciences, UK. All the buffers and solutions used for culture were 
prepared fresh under sterile conditions and details of all the chemicals used are 
given in Appendix 8.1. 
Human hepatoma cell lines Huh7 and Huh7.5 were maintained in culture 
medium made up of Dulbecco's modified Eagle's medium (DMEM) 
(GibcoBRL, UK) supplemented with 10 % Foetal calf serum (FCS, Sigma, 
UK), 2mM L-glutamine (Gibco, UK) and antibiotic/antimycotic solution 
(Hyclone Thermoscientific). Cell culture was maintained at 37°C in a 
humidified atmosphere containing 5% CO2 and passaged when -80-90% 
confluent. Huh7.5 was also grown in the same conditions except that FCS used 
was from Biosera. 
2.2 Preparation of JFH1 subgenomic replicon: 
A subgenomic replicon plasmid (Figure 2.1) based on the HCV genotype 2a, 
JFHI (pSGR -LUC-GFP-JFHI) and GND (pSGR -LUC-GFP-JFHI-GND) was 
a kind gift from John McLauchlan's lab (MRC, Glasgow). The Plasmid was 
linearised by restriction digestion with XbaI (Roche) following the 
manufacturer's instructions. Any overhangs generated in the linearised DNA 
were removed with the help of Mung bean treatment (New England BioLabs) 
at a concentration of I unitlJ.lg DNA, and the resulting template was used for in 
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vitro transcription using the Ambion T7 Megascript kit following its manual. 
Briefly 5 j.lg of D A was prepared in 20 )J.l of reaction containing nitrogenous 
bases (ATP, CTP, UTP, GTP) and enzyme mix and incubated at 37°C for 2 
hours. D Aase was added to remove input DNA and incubated for another 15 
minutes at room temperature. Replicon RNA was further purified using the 
Qiagen RNAesy kit and quantified using the Nanodrop (ND-IOOO UV-Vis 
Spectrophotometer (LabTech International Ltd, Ringmer, UK). Samples having 
an A260/A280 ratio between (1.8-2.00) were considered suitable for 
subsequent steps. 10)J.g aliquots of replicon RNA were store at -80 °C until use. 
RNA quality was assessed after every prep using agarose gel electrophoresis. 
&oRJ · I - C'AAIT C I -
HpoJ m5 - GTI' AA 
Figure 2.1 Plasmid map for subgenomic replicon 
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2.3 Transfection of siRNA, plasmid DNA and viral RNA: 
Pre-designed stealth siRNAs targeting the gene of interest were obtained from 
Invitrogen (Block IT) and their sequence is given in Table 2.1. For transfection 
using Lipofectamine2000, the manufacturer's instructions were followed. In 
brief, Hub7 cells were plated overnight for initial attachment at a density of 2.5 
x 105cells/wel1. The required volume of duplexes was prepared in 500 J.l.I of 
Optimem medium (GIB CO, UK) and incubated with 5 J.l.I of lipofectamine for 
20 minutes at room temperature. The mixture was added to cells cultured in 
antibiotic free medium and incubated for 6 hours at 37°C before replacing with 
fresh Hub7 medium (with antibiotics). Cultures were harvested at 48 hours for 
RNA and protein extraction. For transfection of DNA expression plasmid 
encoding OFP using Lipofectamine2000, the same protocol was followed 
except that the cells were harvested at 48 hours for flow cytometry to analyse 
for OFP expression (Section 2.7). 
For nucleofection, siRNA (at a final concentration of 33-500nM) either alone 
or with viral RNA (5-20J.l.g) were nucleofected by using the Amaxa 
nucleofector device in conjunction with the nucleofector kit T (Lonza) and T-
020 programme. A number ofnucleofection controls were used like pmaxGFP, 
mock-transfected cells, and siRNA for GFP, JFHl and OND alone. Cells were 
resuspended in RPMI medium (GIBCO, UK) and cultured for 48 or 72 hours 
before analysis by flow cytometry and Western blotting. The scrambled control 
has the same bases but arranged randomly and has been recognised to have no 
homology to any known RNA sequence. 
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Table 2.1 Stealth siRNA sequences used in the present study 
Target gene Sense strand (5' -> 3') 
Anti-sense strand (5'-> 3') 
STAT3 UGGCCCAAUGGAAUCAGCUACAGCA 
UGCUGUAGCUGAUUCCAUUGGGCCA 
VAP-A GGGAAUGCUCCGACUGUCACUUCAA 
UUGAAGUGACAGUCGGAGCAUUCCC 
ACTNl GGCCCUGGAUUUCAUAGCCAGCAAA 
UUUGCUGGCUAUGAAAUCCAGGGCC 
APOB-IOO GUCAUCACACUGAAUACCAAU 
AUUGGUAUUCAGUGUGAUGACAC 
2.4 Total RNA (ribonucleic acid) extraction 
RNA was extracted by RNeasy mini kit (Qiagen) following manufacturers 
instruction. In brief, culture medium was aspirated and 600 JlI of buffer RL T 
(lysis buffer) was added to the cells. The cell suspension was pi petted up and 
down several times to ensure complete lysis and filtered through shredder 
columns (Qiagen) for homogenisation. An equal volume of 70% ethanol was 
added to the resulting suspension and applied to the RNeasy spin column for 
centrifugation at 13,000 rpm for 15 seconds. The flow through was discarded 
and the spin column was washed twice with buffer RWl by centrifugation at 
13,000 rpm. DNA free treatment was done by preparing 10JlI of reconstituted 
DNase in 70JlI DNase buffer (supplied with the kit) and applying it to the spin 
column. After incubation for 15 minutes at room temperature, the column was 
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washed with buffer RPE by spinning at 13,000 rpm for 15 seconds (wash 1) 
and 2 minutes (wash 2). Finally RNA was eluted in 30-50 JlI of RNase free 
water and quantified by a NanoDrop ND-lOOO UV-Vis Spectrophotometer 
(LabTech International Ltd, Ringmer, UK). The samples having an A260/A280 
ratio between (1.8-2.00), indicating sufficiently pure RNA were considered 
suitable for subsequent steps. The eluted RNA was stored at -80°C until used. 
2.5 Reverse transcriptase polymerase chain reaction 
(RT-PCR) 
Complementary deoxyribonucleic acid (cDNA) was synthesised by reverse 
transcription of RNA. Briefly, 1 Jlg of RNA was prepared in 20 III of water and 
1111 of random hexamers (PD(N)6) and incubated at 70°C for 10 minutes as 
initial denaturation step. Samples were placed on ice for 5 minutes and a 
master mix was prepared by adding 1 Jll (200 units) of Moloney Murine 
Leukemia Virus Reverse Transcriptase enzyme [M-M LV RT (lnvitrogen, UK)], 
50mM of dithiothreitol [DTT (Invitrogen, UK)] and 1.5 III of 
deoxyribonucleotide triphosphate (dNTP) mix. In RT negative (RT -) samples, 
water was added to replace the enzyme. The master mix was added to each 
sample up to a final volume of 50 III and incubated at 37°C for 1 hour followed 
by 10 minutes incubation at 95°C. 
2.6 Quantitative real time PCR (Q-PCR) 
Primers for real time PCR were designed by the Primer 3 (web version 0.040) 
programme and targeted at exon-exon junctions. PCR amplification was done 
using a SYBR green 11 (reporter dye) based assay (Stratagene). The reaction 
mixture consisted of 12.5 III of IX SYBR Green Master Mix (Stratagene, UK), 
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1 JlI of each forward and reverse primer (final concentration of 250nM), 0.38 JlI 
of ROX (reference) dye and 5JlI of DNA template (lOng/5JlI). Cycling 
conditions were 10 minutes denaturation at 95°C followed by 40 cycles of: 30 
seconds denaturation at 95°C; 30 seconds annealing at a temperature according 
to the primer used (see table 2 below); 30 seconds extension at 72°C and a final 
melt for 60 seconds. The reaction was conducted using a thermal cyeler 
(MX3005P Stratagene, UK) and data analysed by Mxpro-QPCR software 
version 3.20. A standard curve was generated using serial dilution of neat 
cDNA. No template control (NTC) without any cDNA and no RT (RT-) 
control without reverse transcriptase enzyme were used with every reaction. 
Table 2.2 Primers used for real time peR 
Gene Forward primer (FP) (5'-3') Annealing Amplicon 
Reverse primer (RP) (5'-3') Temp (oCl size (bp) 
SLC29AlI AGCCAGGGAAAACCGAGA 55 95 
ENT 1 ACCCAGCATGAAGAAGATAAGC 
HPRT AAATTCTTTGCTGACCTGCTG 60 122 
TCCCCTGTTGACTGGTCATT 
STAT-3 AGTTTCTGGCCCCTTGGATT 58 118 
AAGCGGCTATACTGCTGGTC 
VAP-A CAACACCTGCCAGTTATCACAC 58 133 
GGCATAGGTCCATCTTGCTT 
ACTN-l AAATCGTGGATGGGAATGTG 52 150 
CATTTTTGTAAGGGGCTGTCTT 
ApoB-100 GGGCATGGATATGGATGAAG 60 111 
CGGACCCTCAACTCAGTTTT 
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2.7 Flow cytometry and GFP expression: 
Single cell suspension for flow cytometry was prepared by trypsinising cells 
using low EDTA (Lonza). The cell pellet was washed twice and resuspended 
into Ix PBS. Half of the samples were analysed by Beckman Altra to assess 
GFP expression whereas the rest was used for protein extraction. At least 
10,000 events were collected per sample (usually 50,000 cells) and flow 
cytometric analyses were performed using an EPICS Altra Flow Cytometer 
(Beckman Coulter, Buckinghamshire, UK). Data were analysed using WinMDI 
version 2.9 (Joseph Trotter, Scripps Institute, La Jolla, CA, USA) and 
expressed as mean fluorescence intensity (MFI). Dead cells were excluded 
from analysis according to their forward and side scatter characteristics. 
2.8 Protein extraction and quantification: 
Culture medium was aspirated and cells were washed with cold PBS (IX). 
Lysis solution consisting of RIP A buffer (Thermo scientific) and 1 % protease 
and phosphatase inhibitor cocktail (Thermo scientific) was added to cells and 
incubated for 30 minutes on ice. The cell suspension was then transferred to ice 
cold ependorf tubes and spun in a pre-cooled centrifuge at 13,000 rpm for 30 
minutes. The supernatant was transferred to fresh tubes and aliquots stored at -
20°C until use. Protein quantification was performed using the Pierce® BCA 
Protein Assay kit (Thermo scientific) following the enclosed manual 
(microplate procedure). 
2.9 SDS-PAGE gel and Western blotting: 
10-30 ).1g of protein lysate was treated with 4X SDS loading dye [100mM Tris-
HCI (PH 6.8), 200mM DTT, 4% SDS, 0.2% glycerol and 0.2% bromophenol 
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blue] supplemented with 5% ~ - m e r c a p t o e t h a n o l . . Samples were boiled for 5 
minutes at 95°C in a heat block, and then electrophoresed using 10% SDS-
PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) at 
30mAlgel. Gel composition and preparation method is given in Appendix 8.2. 
Proteins were transferred to a PVDF membrane (Amersham Hybond-P PVDF 
membrane, GE Healthcare, UK) using a semi-dry transfer method at 60mA for 
2 hours. The membrane was incubated in blocking buffer consisting of 5% 
dried milk dissolved in Tris-buffer saline (TBS) with 0.1 % Tween-20 (Sigma) 
for 1 hour at room temperature. Immunoblotting was performed by incubating 
the membrane with mouse monoclonal antibodies for ApoB-l 00 (l :200, Santa-
Cruz Biotechnology), STAT-3(1:50, Abeam), VAP-A (1:500, Abnova) and 
ACINI (l: 100, Abeam) overnight with rolling at room temperature. The 
membrane was rinsed with wash buffer (TBS with 0.1 % Tween-20) three times 
for 5 minutes each and was exposed to horse-raddish peroxidase (HRP) 
conjugated secondary antibody for 1 hour at room temperature. Bands were 
visualized using an Enhanced Chemiluminescence detection kit (Supersignal 
West Pico Chemiluminescent Substrate, Thermoscientific, UK) and exposed to 
X-ray film (Kodak, UK). 
2.10 Isolation and culture of primary human hepatocytes 
Composition and preparation of all the solutions and culture media used in this 
procedure are given in Appendix 8.1. Primary human hepatocytes were isolated 
by a modified two step Collagenase perfusion method described previously 
(Gottschalg et aI., 2006). Briefly, equipment was set up in a class 11 safety hood 
and pump speed was set up at 50rmp. Perfusion channels were sterilised by 
recirculating with 70% ethanol (Sigma) followed by lL of sterile water. 
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Hepatocyte isolation medium and solutions were pre-warmed at 43°C and 
perfusion buffers were also aerated with carbogen (95% Oxygen plus 5% 
Carbon-dioxide). Liver tissue was flushed well with diluted Soltran solution in 
order to remove any blood clots. About 500ml of buffer I was flushed at a 
speed of 45rpm to set up flow. Once the perfusion was established (indicated 
by change in temperature and colour of liver tissue), the liver was perfused 
with IL of buffer I (contains EGTA to break cell-cell interaction). Buffer 2 
(No EGTA) was then flushed to remove any EGT A before shifting to buffer 3 
which was recirculated for approximately 20 minutes. Buffer 3 contains 
collagenase which destroys cell-matrix interactions. Once the liver tissue was 
softened, cells were released by teasing digested tissue with blunt forceps 
placed in a petri dish containing isolation medium. The resulting cell 
suspension was filtered through a nylon membrane and centrifuged at 50g for 5 
minutes. Hepatocytes were pelleted and supematant was removed. The cell 
pellet was resuspended in isolation medium containing 90% Percoll solution 
(3: 1 ratio) and centrifuged at 100g for 10 minutes. The supematant containing 
dead cells was discarded and cells were dissolved in cold hepatocyte plating 
medium. Cell number and viability were assessed by Trypan blue (TB) 
exclusion. An equal volume of cell suspension and TB were mixed and placed 
on a 0.0025mm2 haemocytometer (Sigma, UK) under a glass cover slip. Dead 
cells (blue) were subtracted from the total cells (yellow) and the percentage 
calculated as viability. A viability of -85% was considered necessary to 
proceed. Cell cultures were maintained at 37°C in a humidified atmosphere 
containing 5% C02. Donor infonnation for human liver used is given in Table 
2.3. 
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Table 2.3 Human liver donor information and cell viability 
Liver Sample Age Sex Cell viability Additional information 
# ID (years) % 
Liver I L89/101N 67 M 89 right Hepatectomy 
Liver 2 L90/101N 82 M 84 -
Liver 3 L93/101N 70 M 85 Liver resection VIINIII 
Liver 4 L96/101N 74 F 87 -
Liver 5 LIlO/lOIN 66 M 86 Left Hepatectomy 
Liver 6 LIll/IOIN 64 F 85 Left Hepatectomy 
2. 11 Ribavirin and interferon alpha treatment 
Ribavirin solution was prepared by dissolving 10mg of powder (Sigma, UK) in 
10 ml of water to obtain a concentration of Img/ml. The required volume of 
drug was added to the cell culture medium at a final concentration of 
121lMlwell as found in patients receiving therapy (Tsubota et aI., 2002) and 
cells were incubated for 24hours. Recombinant human interferon alpha-2a 
(Roferon - A, Roche) was obtained as a solution and was added either alone or 
in combination with ribavirin at a final concentration of 5000pg/ml (Lopez-
Cortes et aI., 2008). Parallel samples were taken for HPLC, RNA and cell 
viability after 4, 8 and 24 hours. 
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2.12 High performance liquid chromatography (HPLC) 
2.12.1 Sample preparation (Cell lysis and enzyme diges 
tion) 
Culture medium was aspirated and cells were detached using trypsin-EDTA 
solution (Lonza). The resulting cell suspension was centrifuged at 250g for 5 
minutes to pellet. Cells were lysed by adding 2% Triton X-lOO (Sigma) in PBS 
and vortexing the tubes for 5 minutes until no cell debris were visible. After 
centrifugation at IOOrpm for 5 minutes, the supematant was transferred to fresh 
tubes and stored at -20°C. About 200J.lI of stored cell suspension was treated 
with 300J.lI of 30 J.lM Tris-HCL buffer (PH 7), 25 J.lI of IM sodium acetate 
(Sigma) pH 4.0 and 2.5 J.lI of Acid phosphatase type IV from sweet potato (500 
Units, Sigma) after incubation at 37°C for I hour. The best incubation time and 
concentration of enzyme was determined by monitoring the ribavirin peak at a 
time course of 30, 60, 90 and 120 minutes with a plateau achieved at 60 
minutes. The reaction was stopped by adding 2.5 J.lI of KOH (10M) and 
spinning the tubes to collect the supematant which was then used for column 
extraction. 
2.12.2 PBA column extraction 
Phenylboronic acid cartridges (PBA Bond Elute, Varian) were used to remove 
any impurities from HPLC samples. Cartridges were positioned on a 10 port 
vacuum elution manifold under reduced pressure and washed with Iml of 
methanol containing 0.5% v/v H3P04 (pH=2) and 2ml of Ammonium 
phosphate buffer [(NH4)H2P04 (250mM, pH8.5)]. Samples treated with 
Ammonium phosphate buffer [ ( N ~ ) H 2 P 0 4 4 (250mM, pH8.5)] and 2.5 J.lI 
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(Img/ml) of internal standard (3-methylcytidine methosulfate) were applied to 
the column and washed with 3 ml of Ammonium phosphate buffer 
[(NHt)H2P04 (250mM, pH8.5)] and 2ml of methanol. Finally, ribavirin and the 
internal standard were eluted into glass tubes with 2 ml of methanol containing 
2.5% formic acid. The effluents were dried under nitrogen gas and 
reconstituted in 200 JlI of water. Twenty microliter aliquots of reconstituted 
samples were injected onto the HPLC column. Preparation and composition of 
all the solvents and buffers is given in Appendix 8.3. 
2.12.3 Chromatographic conditions: 
The HPLC system used was HPI050 with a four channel pump, an 
autosampler and UV detector operating at a wavelength of 207nM. Drug 
separation was done at room temperature using an Atlantics dC18 column 
(3Jlm, 150 x 4.6mm, Waters), coupled to a Guard column: AtIantics dC18 3Jlm 
(20mm x 4.6mm, Waters). The mobile phase consisted of 10mM Ammonium 
phosphate buffer after adjusting the pH to 6.5 using 10M NaOH. The flow rate 
was maintained at 1 mVmin. The HPLC assay is further described in Chapter 5 
(section 5.1.1.3) and Figure 5.2 shows a schematic representation of the HPLC 
set up. 
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2.13 Analysis of Huh7 ENT1 gene sequence 
2.13.1 peR amplification of ENT1 coding sequence 
The Hub7 cell line was cultured in DMEM based culture medium (appendix 
8.1) followed by RNA extraction and cDNA synthesis as described before. The 
amplification primers (MWG-BiotecH AG) for the ENTl coding sequence 
were designed manually and had the following sequence: 
Forward primer: 5'-ATGACAACCAGTCACC- 3' 
Reverse primer: 5'-TCACACAATTGCCCGGAACAGG-3' 
1I1Oth of the cDNA reaction mixture was amplified using Phusion (Pfu) high-
fidelity DNA polymerase (Finzyme, NEB, UK) to produce a blunt ended PCR 
product following the manufacturer's instructions. The PCR reaction contained 
primers at a final concentration of 500nM and was performed in a thermal 
cyder (Perkin Elmer GeneAmp peR system 2400) under the following 
conditions: Initial denaturation at 98°C for 30 sec followed by: 40 cycles of 
denaturation 98°C for 10 sec, Annealing 60±lO°C (gradient) for 15 sec and 
extension 72°C for 90 sec, followed by a final extension at 72°C. At an 
optimal annealing temperature of 62.l oC, there was a single product of the 
right size (l.3kb). The PCR product was purified by column filtration using the 
QIAquick PCR Purification Kit (Qiagen) following the manual's instructions. 
DNA was visualised by agarose gel electrophoresis and quantified by 
NanoDrop. 
2.13.2 Agarose gel electrophoresis 
A 2% agarose gel was prepared by dissolving 2g of Agarose powder (Gibco-
BR Life technologies, USA) in 100ml of IX Tris Acetate-EDTA (Oh and Park) 
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buffer (Sigma Aldrich) and heating for 3 minutes in a microwave. The gel was 
allowed to cool at room temperature (RT), and after addition of Ethidium 
bromide (EB) at a concentration of 0.5Jlglml, it was poured into a casting 
apparatus to set. The running gel buffer consisted of 1 xT AE and contained EB 
as a visualising dye. Samples were prepared by adding 2JlI of loading dye to 
5JlI of PCR reaction and loaded on to the gel in parallel with a 10kb DNA 
marker (GeneRuler DNA Ladder mix, Fermentas). Electrophoresis was 
performed at 100v for 45 minutes and bands were visualised under an 
ultraviolet light transilluminator. 
2.13.3 Cloning of ENT1 into pCR® 2.1-TOPO® TA cloning 
vector 
The plasmid vector pCR® 2.1-TOPO® has single 3' deoxythymidine (T) 
residues which permits ligation with deoxyadenosine (A) at the 3' ends of the 
PCR product. As Phusion polymerase generates blunt ended PCR products, 
Taq DNA polymerase (Fermentas) was used to add single adenosines to the 3' 
end of the PCR products. About lOng of the resulting template was used to set 
up a ligation reaction (final volume 6 Jll) containing TOPO vector as given in 
the manual and incubated at RT for 30 minutes. 
Transformation was performed by adding 2JlI of the cloning reaction to a vial 
of TOPI0 chemically competent E. coli (Invitrogen) and incubated on ice for 
30 minutes. Cells were then heat shocked for 45 seconds at 42°C in a heat 
block and immediately transferred back to ice for another 5 minutes. About 
250 JlI of sac medium (Invitrogen) was added to the tubes and incubated at 
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37°C for 1 hour with horizontal shaking at 200rpm. Lysogeny broth (LB) agar 
plates were prepared by dissolving 1.5 g of LB agar (Sigma) into 100ml water 
and heated in a microwave. After addition of 100Jlg/ml of Ampicillin, the 
mixture was poured into sterile petri dishes and left to set. The transformed 
bacteria were spread onto the agar plates containing X-gal (70ug/ml) and 
bacterial colonies containing plasmid allowed to grow overnight at 37°C. 
White colonies indicate the presence of both vector and insert, whereas blue 
colour colonies lack insert. 
2.13.4 Analysis of transformants 
Five white colonies were picked and allowed to grow overnight in LB culture 
medium (Sigma, UK) and ampicillin by gentle shaking at 37°C. Bacterial cells 
were collected by centrifugation and plasmid DNA was isolated by QIAprep 
Miniprep kit (Qiagen) following the steps given in the manual. DNA 
concentration and purity was checked by NanoDrop. Samples were submitted 
for sequencing using M13 forward and reverse primers supplied with the kit 
(Invitrogen). 
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Chapter Three 
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3 Effect of host gene silencing on replication of 
HCV subgenomic replicon 
3. 1 Introduction 
3.1.1 Gene silencing by small interfering RNAs (siRNAs) 
3.1.1.1 Mechanism of RNA interference (RNAi) 
RNA interference (RNAi) is a naturally occurring regulatory mechanism in 
which short double stranded RNA (dsRNA) mediates sequence dependent 
inhibition of a target gene by either degradation or blockage of the 
corresponding mRNA. The concept of RNAi was initially described in a 
nematode worm (Fire et aI., 1998). Two years later, the first evidence for the 
ability of siRNA to block expression of target genes in mammalian cells for 
therapeutic purposes, offered a novel tool to study gene function in vivo and 
develop gene specific therapeutics (Elbashir et aI., 2001). 
The principal players of the RNAi pathway are small interfering RNAs 
(siRNA). These are short double stranded duplexes derived either from the 
processmg of long dsRNA or exogenously introduced synthetic siRNAs. 
Figure 3.1 describes the siRNA pathway and its processing. Synthesis of 
siRNAs begins by entry of long dsRNA in the cytoplasm, followed by their 
cleavage by the endoribonuclease enzyme Dicer to give rise to approximately 
21-23 nucleotide long duplexes (Bernstein et aI., 2001). These siRNAs are 
loaded onto a ribonucleoprotein complex known as RISC. The catalytic action 
of Argonaute 2 (Ago-2), an endonuclease present in RISC, releases the 
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passenger strand (sense strand) from the duplexes resulting in activation of 
RlSC. The guide strand (anti sense strand) then binds to the target mRNA by 
perfect base matching resulting in its cleavage and gene silencing (Matranga et 
al. , 2005) . 
Figure 3.1 Mechanism of RNA interference by siRNAs 
Double stranded RNA or dsRNA (a) is cleaved by Dicer to produce short 
duplexes or siRNA (b) whjch are then unwound by a Helicase (c) into single 
strands (passenger or guide). The release of the passenger strand and binding of 
the guide strand to RISe (d) leads to its activation by Argonaute2 (Ag02) and 
degradation of target mRNA (e). Synthetic siRNAs skip the initial processing 
step (a) by Dicer. 
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3.1.1.2 Advantages and limitations of siRNA based gene 
silencing 
There has been an immense progress in the field of RNAi due to its potential 
therapeutic application and ability to act as a tool to understand protein 
function in biological systems. At present, a number of synthetic siRNA are 
under development to treat various human diseases like cancers and viral 
infections (Guo et aI., 2010, Lares et aI., 2010). However, various challenges 
need consideration before it can be applied in humans, such as off target effects, 
immune recognition, plasma stability and most importantly, efficient delivery. 
siRNA mediated gene silencing can be induced by means of viral or plasmid 
based vectors which, after being transcribed in the nucleus, are exported to the 
cytoplasm in the form of short hairpin RNA (shRNA) (Lares et aI., 2010). 
These are then processed by Dicer to produce siRNA duplexes similar to 
synthetic siRNA. The clear advantage of using this approach is that cells can be 
stably transfected to produce siRNA but the disadvantage is that viral based 
vector can cause immuno-toxicity and mutagenesis (Guo et aI., 2010). 
Another rather simple and convenient way is to directly transfect short 
sequences which by-passes Dicer's processing and can be repeated to achieve 
long term gene silencing (Jackson and Linsley, 2010). These siRNAs can 
potentially cause off target effects which could be either sequence dependent or 
due to immune responses. The former is due to base pair matching of 
nucleotides, which requires as few as eight nucleotides at the 3' end of the 
cellular mRNA to be complementary to the 5'end of the siRNA's guide strand 
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(Jackson et al., 2003). The latter effect is due to the presence of exogenous 
dsRNA molecules which are prone to recognition by immune cells; mainly via 
Toll like receptors (TLRs) resulting in production of inflammatory cytokines 
and up regulation of various IFN stimulated genes (Robbins et al., 2009). 
These can be overcome by improving siRNA design by various means like 
shorter length «30nucleotides), chemical modifications such as addition of a 
2'O-methyl group in the siRNA sense strand, avoiding certain GU rich motifs 
etc (Homung et al., 2005, Judge and Maclachlan, 2008, Robbins et al., 2009). 
Similarly, additions of 3' overhangs, as is the case with Dicer processed siRNA 
not only enhances gene silencing ability but also helps in evading the immune 
response (Marques et al., 2006). 
3.1.1.3 Delivery systems for siRNA 
Despite having some practical challenges in the use of siRNA, their therapeutic 
potential is very promising. In order to exert its action, however, synthetic 
si RNA needs to be transported to their target cells. An important prerequisite to 
achieve this is to devise a suitable delivery vehicle by means of which siRNAs 
can efficiently and specifically achieve mRNA knockdown. Carrier molecules 
for siRNA can be either viral based or non-viral, but the former are least 
preferred because of associated toxicity. Non-viral delivery of siRNA could be 
achieved by siRNA bound to a positively charged vector (e.g cationic cell 
penetrating peptides), siRNA conjugated with small molecules (e.g lipids), 
polymers, antibodies or siRNA entrapped in a nanoparticle formulation (Wang 
et al., 2010) 
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3.1.2 HCV replicons 
Several in vitro model systems have been developed to study HCV infection in 
vitro. One extensively used system is subgenomic replicons (SGRs) in which 
viral structural proteins (Core, Eland E2) are replaced by the neomycin 
phosphotransferase (neo) gene and are translated under the control of the HCV 
lRES. The non-structural proteins (NS3-NS5B) which are responsible for virus 
processing and packaging are under the influence of an IRES derived from the 
encephalomyocarditis virus (EM CV) (Blight et aI., 2003). 
SGRs derived from JFHI (Kato et aI., 2003), are found to be superior to other 
replicons from genotype 1 a (Blight et aI., 2000) or 1 b (Lohmann et aI., 1 999b) 
in terms of both colony formation under G418 selection or transient replicon 
assay without selection (Kato et aI., 2003, Targett-Adams and Mclauchlan, 
2005). Also, these replicons replicate efficiently in Huh7 cells without the 
requirement of cell culture adaptive mutations as is the case with other 
genotype based replicons. This system is useful in analysis ofHCV replication 
and protein function, but production of infectious virus particles is lacking. 
Wakita et af demonstrated that in vitro transcribed full length RNA from the 
JFHl genome cannot only replicate efficiently when transfected into Huh7 
cells but also be incorporated into virus particles which can infect naIve Huh7 
cells (Wakita et aI., 2005). 
A report by Target-Adams and John McLauchlan indicated development of 
such transient replicons based on the JFHl genome containing a Luciferase 
reporter instead of the neo gene (Targett-Adams and Mclauchlan, 2005). The 
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same group subsequently established a JFHI based SGR that includes a GFP 
tagged into the C-terminal of the NS5A protein (Jones et aI., 2007). A clear 
advantage of using this system was its simplicity and ability to act as a direct 
measure of viral RNA replication. In addition to its use in evaluating molecular 
mechanisms of HCV replication, subgenomic replicons can provide a useful in 
vitro system to test the efficacy of antiviral drugs (Randall and Rice, 2001). 
Figure 3.2 gives a schematic representation of subgenomic replicons derived 
from the full length JFH1 HCV genotype 2a genome. 
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Figure 3.2 Schematic diagram of the structure of JFHl (genotype 2a) HeV 
subgenomic replicons 
(A) Full length or wild type virus genome structure, (8) subgenomic (SG) di-
cistronic replicon carrying resistance gene (neo) for selection and EMCV lRES 
for translation of non-structural (NS) proteins, (C) SG replicon containing 
reporter protein (luciferase) replacing neo, (D) SG replicon carrying the green 
fluorescent protein (GFP) gene within the viral NS5A for detection of 
translation in infected cells, (E) Same as 0 but with a point mutation in the 
GDD motif to GND in S58 whjch abolishes the replicative ability of the viral 
RNA polymerase (N 58). 
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3.1.3 Nucleofector technology 
Intracellular entry of large exogenous nucleic acids requires physical methods 
of transfection, which is a process through which genetic material enters the 
target cell, enabling the expression of non-native proteins. Electroporation is 
an established transfection method based on use of an electric wave to induce 
changes in membrane potential causing pores. These temporary pores allow 
naked nucleic acids present in the buffer solution to enter the cells. The ionic 
composition of the electrophoretic solution affects the passage of current and 
its effect on the cell membrane. The nucleofector technology is a specialised 
electroporation system combining specific buffer solutions and an 
electroporation device (Nucleoporator® Amaxa®, AG, Germany) that delivers 
specifically optimised electrical parameters. It has the dual advantage of being 
able to produce efficient transfection (even for difficult to treat cell lines like 
primary cells) without causing massive cell damage. As this technique is 
independent of the type of nucleic acid being transfected, the same protocols 
can be used for delivery of any type of nucleic acid (DNA, RNA or siRNA). 
3.1.4 RN Ai based therapies for human diseases 
The potential benefit of siRNA to act as a therapeutic tool instigated a drive to 
identify possible disease targets. Since its first demonstration as an inhibitor of 
vascular endothelial growth factor in patients with acute macular degeneration 
(Bevasiranib), it became apparent that any human disease can be targeted 
(Mousa and Mousa, 2010). Some of its noteworthy applications entering 
clinical trials belong to eye disorders, cancers, inflammatory diseases and viral 
infections (Lares et aI., 2010). Human immunodeficiency virus (HIV), 
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respiratory syncytial virus (RSV) and HCV are some of the viruses where 
utility of si RNA as an antiviral has been demonstrated (Ali Ashfaq et aI., 2011, 
Liu et aI., 2009, Zhang et aI., 2005). 
Use of single siRNA to target viral infection is associated with development of 
resistant mutants and necessitates combination of multiple siRNAs (Liu et aI., 
2009). Targeting cellular genes involved in virus replication is therefore an 
attractive alternative to circumvent resistance and has been demonstrated to 
work well for difficult targets like HIV (Zhang et aI., 2007). A number of 
cellular targets have also been identified for HCV, and a few are making their 
way to the clinic. Cyclophilins involved in protein folding and trafficking are 
one of these, and are thought to play a role in virus replication by direct 
interaction with NS5A and altering viral protein folding and trafficking to the 
site of replication (Gaither et aI., 2010). Specific cyclophilin inhibitors, such as 
NIM811, have shown potency against HCV when used in combination with 
pegylated IFN (Lawitz et aI., 2011). 
3.1.5 siRNA based therapies for HeV 
Hepatitis C virus infection poses a huge disease burden due to its chronic 
nature and a treatment regimen which is ineffective in half of the patients 
receiving it (Manns et aI., 2001). The exact underlying mechanism for the 
limited success of pegylated IFN and ribavirin remains obscure but various 
viral and host related factors have been implicated (Feld and Hoofnagle, 2005). 
There is a major need to develop new antiviral targets which can be combined 
with current therapy to improve its success (Mchutchison et aI., 2006). Drug 
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targets aiming at the virus itself have gained considerable popularity and some 
of them have already entered clinical trials (Jazwinski, 2011). 
Since the first demonstration of ability of the siRNA to knock down gene 
expression in mammalian cell cultures, virologists have been striving to show 
its efficacy as an anti-HCV agent (Elbashir et aI., 2001). Co-localisation of 
viral replication and siRNA duplexes into the host cell cytoplasm further 
enhances the utility of this system to knock down viral replication (Randall et 
aI., 2003). Similarly, siRNA targeting each step of the viral replication and 
various sites within the viral genome including the 5' UTR, Core, NS3, NS4B 
and NS5B have been tested for their efficacy (Ashfaq et aI., 2011, Jazwinski, 
2011). However, a limitation of virally targeted drug could be emergence of 
drug resistant HCV variants in patients receiving this treatment arising as a 
result of the error prone nature of the HCV polymerase (Lin, 2010). Similarly, 
the majority of these siRNA based anti-HCV drug targets are less effective for 
variants other than those to which they are specifically targeted. To get around 
these hurdles, host genes involved in the viral replication cycle could be 
identified and targeted to knock down viral replication (Lin, 2010 #320). 
3.1.6 Role of host protein in HeV replication 
In HCV infection, hepatocytes are the principal site of viral replication and 
host cell factors are critical in every step of the virus life cycle. The full length 
HCV genome encodes for a large polyprotein (-3,000 amino acids long) which 
is processed by viral and host enzymes to produce structural (Core, El and E2) 
and non-structural proteins (NS2, NS3, NS4A, NSAB, NSSA and NSSB). The 
viral replication complex consisting of NS proteins and host proteins co-
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localise on cytoplasmic membranes derived from the endoplasmic reticulum 
(ER), called a membranous web or lipid raft associated membranous complex 
(Shi et aI., 2003). The precise role of various components of this complex in 
modulating viral replication is poorly understood. 
A number of host genes have been implicated in supporting virus replication 
within the infected cells (Ng et aI., 2007). Expression profiling studies of cells 
containing replicating HeV genomes have identified various pathways 
belonging to oxidative stress, lipid metabolism and vesicular trafficking to be 
significantly differentially regulated (Blackham et aI., 2010). Identification of 
these molecular pathways interacting with Hev will improve our 
understanding of the Hev replication cycle which will in turn aid in devising 
new anti-Hey drugs. Targetting siRNAs towards these cellular genes may also 
circumvent genotype resistance due to the high fidelity of host enzymes and 
reduce genotype specificity in response. Once validated, these can be combined 
with current treatment regimen and would help in improving response rates. 
A report by Blackham et al. highlighted involvement of proteins related to the 
cytoskeleton (e.g. ABLIM), regulation of secretory vesicles (e.g. RAB40B) and 
mediators of oxidative stress (e.g. TXNIP) indicating that knock down of these 
genes result in significant reduction in virus replication (Blackham et aI., 2010) 
Using a wide RNAi screen, Randall and co-workers identified a number of host 
gene interactions with HeV non-structural proteins including vesicle 
associated membrane protein (VAMP)-associated protein A (VAP-A), signal 
transducer and activator of transcription 3 (STAT-3) and alpha actinin 1 
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(ACTN1) (Randall et aI., 2007). The significance of these genes was tested by 
analysing the effects of gene knock down on viral replication and was shown to 
have a more than three fold reduction in production of infectious virus. 
3.1.6.1 Vesicle-associated membrane protein - associated 
protein A (VAP-A) 
Vesicle associated membrane protein (V AMP)-associated proteins or V AP 
proteins are ubiquitously expressed integral ER membrane proteins involved in 
diverse cellular functions like membrane trafficking, neurotransmitter release 
and lipid transport and metabolism (Lev et aI., 2008). In humans, V AP-A and 
V AP-B are the two main subtypes encoded by two genes where V AP-B has 
63% sequence homology to V AP-A and gives rise to an alternatively spliced 
variant i.e. V AP-C, composed of its N-terminal one third only (Nishimura et aI., 
1999). 
Studies have suggested that both V AP-A and B interact with NS5A and NS5B 
and facilitate viral replication in association with lipid rafts. Gao et al. reported 
that human V AP-A due to its intrinsic NS5A and NS5B ability helps the 
association of the viral replication complex to lipid raft membranes and 
knocking down V AP-A with siRNA inhibits HCV RNA replication (Gao et aI., 
2004). Another study suggested that hyperphosphorylation of NS5A prevents 
its interaction with V AP-A which negatively regulates virus replication (Evans 
et aI., 2004). A similar role has been reported for V AP-B in a report by 
Hamamoto et al. which suggested that V AP-B forms a complex with V AP-A, 
as well as binding to NS5A and NS5B, enhancing viral replication (Hamamoto 
et aI., 2005). A contrasting role has been reported for V AP-C. Using a co-
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immunoprecipitation assay, Kukihara et al. revealed that human VAP-C was 
capable of binding to NS5B but not NS5A, due to the absence of the C-
terminal part of the protein or the NS5B binding site, and negatively regulated 
HCV replication through interfering with V AP-A and B binding to NS5B 
(Kukihara et aI., 2009). They also showed that V AP-C was not expressed in 
liver which may suggest that its absence may partly account for the tissue 
tropism ofHCV. 
3.1.6.2 Signal transducer and activator of transcription 3 
(STAT-3) 
STAT -3 is one of the seven members of the ST AT family involved in the 
JAKlSTAT signalling pathway activated in response to various stimuli like 
interferon, interleukins and growth hormones (Schindler et aI., 2007, Zhang et 
aI., 2011). ST AT -1 and -2 are downstream of interferon signalling pathways 
activated in response to viral infection like HCV and induce expression of 
various interferon stimulated genes culminating in an anti-viral state within 
hepatocytes (Chevaliez and Pawlotsky, 2007, Durbin et al., 1996, Park et al., 
2000a). 
STAT-l and STAT-3 have distinct target genes and, depending on duration of 
activation or the cell type involved, display contrasting roles in related 
biological processes like inflammation, tumorigenesis and survival/growth 
(Regis et aI., 2008). As opposed to STAT-l, STAT-3 is an oncogene 
considered to favour cell survival and inhibits apoptosis. Its constitutive 
activation leads to cellular transformation (Azare et aI., 2007). However, the 
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specific function that this molecule exerts appears to be dependent on the 
specific pathological or physiological environment as it is found to be pro-
apoptotic in normal tissues like mammary gland and bone marrow (Chapman 
et aI., 1999, Lee et aI., 2002). Also, in contrast to STAT-1, STAT3 mainly acts 
as an anti-inflammatory factors and it is likely that the relative abundance of 
these molecules will determine the fate of many cells. The role of ST A T3 in 
the case of viral infection is currently unclear. Interaction of HCV core protein 
with ST A T3 has been implicated in its activation and cellular transformation 
(Yoshida et aI., 2002). Similarly HCV induced oxidative stress has been 
associated with activation of cellular kinases and activation of transcription 
factors like STAT3 and NF-KB (Gong et aI., 2001). 
3.1.6.3 Alpha actinin 1 (ACTN1) 
Alpha actinin is an actin binding cytoskeletal protein ubiquitously expressed in 
both muscle and non-muscle tissues. There are four main isoforms classified as 
muscle alpha actinins (3 and 4) and non-muscle alpha actinin Cl and 2) (Dixson 
et aI., 2003). The former group mainly function as cytoskeletal proteins 
providing shape and stability, while the latter group additionally provides a link 
to various transmembrane proteins and receptors (Otey and Carpen, 2004). 
ACTNl and ACTN4 share 80% nucleotide homology but a different 
subcellular localisation. ACTN4 mainly exists in the cytoplasm and nucleus 
while ACTNl is plasma membrane associated (Honda et aI., 1998). The 
different location within intracellular compartments may suggest a distinct 
function for these two isoforms. The exact function and localisation of these 
isoforms in human liver is currently unclear. Some reports have indicated their 
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presence on parenchymal and ductal cells of liver (Inada et aI., 2008) and 
interaction with NS5B (Lan et aI., 2003). 
To explore whether these potential HCV co-factors can act as functional anti-
HCV targets, this study focuses on evaluating effects of silencing these 
molecules on virus replication using a subgenomic replicon model and siRNAs. 
Use of pre-designed stealth siRNAs (Invitrogen) combines the advantage of 
efficient gene silencing and low toxicity with high specificity and no off-target 
side effects. Once validated, these anti-viral drug targets can be either used 
alone or as an adjuvant therapy for patients not responding to conventional 
regimens. 
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3.2 Aims: 
The specific aims of this part of study were to assess the potential utility of 
modulating host gene expression as a therapeutic tool in HeV infection. The 
majority of the host proteins targeted interact with hepatitis C virus non-
structural proteins (Randall et aI., 2007), so a subgenomic replicon was used to 
evaluate changes in viral replication after knocking down these targets by: 
• Preparation of high quality subgenomic replicon RNA derived from 
JFHI 
• Assessment of optimal nucleofection conditions for JFHI 
• Testing gene silencing ability of selected duplexes 
• Optimising nucleofection condition for siRNAs 
• Co-transfection of duplexes with viral RNA and validation of gene 
silencing 
• Monitoring the effects on viral replication by measuring GFP 
expression. 
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3.3 Results: 
3.3.1 Preparation of replicon RNA 
In this study, a subgenomic replicon based on JFHl genotype 2a virus was 
used as a model system to study virus replication in vitro and analyse effects of 
host gene silencing. Plasmid pSGR-LUC-GFP-JFHl (JFHl) and a replication 
incompetent control plasmid pSGR-LUC-GFP-JFHI-GND (GND) were used 
as a template to generate replicon RNA by in vitro transcription (IVT). 
Plasmid linearization was done by restriction digestion using the enzyme XbaI 
as shown in Figure 3.3 (A). Linearised plasmid was then subjected to mung 
bean enzyme digestion to clean overhangs followed by column purification to 
yield neat DNA template (Figure 3.3, B). Replicon RNA was in vitro 
transcribed and after a number of optimisations, high quality RNA was 
obtained as detennined by agarose gel analysis. Figure 3.3 (C) gives a 
comparison between intact vs. degraded RNA. Agarose gel electrophoresis was 
repeated every time to ensure RNA quality was not compromised (Figure 3.3, 
D) and only high quality RNA was used in all the experiments. 
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Figure 3.3 Example images of JFHl plasmid DNA or RNA as analysed by 
ethidium bromide gel electrophoresis. 
Nucleic acids (DNA or RNA) were visualised on agarose gels after every step 
to ensure high quality (A) undigested or circular plasmid DNA (lane 1) vs. 
Xbal digested JFHl (lane 2) and GND (lane 3). Note that undigested plasmid 
has a close circular structure so it migrates a little faster than its linearised 
counterpart. (B) Mung bean treated and phenol chloroform extracted JFH 1 
(lane 4) and GND (lane 5) DNA, (C) example of degraded RNA (lane 6-9) 
illustrated by smearing produced by multiple randomly sized small RNA 
fragments as a result of RNase activity. Intact Huh7 cell line total RNA (lane 
10) is shown for comparison having two distinct 28S and 18S ribosomal bands. 
(D) High quality in vitro transcribed replicon RNA, JFHl (lane 11 ,), GND 
(lane 12) and IVT positive control (13) . 
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3.3.2 Nucleofection of replicon RNA 
In this study, nucleofection was used as a mode oftransfecting both viral RNA 
and siRNAs. A number of optimisations steps were required to achieve 
transfection conditions which would produce optimal JFHl expression in the 
Huh7 cell line with minimal cytotoxicity. Once validated, the same protocol 
was used for co-transfection. 
Nucleofection was initially attempted by using a control RNA derived from the 
phMGFP expression plasmid (Promega) following the same steps as for JFHl 
replicon RNA synthesis. Huh7 cells were nucleofected with control RNA using 
different programmes from the nucleofector device (there are a number of pre-
recorded programmes with different electrical parameters generated by the 
nucleofector device). Cells were then subjected to flow cytometric analysis for 
GFP expression after 24 hours. Figure 3.4 outlines work stages for a typical 
transfection experiment performed in this study. 
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Step 1 Harvest Huh cells + Replicon RNA +/- Duplexes 
D 
Skp 2: Nucleorect using Amaxa nucleorector kit and device 
• 2 million 
• T -020 Programme 
• RPM! mediwn 
! 
Solution T 
D 
Step 3: Flow cytometry to analyse GFP expression 
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Figure 3.4 Work stages for a typical transfection procedure 
Step 1: About 2 million Huh7 cells and 1 0 ~ g g of replicon RNA were prepared 
in 100 ul of buffer olution with or without gene specific duplexes (M = 
marker, lane 1 = JFHl RNA, lane 3 = IVT positive control). Step 2: Cells were 
permeabilised by an electric current generated by the nucleofector device using 
an appropriate programme and specialised buffer solution. Step 3: Cells were 
transferred to plates and GFP expression is analysed after selected time points 
(e.g. 72 hour post electroporation). 
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Transfection efficiency was expressed as a percentage of positive cells above 
baseline fluorescence (mock transfected cells). Cell viability was determined 
by trypan-blue exclusion test and subtracting dead cells (floating in culture 
medium) from total cells (attached to plates) Inumber of plated cells (-2 
million) x 100 after 24 hours. As given in the table in Figure 3.5 (A), all tested 
programmes were associated with cell viability of more than 90% but T -020, 
T-030 and T-014 were chosen as they also had superior transfection efficiency. 
Nucleofection was then performed by means of these three programmes using 
10 Jlg ofreplicon RNA (JFHl) and GFP expression was measured at 72 hours. 
As illustrated in Figure 3.5 (B), the T-020 and T-030 programmes were found 
to have comparable efficiency of - 35 % but T-020 was chosen as it also had 
higher cell viability. A time course and dose response experiment was done as 
illustrated in Figure 3.5 (C and D). In terms of quantity, lOJlg of input RNA 
was clearly better than 5 Jlg as it doubled the % of positive cells (from 10% to 
22%) but, increasing it further to 20 Jlg did not improve it significantly. Time 
course experiments proved that JFHI replication efficiency is greatest at 72 
hours post nucleofection. These optimal conditions were used next for co-
transfections. 
114 
ProglOmme Cell VlOblhty TransfectJ.on eff'lclency fOJ TransfecIJon eff,ciency for 
(%) phIl.1GFP ('Yo) JFHI (%) 
T·020 985 1726 35 19 
T·030 97 160& 36.75 
A T·0 14 96 1024 3120 
A'()20 98 073 
X·OO5 92 423 
X·OOI 98 467 
No programme control 99 
1 •• ? 1'1'111. TO,. l';:'h 
3 
! 
::-'0 
r 
L 
'" ~ ~
B ~ ~
F'S l., 
e 
e JS 19': . 2 e 
~ · 6 6 ~ ~~ ' 6 6
~ ~ r 
Go ~ ~
'" 
e ~ ~
~ ~
'Slln 
" )() 
,. ,. 
: 
~ ~ ,. " 
C 
r D , 
" Ii .0 
f 
•• e 
< 
,. ., 
'0 
TIme ( I ~ ~ e e tl'\Ot.w 1 
" put ,N & '110' 
Figure 3.5 Optimi ation of nucleofection procedure 
Optimal tran fection conditions for replicon RNA were determin d by testing 
different programme as w 11 a varying amount of input RNA; (A) Table 
illu trating cell viability and tran fection efficiency for different nucleofector 
programme, both for control RNA (phMGFP) a well a replicon RNA (JFH1); 
(B) Dot plot demon trating percentage of Huh7 cell expre ing GFP (y-axi ) 
in un-transfected (I) or nucleofected cell by different programme , (2) T -020, 
(3) T-014 and (4) T-030; ( ) Graph showing percentage ffiei ne of JFHI 
replication (y-axi ) as a result of different amounts of input RNA in Ilg (x-axi ); 
(D) Graph howing perc ntage efficiency of JFHl r plication (y-axi ) plotted 
again t variou time point po t-electroporation (x-axi ). 
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3.3.3 Validation of siRNA duplexes by Lipofectamine2000 
Small interfering RNAs (siRNA) designed to target selected host genes were 
tested to verify their ability to silence target genes in this cellular environment. 
Pre-designed stealth siRNAs were obtained from Invitrogen (BLOCK-iTTM) 
and used at a final concentration of 100nM. Huh7 cells were transfected with 
duplexes by means of a commercial reagent Lipofectamine 2000 (invitrogen) 
following the manufacturers ' instructions (siRNA sequence is given in 
materials and methods). At 48 hours post-transfection, Q-PCR and western blot 
were performed to analyse knock down at the rnRNA and protein level 
respectively. 
For real time PCR, RNA extraction and cDNA synthesis was performed as 
detailed in materials and methods. PCR primers were designed with the help of 
the Primer3 programme (version 0.4.0) targeting exon-exon junctions and 
specificity was checked with pnmer blast 
(http ://www.ncbi .nlm.nih.gov/tools/primer-blastD. Optimal primer annealing 
conditions were achieved by doing a gradient PCR with a temperature range of 
60±IODC and the temperature which gave maximum amplification 
subsequently used (primer sequence and optimal annealing temperature are 
given in materials and methods). A standard curve was prepared by serially 
diluting neat cDNA in order to ensure best PCR efficiency (range = 100±15%). 
As depicted in Figure 3.6, the standard curve shows exponential amplification 
with efficiency of 85%, 99%, 106% and 98% for STAT-3 , VAP-A, ACTNI 
and HPRT primers respectively. The melting curve confirmed specificity of all 
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primer paIrs by producing a single peak for the desired amplicon and no 
additional peaks were seen which may appear due to the presence of 
contaminating DNA and primer dimers. Non-template control (NTC) and no 
RT (RT negative) prepared without cDNA template and enzyme in the cDNA 
synthesis reaction respectively were used with every run. The melt curve also 
demonstrated that there was no amplification in NTC and RT negative control 
(baseline). 
STAT3 
VAPA 
ACTN1 
HPRT 
Standard curve 
s .. 
Melting curve 
Figure 3.6 Real time peR plots for STAT3, YAP-A, ACTNl and HPRT 
primer pairs. 
The Standard curve shows change in cycle threshold (Ct on y axis) of 1 with 
every cycle in a 2 fold dilution series (x-axis) and an R2 value close to 1. 
Melting curve demonstrates that every primer pair generated a single product 
and absence of contaminating products which may give rise to additional peaks 
separate from the desired amplicon. No amplification in the NTC and RT 
negative controls is observed (baseline in the melt curve). 
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To ascertain knock down efficiency of these duplexes by real time PCR, gene 
expression was quantified in unknown samples treated with either gene specific 
siRNA or a scrambled control and levels were normalised to the house keeping 
gene HPRT. As shown in Figure 3.7, when compared to scrambled control, 
gene specific duplexes reduced the mRNA level of their respective genes, 
albeit to different degrees. The silencing efficiency was -99% for STAT-3, 
90% for V AP-A and 85% for ACTNI mRNA as compared to that in the 
scrambled control. 
Parallel samples were taken at 48 hours for Western blotting to determine 
knock down at the protein level. Protein extraction followed by quantification 
was performed as detailed in materials and methods. About 10-30 J..Lg of protein 
were separated on a 10% SDS-P AGE gel and imrnuno-blotted with specific 
monoclonal antibodies. Blots were analysed visually and as shown in Figure 
3.7, when compared to control samples; there was almost 90% and 50% 
reduction in STAT -3 and V AP-A protein expression while no significant 
difference was observed for ACTNl. It was hypothesised that ACTNl has a 
long protein half life masking any knock down by Western blot. p-actin was 
used as a loading control and showed equivalent protein levels in parallel 
samples. 
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Real time peR Western blot 
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Figure 3.7 Validation of gene knock down by siRN A (48 hour) 
Gene knock down was performed by 100 nM of gene specific siRNA using 
Lipofectamine2000 and analysed at 48 hours_ For real time PCR, mRNA 
quantification was done using Maxpro software (stratagene) and STAT-3 (A), 
ACTN1 (B) and VAP-A (C) mRNA levels were normalised to HPRT (house 
keeping gene)_ The ratio of specific gene vs. HPRT quantity in nanograms is 
plotted on the y axis_ Bars represent mean and error bar depicts standard 
deviation_ For Western blots, total proteins harvested from parallel samples 
were separated on a 10% SDS-PAGE gel followed by transfer to nitrocellulose 
membrane_ Specific monoclonal antibodies were used to detect each of the 
target proteins and ~ - a c t i n n which was used as a loading control. 
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3.3.4 Optimal nucleofection conditions for duplexes 
In order to assess the importance of host genes in virus replication, 
nucleofection was used for co-transfection of siRNA and viral RNA. To ensure 
that the duplexes can be successfully transfected by this technique and to 
ascertain best concentration of siRNAs, elecroporation conditions were 
optimised. Conditions which produced efficient replication of the subgenomic 
replicon were used to carry out a dose response experiment using a range of 30 
to 500nM si RNA to find the optimal siRNA concentration for use in co-
transfection experiments. Following nucleofection, cells were plated and 
incubated for 72 hours before protein extraction to analyse gene silencing by 
Western blot. 
Figure 3.8, shows that STAT-3 and ACTNI were successfully inhibited at 
200nM (final concentration of siRNA per well) while for YAP-A, there was no 
significant reduction in protein expression at all doses tested. Previous analysis 
at 48 hours demonstrated protein knockdown. It was hypothesised that higher 
protein turn over could replenish any reduction in protein levels if it is left for 
72 hours so the knock down experiment was repeated at 48 hr and showed 
significant reduction in V AP-A protein expression (see section 3.3.5.2 and 
Figure 3.11). p-actin expression was consistent in all samples tested in parallel. 
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Figure 3.8 Dose response for gene silencing by nucleofection (72 hours) 
Gene specific siRNA as shown and respective scramble control siRNA were 
transfected at different doses (final concentration per well). Appropriate 
nucleofection conditions were used to deliver siRNA into Huh7 cells and 
samples were collected at 72 hours to assess knock down efficiency by westem 
blot. 1O-30)lg of protein was separated on a 10% SDS-PAGE gel and immuno-
blotted using specific antibodies. ~ - a c t i n n was used as a control to exclude 
loading artefacts. 
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3.3.5 Co-transfection of duplexes with the JFH1 replicon 
3.3.5.1 Analysis of GFP expression by flow cytometry 
The subgenomic replicon plasmid used in this study has a green fluorescent 
protein (GFP) fused to the NS5A. Therefore, green fluorescence was used as an 
indirect measure of viral replication and translation. Optimised nucleofection 
conditions (10 J..lg RNA and the T-020 programme) and GFP expression was 
measured at 72 hour post-electroporation. 
A number of experimental controls were used to ensure optimal efficiency of 
the procedure and make sure that conclusions drawn from the RNAi 
experiment were valid. These were: (1) Mock transfected cells treated with 
identical transfection conditions but without any viral RNA or siRNA duplexes; 
(2) GFP (DNA) positive control cells treated with a DNA plasmid 
(pmaxGFPTM) encoding GFP protein; (3) Positive siRNA control cells treated 
with positive control plus siRNA targeting GFP (4) Negative siRNA control: 
cells treated with positive control plus scrambled control siRNA (GFP) (5) 
JFHl alone cells treated with subgenomic replicon RNA JFHl fused with GFP 
and (6) GND alone cells treated with a replication incompetent GND mutant 
fused with GFP. 
Cells were subjected to flow cytometric analysis and gated on the basis of 
forward and side scatter signals to restrict the analysis to viable cells. Mean 
fluorescence intensity (MFI) was measured in the cells as a measure of GFP 
expression. As shown in Figure 3.9 (A), mock treated cells had GFP 
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expression close to baseline (0.5%) while the majority of cells treated with the 
DNA positive control expressed OFP at high levels (96%). Knocking down 
OFP expression by specific siRNA not only reduced the percentage of positive 
cells to 88% but more importantly, expression levels (indicated by MFI) also 
showed a three fold reduction. Transfection with scrambled control had 
minimal effect on OFP expression (95% positive). JFHl expression (OFP 
tagged) was positive in 36% of cells whereas in OND (OFP tagged) treated 
cells, only 1 % of cells were positive. 
Figure 3.9 (8) depicts shift in fluorescence in the different populations tested. 
As expected, cells transfected with siRNA specific for OFP show a significant 
left shift as compared to the scrambled control. OFP fused replicon treated 
cells (JFHl alone) show two distinct peaks corresponding to the negative (grey 
area) and positive control populations, whereas the OFP fused OND mutant 
treated cells overlapped the negative control. Transfection efficiency for OFP 
tagged JFHl replicon was 26.7% ± 6.7 (n=7) and 52.1% ± 11.5 (n=7) for Huh7 
and Huh7.5 respectively. Due to the higher transfection efficiency, the Huh7.5 
cell line was used for co-transfection experiments in which a number of host 
genes were selected and targeted using siRNAs. All the graphs and data 
analysis was performed using OraphPad Prism version 4 and unpaired 
student's t test was used to compare the two groups. 
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Figure 3.9 Experimental control for RNAi by nucleofection 
3 
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A) Different t pe of experimental controls were used to validate our 
transfection protocol including (I) a mock tran fected/negative control, (2) a 
GFP (DNA) po iti control, (3) a po itive si RNA control, (4) a negative 
siRNA control. JFHl (GFP tagged) alone (5) and G D (GFP tagged) alone (6) 
are also hown for comparison. Cell were gated on the ba is of forward and 
side scatter to include live c 1I population and baseline fluorescence (y-axis) 
based on negative control wa lected as a cut off for positive populations. B) 
Histogram demon trating change in fluore cence inten ity (x-axi ) and shift in 
different populations as compared to negative cells (grey filled area). (C) Mean 
fluorescence inten it. (MFI) mea ured in the different population (1-6 in A) 
and plotted on -axi . 
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3.3.5.2 Effect of VAP-A knock down on viral replication 
The HCV subgenomic replicon derived from JFHl was used in this study to 
observe the effect of VAP-A knock down on virus replication. Huh7.5 cells 
were co-transfected with GFP tagged JFHl replicon RNA and siRNA targeting 
human V AP-A and GFP expression was calculated by flow cytometry. Mean 
fluorescence intensity (MFI) was measured at 72 hours and compared in the 
knock down sample versus control. As shown in Figure 3.10 (A), VAP-A 
knock down resulted in ~ 3 0 % % reduction in viral replication as indicated by the 
difference in MFI between the two populations (p value = 0.03). 
Western blot was performed to confirm protein knock down but as shown in 
Figure 3.10 (B), there was no reduction in VAP-A protein expression. The 
reduction in virus replication did not correlate with the level of protein knock 
down so it was hypothesized that rate of V AP-A protein turn over is high and 
the half life of protein is short so that its levels come back up again if left 
longer. To prove this, the experiment was repeated with a shorter analysis time 
of 48 hours. As shown in Figure 3.11, there was more than 80% reduction in 
VAP-A protein expression at 48 hours as indicated by the Western blot which 
translated into a more robust or statistically significant inhibitory effect on viral 
replication (p = 0.007). 
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Figure 3.10 Effect of VAP-A knock down on JFHl replication at 72 hour 
Huh7.5 cells were co-transfected with JFH 1 replicon RNA and either VAP-A 
specific siRNA or scramble control by nucleofection and effects on viral 
replication were measured at 72 hours. A) Graph illustrating MFI plotted on y-
axis and significant difference between control and knock down group. Bars 
indicate mean and error bars denote standard deviation B) Western blot image 
showing V AP-A protein (27kDa) in both groups and ~ - a c t i n n as a loading 
control. This diagram is a representative of three repeat experiments with each 
sample performed in triplicate. 
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Figure 3.11 Effect of VAP-A knock down on JFHl replication at 48 hour 
Huh7.5 cells were co-transfected with JFH I replicon RNA and either VAP-A 
specific siRNA or scrambled control and its effect on viral replication was 
measured at 48 hours. A) Graph illustrating MFI plotted on y-axis and 
significant difference between control and knock down group. Bars indicate 
mean and error bars denote standard deviation. B) Western blot image showing 
V AP-A protein (27kDa) in both knock down and control groups and p-actin as 
a loading control. This diagram is a representative of three repeat experiments 
with each sample performed in triplicate. 
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3.3.5.3 Effect of STAT-3 knock down on viral replication 
STAT-3 was next chosen as a target for gene knock down and the effect on 
viral replication assessed by co-transfection with replicon RNA. Huh7.5 cells 
were co-nucleofected with either STAT-3 specific siRNA or respective 
scrambled control together with GFP tagged JFHI viral RNA. Flow cytometric 
analysis of GFP expression was carried out at 72 hours by measuring mean 
fluorescence intensity (MFI) in the knock down sample and comparing it to the 
scramble control. 
As shown in Figure 3.12 (A), silencing STAT-3 had an inhibitory effect on 
virus replication indicated by reduction in fluorescence signal and this 
difference was statistically significant (p value = 0.0004). Western blot was 
performed to confirm protein knock down (Figure 3.12, B) which showed that 
there was almost 100% reduction in STAT -3 protein expression in knockout 
samples in contrast to control treated samples. ~ - a c t i n n expression was equal in 
the samples tested indicating equal loading. 
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Figure 3.12 Effect of ST A T -3 knock down on JFH1 replication 
Huh7.5 cells were co-electroporated with JFH 1 replicon RNA and either 
STAT3 specific siRNAor scrambled control by nucleofection and its effect on 
viral replication was measured at 72 hours. A) MFI plotted on y-axis to 
compare its difference between control and the knock down group_ Bars 
indicate mean and error bars denote standard deviation; B) Western blot image 
showing STA T -3 protein (88kDa) expression only in the control group while it 
is absent in siRNA treated samples_ ~ - a c t i n n expression shows equivalent 
loading in the two samples_ This diagram is a representative of three repeat 
experiments with each sample performed in triplicate_ 
129 
3.3.5.4 Effect of ACTN1 knock down on viral replication 
To analyse the effects of ACTNl knock down, cells were transfected with 
ACTNl specific siRNA along with GFP tagged JFHl viral RNA. Flow 
cytometric analysis of GFP expression was carried out at 72 hours by 
measuring mean fluorescence intensity (MFI) in the knock down sample as 
compared to the scrambled control. As depicted in Figure 3.13 (A), ACTNl 
knock down did not suppress virus replication and the signal was comparable 
in both populations (p value = 0.95). Western blot was performed to analyse 
protein knock down and as shown in Figure 3.13 (B), there was almost 100% 
reduction in ACTNl protein expression while ~ - a c t i n n expression remained 
unaltered indicative of equivalent protein quantity in the parallel wells under 
companson. 
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Figure 3.13 Effects of ACTNl knock down on viral replication 
Huh7.5 cells were co-electroporated with JFHI replicon RNA and either 
ACTN 1 specific siRNA or scrambled control by nucleofection and its effect on 
viral replication was measured at 72 hours. A) Graph illustrating MFI plotted 
on the y-axis and showing no sigruficant difference between the control and 
knock down group. Bars indicate mean and error bars denote standard 
deviation; B) Western blot image showing ACTN 1 protein (l15kDa) 
expression only in the control group while it is absent in siRNA treated 
samples. ~ - a c t i n n expression shows equivalent loading in the two samples. This 
diagram is a representative of three repeat experiments with each sample 
performed in triplicate. 
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3.4 Discussion: 
Limited success in developing an effective form of therapy and lack of a 
protective vaccine has allowed HCV infection to emerge as a significant public 
health problem. Current therapeutic options not only have a low success rate 
(depending on virus genotype) but are also expensive and produce often 
intolerable adverse effects (Ferguson, 2010). All of these features point 
towards the need to develop better treatment regimens. Use of directly acting 
anti-viral agents targeting viral proteins is an important option but remains 
toxic, expensive and may be limited by pre-existing or acquired resistance due 
to the error prone nature of the virus RdRp. A complementary approach would 
be targeting host factors required for virus replication which will provide 
greater barrier to resistance. Designing siRNAs acting on host genes will also 
have the advantage of being effective for different HCV genotypes. A number 
of such siRNAs targeting three host genes were used to analyse effects on virus 
replication. Gene silencing potential of these duplexes was initially validated 
by both real time PCR and western blotting. For real time PCR relative 
quantification using a standard curve method was used. Maxpro real time peR 
software was used to automatically quantify gene expression in ng and 
normalised to house keeping genes to compare between knock down and 
control. This is a simpler method than doing absolute quantification in which 
exact concentration of DNA needs to be measured by an independent method 
for example by cloning into a plasmid. 
Intracellular delivery of molecules into biological systems has been used as a 
useful tool to study gene function or design therapeutic agents. A variety of 
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techniques are in use for this purpose including chemical, liposomal or viral 
based methods. Nucleofection is a type oftransfection technique which allows 
entry of nucleic acids (DNA, RNA or siRNA) into mammalian cells with the 
help of a nucleofector device (electroporator) and special solutions. High 
efficiency and use of identical transfection protocols enables its use for 
simultaneous delivery of both siRNA and viral RNA. Nucleofection is also 
suitable for delivering larger size products like the HCV subgenomic replicon 
(-10 kB) than other lipid based transfection procedures. 
A subgenomic replicon based on HCV non-structural proteins was used in this 
study. The advantages of this system are that it does not require Category III 
facilities and has a GFP reporter protein fused to the viral NS5A, which not 
only makes analysis simple but also enables measurement of HCV 
replication/translation in transient assays without the need for time consuming 
and laborious stable transfection. 
In the current study, strict analysis of subgenomic RNA quality was carried out 
to exclude experimental artefacts arising from poor quality RNA by using fresh 
RNA, preventing repeated freeze thawing by producing aliquots, monitoring 
quality by agarose gel electrophoresis after every step during its production etc. 
Further, we used a number of experimental controls to exclude any sequence 
independent effects, toxicity associated with transfection procedure or 
hypersentivity to introduction of double stranded RNA. These included, i) 
mock transfected or negative controls indicating that the procedure does not 
give rise to any non-specific effects and is not associated with cytotoxicity; ii) 
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a DNA positive control (pmaxGFPTM) to verify that the nucleofector solution 
and programme are suitable for the Huh7.5 cell line which then means that 
similar conditions can be used for RNA or siRNA; Hi) a positive siRNA 
control which successfully knocked down GFP expression showing that 
siRNAs can efficiently enter and knock down the target gene in this cellular 
environment; iv) a negative control siRNA or scrambled control which had the 
same sequence as of the gene specific siRNA but arranged randomly. Of all the 
three siRNAs tested, the scrambled control that had no effect on protein 
expression indicating that the results obtained are real and are due to sequence-
specific silencing of the target genes rather than sequence-independent effects 
associated with the delivery of siRNA into the cells. 
Optimisation of replicon transfection was needed to determine the 
nucleofection conditions which can simultaneously provide high GFP 
expression and moderate cell number. To achieve this, a number of 
programmes were tested to select the one with the highest transfection 
efficiency without causing massive cell death. T ·020 appeared to be the best, 
so it was used for transfection of viral RNA. In addition, the highest replication 
efficiency was achieved by using } O ~ g g of replicon RNA and measuring GFP 
expression at 72 hours. In agreement with Blight et al., when comparing the 
two cell lines, we found that transfection efficiency was higher for Huh7.5 as 
compared to Huh7 cells (Blight et al., 2002). Huh7.5 is a sub clone of Huh7 
cells containing a deletion of the retinoid-inducible gene } (RIG}). The higher 
permissiveness of the Huh7.5 cells is related to loss of the RIG} protein, which 
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plays a role in recognition of viral RNA and triggers production of Type 1 IFN, 
thereby suppressing virus replication. 
The field ofRNAi for gene silencing has been revolutionised in the past decade 
due to its potential to act as a potential therapeutic and screening tool (Lares et 
aI., 2010). Many studies have tested the utility of siRNAs for inhibiting HeV 
replication and some of those specifically which targeted viral proteins are in 
the later stages of clinical trials (Lin, 2010). Although promising, the high 
replication rate and error prone nature of the viral polymerase can be a hurdle. 
A report illustrating the efficacy of RNAi for inhibiting HeV replication also 
showed the development of escape mutants which could limit its utility 
(Randall et aI., 2003). Similarly, some studies have already reported the 
development of mutant HeV replicons resistant to protease or polymerase 
inhibitors (Mo et aI., 2005) or other therapies which target specific binding 
sites in Hev like microRNA122 (Li et aI., 2011). The same effect has been 
observed for other RNA viruses, such as polio viruses where a study by Gitlin 
et al. provided evidence for rapid development of mutant viruses (Gitlin et aI., 
2002). 
A report by Randall et al. identified a number of cellular proteins involved in 
virus replication (Randall et aI., 2007). In the present study, a number of host 
genes were selected and their potential as an anti-viral target was assessed. 
Prior to their use in nucleofection, the intended siRNAs were validated for their 
gene silencing ability. Lipofectamine2000 was used for delivery of duplexes 
and showed that these siRNAs can successfully knock down target genes. In all 
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cases, the transcripts were consistently knocked by 85 to 99% of the levels 
observed in control samples (section 3.3.3). Reduction in protein levels was 
also highly significant for STAT-3 (90%) followed by VAP-A (-50%), 
showing reduction in protein expression in knock down sample. However for 
ACTN1, protein levels remained more or less unaltered and may reflect a 
variation in the dynamics of protein turn over (Figure 3.7). In this study, prior 
to co-transfection of siRNAs with viral RNA, the utility of nucleofector 
technology for delivering siRNA was tested. SiRNAs were successfully 
transfected and silenced target genes in a dose dependant manner. The 
minimum concentration having greatest knock down efficiency was chosen for 
co-transfection experiments in order to minimise toxicity or off target effects. 
Hev NS3 protease inhibitors are the most advanced directly acting anti-viral 
(DAA) as they have now been approved for use as a combination with 
pegylated-interferon and ribavirin. However, a key concern with these viral 
based drug targets is emergence of resistance due to the high replication rate 
producing 1010-12 virions per day and the lack of proof reading ability of the 
RNA polymerase leading to high mutation rate when used as monotherapy. 
Also since virally targeted inhibitors bind to a specific site within the protein, 
even a single nucleotide difference can make it ineffective. Using host based 
therapies has the potential to circumvent these issues and also expand the list of 
available targets. Once validated, these can be used either alone or in 
combination to effectively suppress virus replication. This principle has been 
tested for HCV where siRNA targeting HCV receptors like CD81 and SRBI or 
other cellular proteins like phosphatidylinositol 4-kinase III alpha can inhibit 
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HCV replication (Berger et aI., 2009). In this study, a number of cellular 
proteins involved in viral replication have been tested to evaluate their efficacy 
in suppressing virus replication. 
V AP-A has been previously identified as a NS5A and NS5B binding protein 
(Tu et aI., 1999) and is thought to aid in the fonnation of HCV replication 
complexes while enhancing viral replication (Gao et aI., 2004). Our findings 
validate these results indicating that knock down of VAP-A results in a 
significant reduction in virus replication. HCV has been shown to replicate in a 
complexes consisting of lipid rafts and viral proteins (Shi et aI., 2003), and 
V AP-A is known to be involved in lipid biosynthesis and trafficking, so we can 
speculate that V AP-A knock down interferes with the fonnation of replication 
complex and therefore suppresses viral replication. This is supported by a 
recent report demonstrating that knock down of seven lipid raft associated 
proteins including VAP-A inhibited HCV replication (Chan et aI., 2011). We 
also found that V AP-A protein has a short half life as protein levels recover 
after 48hours and inhibitory effects on viral replication also diminish. 
STAT-3 belongs to the STAT (signal transducer and activator of transcription) 
family but has distinct biological functions. It is mainly activated in response to 
cytokines like interleukin-6 (IL-6) and growth factors like epidennal growth 
factor (EGF) and has been implicated in oncogenesis (Lim and Cao, 2006). It 
has also been reported that in addition to cytokines, disturbance of intracellular 
calcium (Ca +) by viral NS5A results in production of reactive oxygen species 
(ROS) which in turn activate STAT3 (Gong et aI., 2001). A similar 
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phenomenon of STAT-3 activation by ROS has also been observed in 
lymphocytes (Carballo et aI., 1999). A later study by Waris et al. also indicated 
involvement of ROS and Ca + signalling in mediating HCV induced activation 
of STAT-3 (Waris et aI., 2005). They also showed that blocking STAT-3 by 
inhibitors of cellular kinases like tyrosine or MAP kinases which are believed 
to activate STAT3 or using a dominant negative mutant for STAT-3 
suppressed virus replication (Waris et aI., 2005). The results presented in this 
study also validate these findings. We found that in both Huh7 and Huh7.5 
cells, co-transfection and knock down of STAT-3 inhibited replication of the 
subgenomic replicon. Previous studies have suggested that HCV gene 
expression also influences expression of anti-oxidant pathways (Blackham et 
aI., 2010). By causing oxidative stress and production of ROS, STA T3 may 
favour virus induced damage to cells and an inflammatory state, therefore 
favouring viral survival and persistence (Tardif et aI., 2005). 
Contrasting results have been reported by Zhu et al. showing that STAT-3 
activation in response to IL-6 exerts an anti-viral mechanism in HCV infection 
(Zhu et aI., 2004). Similarly, the role ofROS in modulating HCV replication is 
not clear yet and different reports provide diverse results (Choi et aI., 2004) 
(Mccartney et aI., 2008). Expression profile studies have also highlighted the 
importance of host genes involved in oxidative stress in virus replication 
(Blackham et aI., 2010). Another possibility is that inhibition of STAT-3 may 
. result in reciprocal increase in STAT -1 signalling leading to a pronounced 
antiviral response within the cells (Regis et aI., 2008). Differences in results, 
however, may be due to different experimental conditions, including 
138 
differences in siRNA sequences, transfection techniques, HCV genotype or 
replication system. In our system, we found unequivocal evidence that ST AT-3 
acts to support virus replication. 
ACTNl is a cytoskeletal protein with an as yet undefined role in liver disease. 
Lan et al. used yeast two hybrid screening and co-immunoprecipition to 
demonstrate that alpha actinin interacts with viral NS5B and its silencing leads 
to reduction in viral replication (Lan et al., 2003). In our study, ACTNl 
specific siRNA was co-transfected with viral RNA to assess changes in virus 
replication but its silencing did not suppress virus replication. We hypothesize 
that this difference may be isoforrn specific as the previous study did not 
analyse the presence of isoforrns in liver. Contrasting function has been 
reported earlier for ACTNI and ACTN4 in controlling survival and motility in 
astrocytoma (Quick and Skalli, 2010). Using proteome analysis, Fang et al. 
compared the expression profile of proteins in the Huh7 cell line and Huh7 
cells containing replicating subgenomic replicon and found alpha actinin to be 
upregulated suggesting a role for this protein in HCV replication (Fang et aI., 
2006a). This may suggest ACTNI is involved in establishment of infection in 
cells containing replicating virus. Our study, however, found no evidence that 
expression of ACTNI was required to support viral replication as assessed in 
the sub-genomic replicon system. 
In conclusion our study has validated the feasibility and potential of siRNA 
based therapies targeting cellular co-factors in down regulating HCV 
replication and this can be used either alone or in combination with existing or 
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forthcoming therapies to provide additive anti-Hey effect. In this study, VAP-
A and STAT-3 have been shown to positively regulate Hev replication. Other 
cellular targets need to be identified and screened for their anti-Hey efficacy. 
Using drug delivery properties of liposomes/nanoparticles, more than one 
therapeutic agent can be targeted to liver either alone or in combination with 
the current treatment regime to further enhance its efficacy and this suggests 
that our approach could become an important adjunct to new virus specific 
therapies. It will now be important to confirm our findings in a system which 
accommodates viral replication and the production of infectious progeny virus. 
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Chapter Four 
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4 Liposome 
molecules 
4. 1 Introduction 
for delivery of therapeutic 
4.1.1 Principle of targeted delivery for anti-HCV therapy 
Current anti-HCV therapy has a variable outcome and is limited by a low 
response rate so that even the most favourable genotypes (2 and 3) do not have 
100% chance of eradicating the virus. Compliance with therapy and the dose of 
ribavirin appear to be vital detenninants of therapeutic efficacy (Feld and 
Hoofnagle, 2005). Lowering the dose has shown to diminish (Hadziyannis et 
aI., 2004) while increasing it further improves outcome but only at the expense 
of higher adverse effects (Lindahl et aI., 2005). This further lessens both 
patient compliance and quality of life. There is thus a need to devise effective 
and specific delivery system to directly deliver anti-viral drugs to infected 
hepatocytes and thereby minimise adverse effects arising from accumulation of 
drug in non-target tissue. Once successful, the same approach can be employed 
for delivering other small molecule inhibitors. These are a class of anti-HCV 
therapeutics aimed directly at viral enzymes like the protease or the viral RNA 
polymerase. The most successful and advanced are NS3A14B protease 
inhibitors such as Telaprevir and Boceprevir which have now been licensed for 
clinical use. These agents do, however, require to be used together with both 
interferon and ribavirin (Hezode et aI., 2009) and have additional drug specific 
toxicities. 
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This part of the study aimed to investigate whether nanoparticles (NP) could be 
used to specifically and efficiently deliver antiviral agents to hepatocytes. 
There are many advantages of using such an approach; Firstly, NP can be 
readily modified to enhance their physical properties (smaller size, low charge, 
surface conjugation with liver targeting molecules etc). This will improve their 
uptake by hepatocytes so the majority of drug will be concentrated to its site of 
action i.e. virally infected cells. Secondly, the enhanced uptake of drug 
molecules to a particular tissue will not only improve its therapeutic efficacy 
but may shorten total duration of treatment and achieve higher cure rates. 
Thirdly, tissue specific sequestration of drug molecule will reduce side effects 
arising from accumulation of drugs in off target sites, such as red blood cells in 
the case of ribavirin. Fourthly, more than one therapeutic molecule can be 
conjugated in a single formulation that will further enhance therapeutic 
efficacy. All these properties make them a suitable carrier molecule to deliver 
anti-Hey or other therapeutic molecule requiring targeted delivery. 
4.1.2 Liposomes as vehicles for targeted drug delivery 
An ideal drug delivery vehicle should be efficient, non-cytotoxic, non-
immunogenic, biodegradable and specific in delivering a therapeutic molecule 
to its site of action. In case of siRNA, the delivery vehicle should also be able 
to protect duplexes from nucleases during its transit in the circulation and 
prevent rapid clearance by reticulo-endothelial cells. A number of 
nanoparticIes are available for drug delivery (Moghimi et aI., 2001). 
Liposomes, micelles and polymeric nanoparticles are used widely for delivery 
of drugs, genes, imaging agents and vaccines (Fahmy et aI., 2005, 
Schwendener et aI., 2010, Torchilin, 2007). Lipid based drug carriers represent 
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vehicles made up of physiologicallipids such as phospholipids, cholesterol and 
triglycerides and fulfil the above criteria for a delivery vehicle suitable for 
human use. The only recognized side effect of carrier mediated delivery is a 
hypersensitivity reaction caused by complement activation, but this can be 
prevented by altering the dosage administration method, and exhibits 
tachyphylaxis (Szebeni et aI., 2000). 
Liposomes are lipid based nanoparticles. They are spherical vesicles having an 
aqueous core and an outer layer made up of phospholipid (Figure 4.1). 
Hydrophilic molecules like drugs and nucleic acids (e.g. siRNA or plasmid 
DNA) can be enclosed in the water soluble centre while lipid soluble 
compounds can be entrapped in the hydrophobic outer coat (lipid soluble drugs 
e.g. AmBisome). Liposomes mainly enter the cells by endocytosis ( D i i z g i i n e ~ ~
and Nir, 1999, Pollock et aI., 2010) and are characterised in terms of lipid 
content, size (50-1000 run in diameter), surface charge or zeta potential 
(positive, negative or neutral) and number of lipid layers (uni or multi lamellar 
liposomes). Smaller size (<200nm) and neutral surface charge protects them 
from removal by the reticuloendothelial system (V onarbourg et aI., 2006). 
Production of 'stealth' liposomes is achieved by attaching a hydrophilic 
polymer such as polyethylene glycol (PEG) outside the lipid bilayer. This 
prolongs circulation half life due to invisibility by the immune system as a 
result of less interaction with plasma proteins, reduced uptake by reticulo-
endothelial cells (REC) in the liver or spleen, and reduced renal clearance 
(Owens Iii and Peppas, 2006, Rawat et aI., 2008). Pegylated interferon alpha-
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2b (PEG-Intron) i a cia sic example of using the pegylation technique to 
significantly improve response rate when compared to the unmodified drug 
(Glue et aI., 2000). 
Hydrophilic head 
Hydrophobic tal ... 1 I-----,Vl 
Clrculanon ---+1 
Liver 
Figure 4.1 Lipo ome for drug delivery 
Liposome 
• = drug molecule 
.f' = SIRNA 
(!) = Cell 
• = red blood cells 
. , = Ilposome 
Liposome are made of a pho pholipid bilayer (a) having an inner hydrophilic 
core which can be loaded with drug or siRNA molecules (b). These can be 
used for s stemic admini tration (c) and protect drug molecules from 
degradation or uptake by non-target cells (d). Further specificity can be 
improved by urface conjugation with ligands like antibodies or antibody 
fragment to improv uptake in pecific locations, like the liver (e). 
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Target specificity of a liposomal delivery agent can be further increased by 
anchoring a ligand molecule on its surface which can identify and bind to a 
biological antigen or receptor enabling by the target organ. This is called active 
or ligand mediated drug targeting. One of the most frequently used methods of 
active targeting is immuno-liposomes, in which liposomes are coated with 
antibody or its antigen-binding or Fab fragment as a surface moiety to mediate 
uptake in tumour sites or other specific locations (Mastrobattista et aI., 1999). 
Using haemoglobin conjugated ribavirin-HRC 203 (Levy et aI., 2006) and 
lactosylated liposomes-CL-LA5 (Watanabe et aI., 2007) are methods to 
mediate targeted delivery of therapeutic molecules to the liver. Apolipoprotein 
A-I (apo A-I) is a protein component of high density lipoprotein (HDL). 
Cationic liposomes artificially associated with apo A-I have been targeted to 
the liver through its cellular receptor. This vehicle has been shown to be able to 
transport siRNA to the liver thus mediating effective and specific delivery 
(Kim et aI., 2007). In a later study based on an HCV mouse model (expressing 
all the structural proteins in liver), Kim et al also showed that the apo A-I 
targeting delivery vehicle can transport siRNA targeting HCV and cause 65-
75% inhibition of viral replication (Kim et aI., 2009). 
Several liposome or polymer based nanoparticle drugs are already in clinical 
use for the treatment of human diseases such as cancer and fungal infections 
(AlIen and Cullis, 2004, Schwendener, 2007). This approach is particularly 
advantageous in cancer treatment, where accumulation of a drug at the tumour 
site can improve its effectiveness and minimise non-specific adverse effects 
associated with conventional chemotherapeutics. Additionally tumours usually 
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have less efficient lymphatic drainage which further reduces drug clearance 
from its site of action and hence improves its efficacy. Doxorubicin 
(DoxiVCaelyx) indicated for use in the treatment of Kaposi's sarcoma and 
refractory ovarian and breast cancer, was one of the first pegylated liposomal 
formulations approved for human use (AlIen and Cullis, 2004). In comparison 
to free drug, liposomal doxorubicin considerably improved the therapeutic 
efficacy due to higher bioavailability and reduced cardiotoxicity and 
myelosuppression (Martin et al., 2011, Soloman R, 2008, Uziely et aI., 1995). 
Other examples of liposomal drugs approved for clinical use include liposomal 
amphotericin B (AmBisome) (AlIen et aI., 1994) and cytosine arabinoside 
(DepoCyt) indicated for lymphomatous meningitis (Murry and Blaney, 2000). 
4.1.3 Role of Apolipoprotein 8-100 in HCV replication 
Plasma lipoproteins are particles made of phospholipids, cholesterol and 
apoproteins and function mainly to transport lipid and lipid soluble materials to 
and from the liver. Within an infected host, HeV particles circulate in 
association with lipoproteins such as very low density lipoprotein (VLDL) and 
low density lipoprotein (LDL). These are referred to as lipo-viral particles 
(LVP) (Andre et aI., 2002). Apolipoprotein B-100 (apoB-100) forms the 
protein component of lipoproteins and is required for the assembly and release 
of L VP from the liver (Blasiole et aI., 2007). The microsomal triglyceride 
transfer protein (MTP) present in the ER lumen regulates VLDL assembly by 
enhancing apoB-100 lipidation and preventing its degradation. Huang et al 
used an immuno-isolation approach to purify membrane vesicles containing 
HeV replication complexes. Proteome analysis of Hev containing membranes 
revealed that these vesicles are rich in apoB-100, apoE and MTP. They also 
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reported that blocking VLDL secretion by the liver through inhibiting apoB-
100 expression by siRNAs and MTP inhibitor (BMS-2101038) decreases the 
release of infected viral particles in the circulation (Huang et al., 2007). 
In this study, we planned to test the capability of liposomes to deliver two 
different types of therapeutic molecules i.e. siRNAs (targeting apoB-IOO), and 
drug (ribavirin). ApoB-IOO was chosen as a siRNA target as it's related to 
HCV and is specifically expressed in the liver. For this, apoB-IOO expression 
was silenced using siRNAs and knock down efficacy was compared following 
delivery by either using liposomes (supplied by Lipoxen) or a commercially 
available reagent like Lipofectamine 2000 (Invitrogen). Similarly, we planned 
to measure cellular uptake of free and liposomal ribavirin by Huh7 cells, a 
human hepatoma cell line used for propagation of infectious clones of H CV . It 
was hypothesised that once a suitable delivery vehicle has been identified, the 
same fonnulation could be used to deliver current drugs (ribavirin) alone or in 
combination with other directly acting or siRNA-based antiviral therapeutics. 
The ultimate aim of the project was to generate preclinical data resulting in the 
declaration of a candidate product suitable for phase-I clinical trials. 
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4.2 Aims: 
The aims of this part of the study were to test the utility of liposomes for 
delivering siRNA (ApoB-! 00) and drug (ribavirin) by: 
• Validating gene knock down of naked duplexes and comparing gene 
knock down efficiency of naked duplexes (delivered by 
lipofectamine2000) and those enclosed in liposomes. 
• Analysing cellular uptake of a GFP encoded plasmid DNA when using 
liposomes or Lipofectamine2000 as a delivery vehicle. 
• Analysing intra-cellular uptake of liposomes by using fluorescent 
labelled liposome. 
• Modifying liposomal formulation or cell culture conditions to improve 
cellular uptake. 
• Validating efficacy of liposomes as a delivery vehicle using apoB-! 00 
siRNA and ribavirin as test molecules. 
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4.3 Results: 
4.3.1 Comparisons of ApoB-100 knock down by using 
naked siRNA vs. liposomally entrapped siRNAs 
4.3.1 .1 Validation of gene silencing ability of anti-ApoB100 
siRNA 
Before analysing siRNA delivery by liposomes, the capacity of naked siRNA 
to silence ApoB-lOO was asses ed by using lipofectamine2000 (Invitrogen). 
ApoB-) 00 targeting iRNA used in this study was supplied by our commercial 
collaborator Lipoxen. The sequence of siRNA and details of transfection 
method is given in materials and methods. Briefly, Lipofectamine2000 manual 
instructions were followed to transfect 2.S x 105 Huh7 cells/well in six well 
plates. Cells were pre-plated by overnight incubation and once SO-70% 
confluent, duplexes in transfection medium were added to the wells at a final 
concentration of 100nM. RNA extraction and cDNA synthesis was performed 
after 48 hours. 
PCR primers for quantification of ApoB-100 and HPRT expressIon were 
designed u ing Primer3 programme (version 0.4.0) targeting exon-exon 
junction. pecificity was checked with pnmer blast 
(http://v\,ww.ncbi .nlm.nih.go Optimal primer annealing 
condition were achje ed by gradient peR with a temperature range of 
60±10°C (primer sequence and optimal annealing temperature are given in 
material and method ). A standard curve was prepared by serially diluting 
neat cDNA in order to ensure best PCR efficiency (range = 100± IS%). As 
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shovm in Figure 4.2 (A and B), the efficiency fo r both primer pairs was close 
to 100% as depicted by linear standard curve. Melting or di ssociation curve 
confirmed that the primer pairs generated a single product indicated by the 
presence of a ingle peak . Simi larly, the RT negative control and non-template 
control did not ampli fy , indicating that there is no genomic DNA or exogenous 
contamination (Fi gure 4.2, C and D). 
StCfldard curve Dissociation curve 
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Figure 4.2 Real time peR plots for ApoB-lOO and HPRT primer 
Standard curve for apoB- l OO (A) and HPRT (B) was prepared by serial 
dil ution of neat cDNA (x-axis) and change in cycle threshold (Ct, y axis) was 
measured . PCR efficiency was 98% for ApoB-100 and 104% for HPRT 
whereas R2 value close to 1. Melti ng curves for ApoB-lOO (C) and HPRT (D) 
demon trated that both primer pairs generated a single product and absence of 
contaminating products, which may give ri se to additional peak separate from 
the desired amplicon. No ampli fication of NTC and RT negative controls is 
observed (ba eline in the melt curve). 
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MaxPro real time peR software was used to quantify ApoB-lOO expression in 
samples treated with either gene specific si RNA or a scrambled control and 
levels were normalised to the house keeping gene HPRT. As given in Figure 
4.3 (A), cells treated with siRNAs had a 3 fold reduction in the expression of 
apoB-lOO in comparison to cells treated with scrambled control. We then 
sought evidence that knock down at the message level was correlated with 
reduction in ApoB-lOO protein expression. Figure 4.3 (B) shows results of a 
dot Blot which confirms that ApoB-lOO specific siRNAs but not scramble 
control caused a significant reduction in ApoB-l 00 protein expression. In view 
of very faint detection of ~ - a c t i n n in these dot blots, implying inadequate protein 
detection, we elected to confirm specific protein knock down using Western 
blot. 
ApoB-100 encodes for a large protein with a molecular weight of -51 OkDa. 
Such a large molecule required optimisation of the western blot protocols. A 
number of methods, including agarose gel electrophoresis were tried 
unsuccessfully. Finally, protein expression was successfully quantified using a 
4% SDS-PAGE resolving gel. ~ - a c t i n n was used as a loading control. The 
Western blot shown in Figure 4.4 (A) demonstrated that there is 100% 
reduction in expression of apoB-100 protein in siRNA treated samples as 
compared to the control siRNA. ~ - a c t i n n expression remained consistent in the 
parallel samples, indicating equal loading. The specificity of the Western was 
confirmed by using two other apoB-IOO negative cell lines and secondary 
antibody alone (Figure 4.4, B). As expected bands were only detected in Huh7 
cells exposed to both primary and secondary antibody. 
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Figure 4.3 Analyses of apoB-lOO knock down by siRNA delivered by 
Lipofectamine2000. 
(A) Real time peR: ApoB-IOO expression (ng) was normalised to HPRT and 
the ratio plotted on the y-axis to compare levels in knock down samples vs. 
control. Bars indicate mean and error bars denote standard deviation. 
(B) Dot Blot indicating absence of ApoB-l 00 protein in knock down samples 
as opposed to cells treated with the scrambled siRNA control. p-actin protein, 
although faintly detected, shows equal expression. 
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Figure 4.4 Western blot for ApoB-lOO knock down by naked duplexes 
CA) ApoB-1 00 expression by western blot confirmed complete loss of protein 
expression in knock down samples while ~ - a c t i n n expression was equivalent, 
demonstrating equal loading_ 
CB) The specificity of ApoB-1 00 antibody was demonstrated by using an apoB-
lOO positive (Huh7) and two negative (OLDI and T470) cell lines. As 
expected, a 514 kOa band representative of ApoB-1 00 was only detected in 
Huh7 cells (top panel ). Specificity of the secondary antibody was also 
confirmed by exposing the membrane to secondary antibody only. No signal 
was present in membrane incubated with secondary antibody alone (lower 
panel) . 
(1 0 = ApoB-100 primary antibody, 20 = Anti-mouse secondary antibody, 
Huh7= Human hepatoma cell line, T470= Breast cancer cell line, OLOI = 
Colorectal cancer cell line). 
154 
4.3.1.2 ApoB-100 knock down by liposomally entrapped 
siRNAs 
After validating the gene silencing ability of duplexes, the efficacy of 
liposomally entrapped siRNAs was investigated. Huh7 cells were plated 
overnight for initial attachment as before. Liposomes made up of egg 
phosphatidylcholine were supplied by Lipoxen (Lipoxen Technologies Ltd) in 
a freezedldried form and were resuspended in nuclease free water by vortexing 
to form siRNA containing vesicles. The volume of liposome suspension 
required to give a final concentration of IOOnM siRNA was added to the wells 
and incubated for 48 hours prior to RNA extraction. siRNA delivered by 
Lipofectamine2000 was used as a positive control. 
In order to compare efficiency of the two delivery methods, real time peR was 
performed to quantify inhibition of apoB-1 00 mRNA expression. It was found 
that siRNA delivered by Lipofectamine2000 caused a significant reduction in 
transcript levels in knock down samples vs. control. In contrast, siRNA 
delivered by liposomes appeared to have no significant effect on apoB-IOO 
mRNA levels (Figure 4.5). Dose response was assessed by increasing the 
amount of duplexes (range 30 - 300nM) but did not improve knock down with 
either of the delivery systems. Similarly, longer incubation of cells with 
liposomal siRNA (24-72 hours) also failed to cause any reduction in gene 
expression. 
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Figure 4.5 Comparison of apoB-100 knock down by naked vs. liposomally 
entrapped siRNA 
Huh7 cell were expo ed to either naked siRNA using Lipofectamine2000 or 
duplexe enclo ed in liposome at a fi nal concentration of 100nM/well and 
har ested after 48 hour . Real time pe R was done to quantify gene expression 
and nonnali ed to HPRT. ing Lipofectamine2000 (LF) as a delivery vehicle, 
apoB-100 specific duplexes produced a significant reduction in tran cript 
levels (Ies than 10% of contro l treated cells) . In contrast liposomal (LP) 
siRNA failed to cau e any significant reduction in mRNA levels. (LF = 
lipofectamine2000, LP = lipo omes, .control = scrambled control ). Bars 
denote mean of ApoB- l 00 vs. HPRT ratio and error bars represent standard 
deviation. 
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4.3.2 Cellular uptake of liposomes (F1 and F2) containing 
a GFP expression vector 
Liposomal siRNAs failed to silence target gene expression. This could be 
either due to liposomal failure to deliver siRNA, siRNA degradation or 
something unique to Huh7 cells. The ability of liposomes to deliver a GFP 
expression vector was next assessed in two cell lines i.e. Huh7 cells and the 
colorectal cancer cell line HCT116, to exclude that results are siRNA or cell 
line specific. Plasmid pGFP was entrapped in liposomes made up of egg 
phosphatidy1choline lipid either without cholesterol (Fl) or with cholesterol 
(F2) and were supplied as a suspension by Lipoxen (Table 4.1). Huh7 and 
HCTl16 cells were treated with a volume of liposome suspension required to 
give a final concentration of 2.8 ~ g g of plasmid DNA/well (this dose has been 
previously validated by Lipoxen). The positive control consisted of plasmid at 
the same concentration delivered by means of Lipofectamine2000. 
Liposomal uptake was expressed as percentage of cells positive for GFP above 
baseline fluorescence (negative control). As demonstrated in Figure 4.6 (top 
panel), a substantial population ofHuh7 cells in the positive control population 
expressed GFP. On the other hand, Huh7 cells exposed to plasmid entrapped in 
liposomal formulations had GFP expression indistinguishable from the 
negative control. Similar results were found in HCT116 cells where the 
majority of cells in the positive control expressed GFP above baseline whereas 
expression was negligible in liposomally treated lines (Figure 4.6, bottom 
panel). 
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Figure 4.6 Transfection efficiency of GFP labelled liposome 
Huh7 (top panel) and HCT116 cells (bottom panel) were either untreated 
(negative control), delivered with 2.8Ilg/ml of plasmid DNA encoding GFP 
protein using either lipofectamine2000 (positive control) or liposome 
formulations (FI and F2). After 48 hours, the cell suspension was subjected to 
flow cytometric analysis for GFP expression. Cells were gated on the basis of 
forward and side scatter to exclude apoptotic or dead cells. Any cells 
expressing GFP above the levels in the negative control (untreated) were 
measured as percentage (%) of GFP positive cells in the total population. GFP 
expression is shown on the y-axis while forward scatter (FS) in presented on 
the x-axis. 
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4.3.3 Analysis of liposomal uptake by labelled vehicles 
In order to further understand the failure of liposomally entrapped siRNA to 
effectively silence apoB-100, we next planned to evaluate liposome uptake 
inside Huh7 cells using fluorescent labelled liposomes. Information regarding 
various fluorescent liposomal preparations used in this study is given in Table 
4.1. 
4.3.3.1 Cellular uptake of positive control nanoparticles and 
carboxy-fluorescence labelled liposomes 
To demonstrate intra-cellular uptake, liposomes made up of either DPPC (F3) 
or HSPC (F4) lipid and conjugated with carboxy fluorescent (CF) dye were 
prepared by Lipoxen (Table 4.1). A positive control consisting of nanoparticles 
made up of polyglyceroadipate (PGA) and labelled with Rhodamine B 
isothiocyanate (RBI), known to be avidly taken up by cells, was prepared and 
supplied by Weina Meng (School of Pharmacy, University of Nottingham). 
Huh7 cells were exposed to 500Ilg/ml of nanoparticles for 2 hours and 
analysed by F ACS. We found that Huh7 cells treated with nanoparticles were 
strongly positive for RBI with an uptake efficiency of 100% when compared to 
the negative control (Figure 4.7, A-C). 
We next performed a series of dose response experiments using different 
concentration of liposomes F3 and F4. Cells were incubated with different 
concentrations (0-500Ilg) of liposome suspension for 2 hours and fluorescence 
expression was analysed by flow cytometry. In contrast to the positive control, 
cells treated with liposome formulations F3 and F4 at all doses tested, had 
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minimal fluorescence expression (Figure 4.7, D). The same experiment was 
repeated by prolonging incubation duration to 24 hours but failed to enhance 
uptake significantly. Analysis in HCT116 cell line produced identical findings 
and ruled out the possibility that results are Huh7 cell specific. 
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Figure 4.7 Cellula r uptake of carboxy-fluorescence labelled Iiposomes 
Huh7 cells were exposed to either REI labelled nanoparticles or various doses 
of liposome formulation F3 and F4 composed of DPPC and HSPC lipid 
respectively. Cellular uptake was expressed as number of cells containing 
fluore cent dye (RBI or CF) above the baseline in untreated cell s. Dot plot 
demonstrated 100% of cells positive for nanoparticles (B) when compared to 
the untreated population CA). Histogram depicts shift in fluorescence signal in 
the two populations on the x-axis (C). Red filled area = negative control and no 
filled area = nanoparticle treated Huh7. Table shows MFI and uptake of CF 
labelled Iiposomes by Huh7 cell (D). MFJ = mean fluorescence intensity. 
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4.3.3.2 Altering physical characteristics of liposomal 
formulations to improve cellular uptake 
Fluorescent labelled liposomal data showed that there is no fluorescence inside 
the cells. This suggested that either the liposomes are not being taken up by the 
cells or the fluorescent marker is leaking out of the liposomes. The leakage of 
fluorescence was ruled out by using liposomes incorporating a fluorescent label 
embedded within the lipid bilayer (F5-FI2). These liposomes were supplied as 
a suspension by Lipoxen and varied with respect to lipid composition, molar 
ratio causing variation in surface charge and sucrose content. Details of the 
fluorescent liposomal preparations (F5-FI2) are given in Table 4.1. Huh7 cells 
were exposed to various liposome formulations at different concentrations and 
sUbjected to flow cytometric analysis. 
Figure 4.8 illustrates the cellular uptake of various liposomal preparations. 
Dose response analyses indicated that using 500 Ilg/ml of liposomes achieved a 
higher uptake than using a lower dosage. Among the first four liposomal 
fonnulations (F5-F8), F5 demonstrated the highest uptake level of around 10%. 
Notably among these preparations, F5 had the least surface charge or zeta 
potential, so it was hypothesised that this property may have accounted for the 
higher liposomal uptake. To prove this, further formulations with lower zeta 
potential (F9-12) were prepared and supplied by Lipoxen. In addition, F12 
liposomes also had lowest sucrose content. Data in Figure 4.8 shows that the 
F12 fonnulation demonstrated a substantial uptake of around 63% which was 
superior to any of the preparations tested so far and was even five times higher 
than F5. 
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Table 4.1 Physical properties of liposomal formulations used ID the 
current study. 
A number of liposomal form ulation labelled with the below mentioned 
fluorescent marker were u ed to track intra-cellular entry of delivery vehicles. 
(PC = egg Phosphatidylcholines, DPPC = dipalmitoylphosphatidylcholine, 
HSPC = h drogenated soy phosphatidylcholine, CHL = cholesterol, CF = 
carboxyfluorescein. DPE = -dansyl phosphatidyl ethanolamine, NBD = I , 2-
dioleoyl- n-glycero-3-phosphoethanolamine, 7-nitrobenzofurazan-labelled 
lipid). Different colour indicate various batches. 
Formulation Lipid Fluorescent Particle size Zeta potential 
ID composition material (nm) (mY) 
FI PC GFP - -
F2 PCICHL GFP - -
F3 DPPC CF 227.3±42.6 -
F4 HSPC CF 153.l±30.3 -
F5 DPPC DPE 92.7 -26.7 
F6 DPPCICHL DPE 102.7 -41.9 
F7 DPPC DPE 94.77 -40.7 
F8 DPPC/Gal-Lipid DPE 70.52 -37.4 
F9 DPPC DPE 92.3 -16.4 
FIO DPPC DPE 79.52 -14.1 
Fll DPPC DPE 95.76 -7.01 
F12 DPPC NBD 109.5 -6.05 
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Figure 4.8 Cellular uptake of DPE and NBD labelled liposomes with 
variable physical characteristics 
Huh7 cell were expo ed to different liposomal formulation (F5-F12) and 
uptake was analysed by flow cytomtery. A dose response for F5-F8 was 
performed at the indicated concentrations (x-axis) to evaluate liposomal uptake 
after 2 hour (-axi). Huh7 cells were also treated with liposomes with 
variable surface charge (F9-F 12) and lower sucrose content (F 12) in order to 
analyse uptake efficiency. LiposomaJ uptake was expressed as percentage of 
positive cells expre ing fluorescent marker above the baseline fluorescence 
(negative control). 
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4.3.3.3 Altering serum conditions to enhance liposomal 
uptake 
Liposomal formulations with a lower surface charge generally had higher 
uptake efficiency. In order to further enhance cellular entry, the effect of serum 
on liposomal uptake was evaluated. Huh7 cells were delivered with liposomes 
with the lowest surface charge (F5, F9, Fl 0, FIl and FI2). For this, cells were 
plated overnight and incubated with 500Jlg/ml of liposomes in Huh7 culture 
medium with or without serum for 4 hours. 
It was found that depriving cells of serum improved liposomal uptake by at 
least 2 fold (Figure 4.9-A). The Highest uptake levels were achieved by 
formulation Fl2 in which 80% of cells expressed the fluorescent marker above 
the baseline. In contrast, the same delivery vehicle in the presence of serum 
produced an uptake level of 60% as illustrated in Figure 4.9-B. In light of these 
findings, F12 was considered to be suitable for subsequent analysis. 
164 
100 
;g 90 
~ ~ 80 41 
~ ~ 70 /11 
C. 60 ~ ~
(ij 50 
E 40 0 
A 
VI 30 0 
Cl. 20 :,:j 
10 
F5 F9 F10 F 11 F12 
LlpOSOmB forrrulatlon 
(+) SERUM . (-) SERUM 
r 
-
------. 
Negative F12 F1 2 
'I control (wi th serum) (without serum) B 
. "1 ~ ~ . • •• = I · . ; ; ; ; l l ,:::'., ! tl .:1) " I . , , ~ ; : : : ~ ~ ; J . ~ ~ - . , : , ,- . ~ ~ . ~ - ~ ~.. , ! -I :"tl',' .• ,; 'y " 'I ; , 
~ ~ ~ ~ ~ ~
Figure 4.9 Influence of serum conditions on liposomal uptake by Huh7 
cells 
CA) Huh7 cells were exposed to different liposomal formulations (F5, F9-1 2) in 
the presence or absence of serum and cellular uptake was analysed by flow 
cytomtery. Bars indicate average and error bars indicate standard deviation. 
(B) Dot plot indicating liposomal uptake in Huh7 cells treated with 500J..l.g/ml 
of F 12 in the presence or absence of serum. Y-axis = fluorescence, x-axi s= 
forward scatter. 
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4.3.4 Efficiency of liposome as a drug delivery vehicle 
Analysis of fluorescent liposomes (FI2) revealed that lowering the surface 
charge and sucrose content of liposomes significantly enhanced intracellular 
uptake achieving optimal uptake in vitro. These liposomes were then tested for 
their efficacy to deliver exogenous molecules, either siRNA or ribavirin. 
4.3.4.1 ApoB-100 gene silencing by liposomal siRNAs 
A new liposomal formulation enclosing ApoB-IOO specific si RNA was 
supplied by Lipoxen. These liposomes had physical properties similar to the 
Fl2 formulation which was found to be efficiently taken up by Huh7 cells. 
Liposomes were packaged with siRNA and supplied fresh as a ready to use 
suspension by Lipoxen. The siRNA sequence is the same as mentioned earlier. 
Huh7 cells were delivered with 100nM of either naked siRNAs or liposomally 
entrapped siRNAs. Lipofectamine2000 was used for delivery of naked 
duplexes. For liposome delivery, Huh7 cells were plated overnight and the 
required volume of liposomes was added to the culture medium. Cells were 
harvested for RNA and protein extraction at 48 hours. Real time peR and 
Western blot analysis was done to evaluate gene knock-down. 
ApoB-lOO mRNA expression was compared between knock down and control 
samples, and transcript levels normalised to HPRT. As shown in Figure 4.10, 
naked siRNA delivered by Lipofectamine2000 caused a drop of more than 
80% in mRNA levels (A) which also translated into approximately 90% 
reduction in apoB-IOO protein expression (B). In contrast, the same duplexes 
when delivered by liposomes failed to produce such an effect where apoB-l 00 
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mRNA dropped less than 10% in the control vs. siRNA treated samples and 
protein levels also remained unaltered between the two sets of samples. 
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Figure 4.10 Analysis of siRNA delivery ability of low sucrose liposomes 
Huh7 cells were treated with gene specific and control siRNA at a final 
concentration of 100nM. Effects of gene silencing were analysed at 48 hours 
by real time peR and Western blot. (A) ApoB-IOO mRNA was quantified in 
knockdown and control samples and after normalisation, the ratio of ApoB-l 00 
and HPRT was plotted on the y-axis to examine differences in expression 
levels among different samples. CB) Protein samples extracted from parallel 
samples were run on a 4% SDS-PAGE gel and immuno-blotted with mouse 
monoclonal antibody. p-actin was used as a loading control. (LP = liposome, 
LF = lipofectamine2000, S.control = scrambled control). 
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4.3.4.2 Comparison of free and liposomal ribavirin uptake 
The capacity of liposomes to deliver drug was next analysed by comparing 
efficacy of free ribavirin uptake to that packaged inside liposomes. These were 
supplied by Lipoxen as a ready to use suspension and had physical properties 
similar to F12 previously shown to have the highest cellular uptake .. Huh7 
cells were pre-plated overnight and exposed to various doses of both free and 
liposomal ribavirin. Samples were extracted at 1, 2, 4 and 24 hours to measure 
total ribavirin uptake by Huh7 cells. The drug uptake experiments were done 
by Weina Meng (School of Pharmacy) using high performance liquid 
chromatography (HPLC). Uptake of liposomal ribavirin by Huh7 cells was 
very limited. Almost all of the drug was recovered from the cell culture 
medium and less than 1 % of the total drug from the cellular compartment. 
Surprisingly, it was found that Huh7 cells did not take up free ribavirin either. 
This finding has subsequently been confirmed in repeat experiments during this 
study (given in Chapter 5). In order to further analyse the failure of liposomes 
to transport ribavirin, the stability of these liposomes was assessed. Liposomes 
were resuspended in Huh7 culture medium in a dialysis bag and incubated at 
37° C in a shaker bath at a speed of 90 cycles per min. Samples were taken out 
at pre-determined time points and replaced with fresh culture medium. It was 
found that almost 50 % of the ribavirin was released after 4 hours. This figure 
rose to -70 % after 24 hours. It is therefore likely that for incubation times 
longer than four hours, Huh7 cells were exposed to higher concentration of free 
ribavirin than liposomally entrapped drug. There was, however, no evidence of 
early uptake suggestive of liposomally mediated entry of ribavirin into cells. 
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4.4 Discussion 
Drug delivery systems (DDS) have been recognised as an important tool for 
specific delivery of large number of therapeutic molecules. Since their 
discovery in 1961 by Alec D. Bangham, liposomes have been used as a 
versatile tool in various fields of science and medicine including DDS, for both 
lipophilic and hydrophilic molecules. Physical properties such as the ability of 
targeted delivery and a non-toxic, non-immunogenic, bio-degradable, flexible 
structure makes them an ideal carrier molecule for delivering drugs, imaging 
molecules or vaccination peptides. This could be particularly valuable for 
treating diseases like cancers in which entrapment of drug molecules in non-
target sites not only compromises the efficacy but also produces intolerable 
adverse effects. Hepatitis C virus is another example in which delivery of anti-
virals to hepatocytes might play a vital role in a patient's response to the 
treatment. Ribavirin is a vital component of current HCV therapy but causes 
severe haemolytic anaemia due to its accumulation in the red cell compartment, 
reducing its efficacy as well. Similarly, the cure rate can be boosted by using a 
higher dose but occurs at the expense of more side effects. Both of these 
factors can be surmounted by using a specific and targeted drug delivery 
vehicle. 
This study was aimed at evaluating efficacy of liposomal formulations 
(supplied by Lipoxen) as a carrier to transport therapeutic molecules. To do so, 
siRNAs targeting apoB-100 and ribavirin were used as test molecules. It was 
anticipated that liposomal preparations which could successfully deliver these 
test molecules may then be used to deliver other siRNA or small molecule 
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based drug targets. Moreover, more than one agent can in theory be conjugated 
in a single formulation to produce a synergistic effect. This concept is in line 
with other studies showing feasibility of use of liposomes for delivery of more 
than one agent, particularly chemotherapeutic drugs which usually require 
separate administration and more complex dosing regimens (Mendon9a et aI., 
2010, Wong and Chiu, 2011). We set out to test a number of liposomal 
formulations which varied in physical properties like particle size, surface 
charge, and lipid content. 
ApoB-lOO plays an integral role in assembly and release of VLDL and LDL 
required for the transport and metabolism of cholesterol (Blasiole et aI., 2007, 
Brown and Goldstein, 1986). Drug targets for apoB-100 based on anti sense 
oligonu1ceotides (Crooke et aI., 2005), MTP inhibitors (Magnin et aI., 2003) or 
siRNA (Zimmermann et aI., 2006) are being evaluated for the treatment of 
hypercholesterolemia. Previous studies have found that apoB-l 00 plays a role 
in the release of infectious HeV particles from the liver (Huang et aI., 2007). 
We therefore planned to use apoB-lOO as a target for inhibiting HCV infection. 
The gene silencing ability of siRNAs incorporated in liposomes was compared 
to that of naked duplexes delivered by Lipofectamine2000 as a control. The 
results presented earlier demonstrated no inhibition of apoB-1 00 expression by 
liposomally delivered siRNA while it was significantly reduced in control cells. 
Similarly, GFP containing liposomes also failed to produce any evidence of 
liposome mediated uptake of plasmid DNA and hence GFP expression and 
confirmed that the findings are not unique to siRNA or Huh7 cell line. We 
rationalised that one or more factors may account for the failure of liposomally 
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entrapped iRN to modulate target gene expression in two distinct cell lines. 
The e factor are de cri bed below in Figure 4.11. 
In vitro cultIJre 
e liposome 
Cytoplasm -----'-.. 
Figure 4.11 Possible mechanism of liposomal failure 
• = d"'9 molecule 
.f' = s,RNA 
~ ~ =Cell 
Extra-cellular space 
FajJure of liposome to silence apoB-1 00 gene expression and deliver ribavirin 
may be due to one or more of the following factors: 
i. Lipo ome are unable to enter the cells or liposomes are taken up, but at low 
le el deli ering in ufficient iRNAs to mediate gene silencing or GFP 
expre ion b pIa mid 
ii. Lipo ome are taken up by the cells but intracellular processing i inhibiting 
relea e of iRN , pia mid DNA or drug 
iii. Intracellular inhibition of molecules by degradation 
i . Di integration of lipo orne due to intrinsic instability IS resulting In 
degradation of particle prior to intracellular uptake. 
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The first logical measure was to assess whether liposomes are being 
transported inside Huh7 as the first three questions are completely (i) or partly 
dependent on it (ii and iii) as given in Figure 4.11. We used fluorescent 
labelled liposomes for characterising liposomal uptake as it is the most 
common approach to monitor particle entry under physiological conditions 
(Madeira et aI., 2011). We also used RBI labelled PGA NPs shown to be avidly 
taken up by primary brain cells and brain tumour cells in previous studies by 
our colleagues in Pharmacy (Meng et aI., 2006). Fluorescent analysis carried 
out by flow cytometry revealed that almost all the cells expressed the 
fluorescent marker in the positive control but it was minimal in the liposomally 
(F3-F4) treated group. 
Failure ofliposomal uptake suggested that either the formulation themselves (a) 
or the in vitro culture conditions (b) were not suitable for uptake. To address 
(a), factors like the vehicle's physical properties (size, charge, lipid and sugar 
content etc) were altered whereas the osmotic environment and serum 
conditions of culture were modified to overcome (b) and further improve 
uptake. Additionally, use of another cell line (HCTI16) and a positive control 
NP ensured that the culture conditions were appropriate. 
The physical characteristics of a lipid carrier are an important determinant of 
its cellular uptake. Important variables are vesicle size and surface charge, and 
these can be altered by modifying the preparation method and lipid content 
(molar ratio). We initially tested F5-F8 formulations and of these, F5 had the 
highest uptake. Especially, this preparation had the lowest negative charge so 
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further carrier molecules with lower zeta potentials were supplied by Lipoxen 
for testing. Our data showed that formulation F12 having the lowest or near 
neutral charge showed a significant uptake of almost 60 percent. This may be 
due to the cell membrane's hydrophobic nature that causes electrically neutral 
and small molecules to pass through the membrane easier than charged or large 
ones. So a neutral or near neutral surface charge facilitates liposomal 
penetration through the plasma membrane (Lee et aI., 2011). In the case of 
siRNAs incorporated in liposomes, this further helps by forming stable 
complexes between negatively charged si RNA molecules and neutral or 
positively charged liposome. Our data also validates these earlier reports as 
lowering particle size and surface charge seemed to improve intracellular 
uptake. 
Since the ultimate aim of this study was to test a formulation suitable for in 
vivo testing, factors favouring physiological stability of particles were also 
considered. After entering into the circulation, the fate of a carrier molecule 
also depends on its size, range between 70 and 200nM. Smaller particles are 
likely to be lost via renal excretion or by crossing the endothelial barrier, and 
larger particles can be removed by the bone marrow, heart, kidney and stomach 
(Gaumet et aI., 2008, Litzinger et aI., 1994, Vonarbourg et aI., 2006). In a 
report assessing role of liposome characteristics, Rhomberg et al found that 
liposomes with a mean size of 120 nm were removed from the bloodstream at a 
lower rate than liposomes of 230 and 360 nm, respectively suggesting that 
particle size of less than 150nM had long circulating life than larger size 
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vesicles (Romberg et al., 2007). All the liposomal preparations used in this 
study had sizes within this range. 
Another observation was that most of the formulations used in this study were 
prepared with high sucrose content except F12 formulation. Sugar molecules 
are known to interact directly with the polar head group of phospholipids by 
forming a hydrogen bond (Crowe et al., 1994). Addition of carbohydrates like 
sucrose and trehalose to the liposomal preparation helps in stabilising the 
vesicle membrane and preventing tiposome flocculation and fusion 
(Anchordoguy et al., 1987, Womersley et al., 1985). Our results suggest that 
the high sugar content of the majority of vehicles may have increased osmotic 
forces in the cell culture environment disfiguring particle structure and thus 
contributing to poor uptake levels. 
It has been previously suggested that serum free medium can alter efficiency of 
liposomal uptake by the cells ( D i i z g i i n e ~ ~ and Nir, 1999). In order to enhance 
delivery properties of vehicles, influence of serum on liposomal uptake 
compared by incubating cells in the presence or absence of serum. We found 
that, starving cells with serum improved liposomal uptake least 2 fold. This 
might suggest that either the serum components alter cell:liposome interactions 
or cells in the presence of serum remain in a comparatively quiescent state, 
while depriving them of serum which contains essential lipids for cell 
proliferation induces an activated phagocytic state to uptake more extra cellular 
molecules. This is consistent with the observation that liposomes are mainly 
taken up by endocytosis as in most of cases the cell's outer exoskeleton 
prevents direct attachment and fusion ( D i i z g i i n e ~ ~ and Nir, 1999). The same 
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effect can be achieved in vivo by using PEG coating that prevents interaction 
with serum protein and hence improves their stability and uptake. Such an 
example is use of stable nucleic acid liposomes (SNALP). 
Among all those tested, F12 was identified as a formulation suitable for 
delivery of therapeutic molecules like siRNA or drugs so its ability to transport 
these molecules was assessed. Huh7 cells were treated with apoB-100 siRNAs 
entrapped in the F12 preparation but failed to cause gene silencing. Similarly, 
no significant difference was achieved by using free or liposomal ribavirin. In 
order to further understand the basis of this failure, the stability of liposomes 
was assessed at 37°C. An In vitro release assay revealed that these formulations 
were very unstable in serum and the majority of the drug leaked out within 24 
hours, thus accounting for poor uptake in the cells. 
Stability of liposome in vivo has been questioned by many investigators and 
has been rationalised to liposome-plasma protein interactions. These studies 
generally suggested that these interfaces result in destabilisation and break 
down of vesicles or opsonisation thus reducing their efficacy in vivo (Semple et 
aI., 1998). Liposomal charge and lipid composition seemed influence 
adsorption of proteins on the liposomal surface. A report by Hemandazcaselles 
et al showed that liposomal instability indicated by release of the entrapped 
fluorescent probe positively correlated with the amount of protein adsorbed on 
its surface. They also demonstrate that liposomes with neutral or positive 
charge bound the least protein, while those of negative charge were dependant 
on lipid composition, as the vesicles with phosphatidylcholine bound less 
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protein than the ones devoid of it (Hernandezcaselles et aI., 1993). Thus there 
is need to improve these formulation by either changing lipid content and 
include helper lipids like cholesterol, which will increase liposomal stability. 
Similarly use of stealth liposomes can be advantageous (8ege et aI., 2011). 
Surface coating of liposomes with hydrophilic molecules like PEG not only 
prolongs circulation time but also increases their stability. This has been found 
due to blockage of direct attachment of serum proteins with the liposomal 
membrane (Hioki et aI., 2010). In the present report, positive control PGA 
nanoparticles were shown to be avidly taken up by cells and have been 
identified as highly potent delivery vehicle in previous studies (Meng et aI., 
2006) so these can be used for intracellular delivery of siRNAs or anti-Hey 
medicine instead of liposomes. 
Surprisingly, uptake levels of free ribavirin by Huh7 cells were very poor. This 
was a much unexpected finding as a number of studies have shown efficacy of 
ribavirin in inhibiting HCV replication in Huh7 cells in vitro (Kato et aI., 2005). 
However, this is in line with the data produced by our collaborator in Glasgow 
who found that free ribavirin failed to inhibit JFH-l replication in a SEAP 
assay by Huh7 (Arvind et aI, personal communication). SEAP is a cell based 
reporter assay which serves as a direct measure of viral translation and 
replication. In this system Enhanced Green Fluorescent Protein (EGFP) is 
fused in frame with Secreted Alkaline phosphatase (SEAP) via a viral N3/4A 
serine protease recognition sequence and is secreted in the culture medium 
when cleaved by HCV NS3/4A protease (lro et aI., 2009). We next wish to 
examine the presence of the ribavirin transporter in primary human hepatocytes 
176 
and compare it to the Huh7 cell line. We will then be able to evaluate if 
ribavirin uptake correlates with the expression of major ribavirin transporters 
such as the equilibrative nucleoside transporter. 
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Chapter Five 
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5 Correlation of ribavirin uptake and ENT1 
expression by primary human hepatocytes 
5.1 Introduction 
5.1.1 Treatment for chronic hepatitis C virus infection 
(HCV) 
5.1.1.1 Combination therapy with ribavirin and interferon 
The current standard of care for patients with chronic HCV infection consists 
of pegylated interferon alpha (IFN-a) and ribavirin. Ribavirin is a purine 
nucleoside analogue used as an adjuvant with interferon based therapy. When 
used as monotherapy, its effects on viral replication are negligible but improve 
dramatically when combined with IFN-a (Mchutchison, 1999). The exact 
mechanism ofribavirin's anti-viral action is currently not known but a number 
of mechanisms have been proposed. These are summarised in Figure 6.1 and 
discussed in greater detail in Chapter 1 (General introduction). 
Of the proposed mechanisms for ribavirin action, most require ribavirin to be 
transported into the cells. Levy et a1 found that targeting ribavirin to 
hepatocytes improves its antiviral potency and survival rate in mice with 
hepatitis (Levy et aI., 2006). Further, the response rate to ribavirin improves 
with increasing dose of ribavirin (even for the less responsive genotype 1) but 
at the expense of more side effects (Lindahl et aI., 2005). Conversely, a recent 
prospective study comparing efficacy of ribavirin with a reduced initial dose 
showed that despite having higher haemoglobin levels, SVR cannot be 
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achieved with a lower dosage (Konishi I , 2010). It is therefore evidently 
clinically important to achieve as high levels of ribavirin as possible, but the 
capacity to do so is limited by increasing side effects. In these circumstances, it 
is legitimate to interrogate the factors which regulate ribavirin entry into 
hepatocytes, particularly those which may provide a mechanistic basis for 
variations in the outcome of therapy. 
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Figure 5.1 Possible mode of ribavirin anti-HCV actions 
A number of mechanisms have been proposed for ribavirin effects in 
combination therapy for hepatitis C virus. a) Immunomodulation (by eliciting a 
strong helper T cell response), b) Inhibition of IMPDH (by reducing GTP 
levels) c) Inhibition of viral RNA polymerase, RdRp (by RTP) and d) RNA 
mutagenesis (by incorporation of RIP into replicating RNA chains and 
inducing mutagenesis resulting into production of defective HCV particles) 
(Feld and Hoofnagle, 2005) 
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5.1.1.2 Limitations of current regimen 
Established treatment guidelines for chronic HCV comprise either a 24- or 48-
week course of pegylated interferon and ribavirin, depending on the viral 
genotype (Excellence, 2004). Using these regimens, an SVR has been reported 
in 42-52% of patients infected with HCV genotype 1 and in 76-82% of those 
with genotype 2/3 infection (Manns et aI., 2001, Fried et aI., 2002, Hadziyannis 
et aI., 2004, Zeuzem et aI., 2004). Combination therapy, however, has a 
significant and often serious side effect profile, including depression, insomnia 
and flu like symptoms attributed to interferon and haemolytic anaemia due to 
accumulation of ribavirin in the red blood cell compartment. 
Owing to great disease burden (having approximately 180 million people 
infected worldwide), there has been tremendous effort to improve treatment 
response rate by identifying new drugs (Lin, 2010 #320) or revising the current 
regimen. This includes a better understanding of the mechanisms of action of 
interferon and ribavirin. One study explored the pharmacokinetic interactions 
of interferon and ribavirin and found that interferon does not affect ribavirin 
metabolism or prolong its availability or vice versa, and the safety profile of 
these drugs in combination is similar to that of either drug used alone (Khakoo 
et aI., 1998). Feld et al provided evidence that ribavirin acts by improving 
interferon signalling via upreguIating cytokine production (Fe Id et aI., 2010). It 
is, however, still unclear how these two drugs act to provide synergistic effects 
and dramatically improve response rate. 
181 
5.1.1.3 Assay for ribavirin quantification 
A number of assays have been developed for ribavirin quantification. High 
performance liquid chromatography (HPLC) is one of the widely used 
techniques due to the simplicity of the method and lack of the radioactivity 
associated with some other methods (Granich et aI., 1989). It is a type of liquid 
chromatography which separates compounds based on differences in their 
polarity to solid phase as detected by ultraviolet light. 
Figure 5.2 shows the HPLC flow scheme. A pump provides constant pressure 
to propel the solvent (mobile phase) through the column at a fixed rate. An 
unknown sample is injected into the column which is pre-packed with a solid 
material (solid phase). The speed at which any specific substance moves 
through the column depends on its relative polarity with the solid phase. 
Compounds with least polarity will elute first and those with high polarity will 
come out later. The UV lamp detects any eluted metabolite and a signal is 
produced in the form of a specific peak proportion to the amount of substance 
eluted. 
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) 
Sample 
Mobile phase 
Flow »»» 
Column 
(stationary phase) 
Figure 5.2 Flow cheme for HPLC 
= 
Mobile pha e (buffer) is propelled into the column with the help of constant 
pres ure generated by a pump at a flow rate of 1 mllmin. the sample is injected 
into the column and i separated as it passes through the column. The detector 
ha a V ource which detects the sub tance at a specific wavelength. The 
ignal i th n tran mitted to a computer and is di played in the form of 
chromatogram (peak). 
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5.1.2 Nucleoside transporters 
5.1.2.1 Introduction 
transporters 
and classification of nucleoside 
Nucleosides are the building blocks of nucleic acid synthesis and play a vital 
role in growth and metabolism. Several nucleoside analogues are being used as 
antiviral and anti-cancer molecules like ribavirin, acyclovir, 
fluorouracil, cytarabine (Ara-C), gemcitabine etc. Due to their hydrophilic 
nature, nucleoside analogues require a transport system to gain entry inside the 
cells and exert their action. Expression levels and function of these transporters 
are therefore probably an important determinant of the efficacy and toxicity of 
various antiviral and anticancer drugs (Clarke et aI., 2006). 
There are two mam types of nucleoside transporters; the Equilibrative 
nucleoside transporter (ENT), encoded by SLC29A, is a faciIitative type of 
transporter in which the substrate concentration is the driving force. The other 
type, the concentrative nucleoside transporter (CNT, SLC28A), is a Na+ 
dependent secondary active transporter (Kong et aI., 2004). Each of these 
transporters is further classified into subtypes. ENTs have two major classes 
depending on their inhibitor sensitivity to a compound called 
Nitrobenzylthioinosine (NBMPR). The ENTl gene is located on chromosome 
6 and is inhibited by nanomolar concentrations of NBMPR whereas ENT2 
requires micromolar concentrations of NBMPR to be inhibited. ENT3 and 
ENT4 are two less well characterised types of nucleoside transporters. ENT3 
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transports purines and pyrimidines and ENT4 transports adenosine only 
(Baldwin et aI., 2004). 
CNTs are also classified into subtypes (1-3) based on substrate selectivity. 
CNTl and 2 transport pyrimidines and purines respectively whereas CNT3 
transports both (Marzena Podgorska, 2005). 
5.1.2.2 Functional importance and regulation of human 
equilibrative nucleoside transporters 1 (hENT1) 
Human ENTl is a 456- residue glycoprotein made up of 11 transmembrane 
domains (TMDs) with an intracellular N-terminus and extracellular C-terminus 
(Sundaram et aI., 2001). It is widely distributed in mammalian tissue with high 
levels of expression found in erythrocytes, placenta, brain, heart, liver, lung 
colon etc. In contrast, CNTs have specific expression sites like the liver, kidney 
and intestine (Kong et aI., 2004). hENTl are mainly localised to the plasma 
membrane where they play a key role in movement of nucleotide and nucleic 
acids in and out of cells. For cells that lack intrinsic biosynthesis pathways like 
erythrocytes, these are supplied by the liver (Griffith and Jarvis, 1996). By 
modulating concentration of nucleoside substrates like adenosine (a purine 
nucleoside) these transporters play an important physiological role in tissues 
like the heart, brain and placenta (Baldwin et aI., 2004). 
Inflammatory cytokines have been shown to alter hepatic gene expression and 
alter transporter function (Petrovic et al., 2007). It has been shown that nitric 
oxide alters SLC29Al promoter activity and reduction in ENTl expression 
leading to reduced adenosine uptake by the cell and vascular abnormalities 
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(Far1as et aI., 2010). Stress induced c-Jun N-terminal kinases (JNK), a type of 
mitogen-activated protein (MAP) kinase has been implicated in down 
regulating ENTl function, mRNA expression and promoter activity (Leisewitz 
et aI., 2011). It has been shown that TMDs 3-6 are implicated in nucleoside 
binding and transport (Sundaram et aI., 1998). A later study by Sengupta et al 
identified a highly conserved glycine residue at position 179 of TMD 5 of 
human and rat ENT 1 (Sengupta et aI., 2002). By using a yeast based transporter 
model, they showed that this residue is essential for transporter function and 
sensitivity to NBMPR regardless of its localisation in the plasma membrane. 
The requirement of nucleoside transporters in cellular uptake of many 
nucleoside analogues used as anticancer or antiviral agents necessitates 
studying the mechanisms regulating their expression and function. This is 
clearly also true for ribavirin (purine nucleoside analogue) used for HeV 
infection. 
5.1.2.3 Ribavirin uptake is mainly mediated by equilibrative 
nucleoside transporters 1 (ENT1) 
Hepatocytes are the principal site of viral replication in HeV infection. To 
exert its antiviral actions, ribavirin must be transported into hepatocytes via a 
nucleoside transporter. Jarvis et al demonstrated that ribavirin transport into 
human erythrocytes is mainly mediated through an NBMPR sensitive 
equilibrative nucleoside transporter (Jarvis et aI., 1998). Studies done by 
Endres et al also suggest that ENTl plays an important role in erythrocyte 
uptake of ribavirin, both in vitro and in vivo (Endres et aI., 2009). Using in situ 
hybridization, Govindarajan et al showed that higher levels of mRNA were 
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present for ENTl, CNTl and ENT2 than for CNT2 in human hepatocytes 
(Govindarajan et aI., 2007). A later study showed that ENTl and CNTl as well 
as ENT2 and CNT have comparable expression and the majority of ribavirin 
transport into hepatocytes is mediated through ENTl (89%) (Govindarajan et 
aI., 2008). A study using cryopreserved hepatocytes also suggested that ENTl 
may be the major transporter involved in ribavirin uptake (Fukuchi et aI., 2010) 
5.1.3 In vitro model based on primary human 
hepatocytes 
5.1.3.1 Indication for use of primary human hepatocytes 
Although there are well defined limitations to growth and maintenance of 
hepatocyte specific functions in vitro, primary hepatocyte culture remains the 
most suitable system to study hepatocyte function in vitro. Maintenance of 
metabolism and transporter systems makes them a good model to undertake 
drug based studies (Runge et aI., 2000). Also, as humans are the only natural 
host for hepatitis C, primary human hepatocytes provide a useful tool to study 
response to anti-virals and host virus interaction (Runge et aI., 2000). Although 
rodent hepatocytes are a useful alternative to human cells for certain purposes, 
species differences and earlier loss of liver specific function are limiting factors 
(Battle and Stacey, 2001, Morel et aI., 1990, Runge et aI., 2000). Another 
advantage of human cells is that expression of sinusoidal transport proteins 
remains relatively constant and mimics closely that found in vivo when 
compared to rat hepatocytes (Jigorel et aI., 2005). 
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5.1.3.2 Culture systems 
Hepatocytes in vivo are arranged in a three dimensional (3D) configuration 
surrounded by non-parenchymal cells and extra cellular matrix components 
(Figure 5.3). This environment is required for cells to proliferate, maintain 
phenotype and perform specific functions. Advances in tissue culture 
techniques, such as the addition of extracellular matrix component (e.g. 
collagen), co-culture with other non-parenchymal cells (e.g. hepatic stellate 
cells) and serum free conditions have allowed development of healthy longer 
living cultures (Battle and Stacey, 2001, Chen et aI., 1998, Katsura et aI., 2002, 
Thomas et aI., 2005) . Growing cells on extracellular matrix also helps in 
maintenance of liver specific function and receptor expression (Kataropoulou 
et aI., 2005). Further, cells grown on extracellular matrix components grow in a 
spatially organised manner, rather as a flat monolayers when cultured on tissue 
culture plastic, and form well characterised structures known as spheroids. 
Spheroid formation promotes hepatocyte polarisation, cell-cell and cell-matrix 
interaction and therefore creates a micro-environment in which cellular 
transporters such as ENTl may be physiologically localised. 
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B 
Figure 5.3 Schematic illustration of various liver cells arranged in vivo 
A) Relationship between hepatocytes to other non-parenchyma1 liver cell types 
such as sinusoidal endothelial cells, Kupffer cells and hepatic stellate cells. 
B) Three dimensional structure of a hepatocyte having a basal (facing sinusoid 
and space of Disse) apical (facing bile canaliculous) and lateral side (facing 
adjacent hepatocytes) . 
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5.2 Aims: 
New agents are currently being evaluated for a better efficacy against HCV. 
Although a number of these agents are likely to be used for human therapy in 
future, current data suggest that ribavirin will remain a cornerstone of any 
future therapy for HCV infection. It is therefore important to study mechanisms 
involved in ribavirin action including transporter systems responsible for 
uptake into hepatocytes. In order to do so, primary human hepatocytes provide 
a most suitable model to study hepatocyte function in vitro. The specific aims 
of this study were: 
• To isolate and culture primary human hepatocytes in vitro. 
• To quantify ribavirin uptake into human hepatocytes by HPLC. 
• To quantitatively evaluate expression of the major ribavirin transporter 
(ENT!) in human hepatocytes. 
• To correlate drug uptake with receptor expression. 
• To assess whether interferon alpha treatment modulates ENT 1 
expression and ribavirin uptake. 
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5.3 Results 
5.3.1 Experimental design and data analysis 
Human hepatocytes were isolated and cultured according to a procedure 
described in material and methods (section 2.10). After the addition of 
ribavirin, samples were taken at 4, 8 and 24 hour for liver 1-4 and 24 hour for 
liver 5-6, and the Hub7 cell line. The 24 hour time point was chosen to 
compare drug uptake and receptor expression as ribavirin uptake was 
maximum at this point. Additionally, at this time point cell number remains the 
same or comparable between the different liver preps (Tissue Engineering 
group, University of Nottingham). Although a similar seeding density was 
used for all livers, total protein concentration measured in the cell suspension 
used for HPLC was used to normalise for variation caused by cell number 
which may arise due to errors during cell count. Non-parametric Spearman's 
Correlation test (rs) was used to correlate ribavirin uptake with total ENTl 
expression. All the graphs and data analysis was done in GrapbPad Prism 
version 4. Bar graph shows means ± standard deviation from three repeat 
experiments. 
5.3.2 Human hepatocytes culture 
Liver tissue was obtained from human donors undergoing liver resection. Full 
ethical approval and patient consent was obtained for the use of human tissue 
in this study. This work was done in collaboration with the FRAME group 
(Biomedical Sciences, University of Nottingham). Donor information is given 
in Table 2.3 and liver from each of these donors is referred to as Liver 1-6. 
Primary human hepatocytes were isolated by a modified two step collagenase 
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perfusion and after being resuspended in plating medium, cells were seeded on 
6 well collagen coated plates at a density of 1.68 million/well (cell density 
previously optimised by Tissue Engineering Group, University of Nottingham). 
The use of optimal seeding density and collagen as a culture surface has been 
found to create in our hands a healthy in vitro environment for hepatocyte 
growth. For hepatocytes grown on standard tissue culture surface, identical 
conditions were used except that the cells were cultured on tissue culture 
plastic instead of collagen. After overnight attachment, medium was changed 
to hepatocyte culture medium. 
Human hepatocytes were successfully isolated with consistently good cell 
viability of - 85% and purity (Figure 5.4). Cells grown on collagen coated 
plates maintained typical cuboidal shape characteristic of hepatocytes, with 
prominent nuclei and cell boundaries throughout the culture period (yellow 
arrows in Figure 5A-A). Hepatocytes also continued to proliferate in the form 
of three dimensional spheroids (white arrows in figure 5.4-A). In contrast, 
hepatocytes grown on tissue culture plastic lost their cuboidal shape and 
appeared circular because of failure to properly adhere to the culture surface 
(Figure 5.4-B). Despite having used the same initial density, hepatocytes were 
less confluent on tissue culture surface, indicative of lower proliferation rate. 
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A B 
Figure 5.4 Human hepatocytes on day 3 of in vitro culture 
A) Human hepatocytes cultured on collagen coated plates yellow arrows show 
hepatocytes attached to culture plate majntaining liver cell morphology 
whereas white arrows show areas of spheroid formation (cells growing in a 
three dimen ional pattern). B) Human hepatocytes cultured on tissue culture 
pia tic: cell grow in a two dimensional mono-layer rather than forming 
spheroids and appear less proliferative than A. 
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5.3.3 Optimal chromatographic conditions for ribavirin 
HPLC was used to quantify ribavirin uptake by the cells. For this, cells were 
treated with ribavirin and the sample extracted at given time points. Samples 
for HPLC were prepared by cell lysis and enzyme digestion followed by PBA 
column extraction (to purify the sample for the subsequent step). Ribavirin 
levels in the cell fraction were quantified by a method described previously 
(Loregian et aI., 2007). The HPLC conditions for measuring ribavirin in the 
cell fraction had been previously validated by Weina Meng (Pharmacy) and are 
described in section 2.12. 
HPLC conditions were re-validated to exclude operator related variation and 
ensure reproducibility. For this, samples with known ribavirin quantity were 
either prepared in water (to identify specific peak for ribavirin) or in cell 
suspension (to exclude interference from any metabolites in the cell 
suspension). Initially, there were some difficulties in obtaining optimal peaks. 
Peaks either become very broad or split, leading to double peaks and unreliable 
data. These difficulties were entirely resolved by revalidating and using a new 
column. 
Inter-assay precision (one reading taken on three separate days) and intra-assay 
precision (three separate readings taken on the same day) tests were performed 
to indicate both long term and short term reproducibility and accuracy for 
ribavirin quantification. Table 5.1 shows that at a given ribavirin dose, the 
variation in observed levels was low as indicated by standard deviation and 
relative standard deviation (RSD). The assay linearity was determined by 
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means of a calibration curve in which a known ribavirin concentration was 
plotted against the ratio of the area for ribavirin (RV) vs. the area for the 
internal standard (IS). As shown in Figure 5.5, the data points form a straight 
line and the value of correlation co-efficient (R2) is 0.999 indicating that there 
is a good linear relationship. This calibration curve was repeated along with 
any unknown samples in order to quantify drug uptake and ensure assay 
conditions were identical. Drug sensitivity was also measured by using a 
number of serial dilutions and it was found that the method is sensitive enough 
to measure drug concentration down to 0.04 Jig/ml. Figure 5.6 shows 
specificity of ribavirin and internal standard peaks, prepared either in water 
(top panel) or cell fraction (bottom panel). It can be seen that there is a single 
sharp peak for both ribavirin and internal standard showing no interference 
from any non-specific metabolites. 
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Table 5.1 HPLC assay reproducibility and precision 
Samples were prepared by adding known ribavirin quantities (2, 4 and 8 
ug/ml) to cell suspension. These samples were injected through the 
column and repeated on the same day (to measure intra-assay variation) 
or on a different day (to measure inter-assay). Mean indicates the average 
of three experiments and variation is denoted by standard deviation 
(Baldwin et al.) and relative standard deviation (RSD). 
Observed concentration (ug/ml) 
Added concentration Intra-assay (n=3) Inter-assay (n=3) 
(ug/ml) 
Mean SOl!) RSO (%) Mean SO(!,) RSO(%) 
8 7.9 0.03 0.42 7.8 0.30 3.9 
4 4.1 0.05 1.30 4.0 0.12 3.0 
2 2.0 0.01 0.60 1.94 0.13 6.7 
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Figure 5.5 Calibration curve for ribavirin in cell fraction 
rie of amples \ ere prepared by adding known ribavirin quantity 
and th n doing a double dilution to produce a caJibration curve. Area 
und r th curve wa automaticaJly determined by the machine for both 
riba irin and internal standard. Data points were obtained by plotting the 
ratio of the ar a of riba irin . the area of internal standard on the y-axis 
again t known riba irin concentrations on the x-axis. Equation 
=O.1207x-O.0075) wa deri ed from the e data points and used to work 
out th riba irin concentration in unknown san1ples. Co-relation co-
efficient (R2) clo e to I indicates good linearity. 
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Figure 5.6 Typical chromatogram for ribavirin 
Top: Samples prepared by adding ribavirin (RV) and internal control (rC) 
in water to identify specific peaks for each of them. Blue circle indicates 
lC peak and red circle indicates RV peak. Corresponding retention times 
are gi en on the left. Bottom: Samples from a cell fraction with or 
without riba irin ere added to the culture medium to show that there is 
no interference cau ed by any metabolites in cell suspension. 
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5.3.4 Time course for ribavirin uptake and ENT1 
expression by primary human hepatocytes (liver 1-4) 
Human hepatocytes from livers 1-4 were cultured on 6 well collagen coated 
plates and exposed to ribavirin diluted in culture medium at a concentration of 
3J.lglml for 24 hours. Quantification of ribavirin uptake by cells was based on 
the equation derived from the calibration curve (Figure 5.5). Value of x 
(unknown) was calculated by taking a ratio of the area ofribavirin with that of 
the internal standard (y) and using the equation derived from the calibration 
curve. The resulting figure gives ribavirin concentration (J.lglml) which is then 
divided by the total protein content (mglml) in each sample to normalise for 
cell number. The protein levels were used as a control for discrepancies arising 
as a result of variable cell count and were found to be equivalent between 
triplicate wells. As shown in Figure 5.9(A), liver 1, 2 and 4 showed a 
progressive increase in drug uptake over a period of 24 hours whereas this was 
less evident in liver 3. At 24 hours, Liver 4 had the highest uptake ofribavirin 
whereas liver 3 had the least. 
ENTl expression was estimated by real time peR. RNA extraction and reverse 
transcriptase peR was done as described in sections 2.4 and 2.5. Gene specific 
primers were designed with the help of Primer 3 programme and blasted 
against the known sequences present in the database to check for specificity. 
Primer sequences are given in Table 2.2 while method for real time peR is 
described in section 2.6. Gene expression levels were measured by Maxpro 
software (Stratagene) by deriving a standard curve and normalised to a house 
keeping gene (HPRT). Figure 5.7 shows representative real time peR plots for 
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both ENT1 and HPRT. The standard curve shows almost 100% efficiency of 
the PCR reaction, indicating exponential multiplication of PCR products with 
every cycle. Further, the dissociation curve shows a single peak for each primer 
pair, confirming the absence of non-specific products or primer dimers. PCR 
products were also run on a 2% Agarose gel and gave single bands of the 
expected size as shown in Figure 5.8. Quantification of total ENT1 expression 
by real time PCR is shown in Figure 5.9B. Consistent with trends in ribavirin 
uptake shown in Figure 5.9 A, livers 1,2, and 4 had comparable expression of 
ENT-1 but levels were much lower in liver 3. 
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Figure 5.7 Real time peR plots for ENTl and HPRT primer pairs 
A typical standard curve for ENTI (top panel) and HPRT (bottom panel). 
Each data point indicates amount of gene (nanograms) on the x ax is 
plotted again t c cle thre hold value on y axis. Also shown are 
amplification plot (top right) and dissociation peaks (bottom right). All 
ample were done in trip licate. 
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100bp 
M 
M = DNA marker 
1 = Total ENT1 (SOng) 
2 = Total ENT1 (2Sng) 
3 = Negative control 
2 3 
Figure 5.8 Analysis of rea l time pe R amplified ENTl by agarose gel 
electrophoresis 
SOng (lane 1) and 25 ng (lane 2) of human li ver cD A wa amplified by 
real time PCR using primer for total ENT l . The resulting PCR reaction 
wa anal d for th pre ence of a ingJe band in order to validate 
pecificit of the primers u ed in this study. 
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Figure 5.9 Time course for ribavirin uptake and ENT] expression 
Human hepatocytes from livers 1-4 were cultured on collagen coated 
plates and exposed to Ribavirin diluted in culture medium. After 4, 8 and 
24 hours, cells were harvested and analysed for ribavirin uptake CA) and 
ENT1 expression (B). Bars indicate mean and the standard deviation is 
represented by error bars. 
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5.3.5 Correlation of ribavirin uptake and ENT1 expression 
in human hepatocytes (Livers 1-6) and Huh7 at 24 
hours 
Hepatocytes were treated with ribavirin at a final concentration of 12J.lM and 
samples were harvested at 24 hours. A concentration of 12J.lM ribavirin lies 
within the therapeutic range achieved in patients on anti-viral therapy (Kato et 
aI., 2005, Khakoo et aI., 1998). Ribavirin levels in primary hepatocytes from 6 
human livers and the Huh7 cell line were analysed and correlated with total 
ENTl expression. As illustrated in Figure 5.10, there was a greater than 
threefold variation in the levels of ENTl expression in the six human livers. 
Further, this variation was associated with a similar order of difference in 
ribavirin uptake. Thus, liver 4 had the highest total ENTl expression and the 
highest drug uptake, whereas livers 3 and 6 had lower levels of receptor 
expression and proportionately lower levels of ribavirin uptake. Liver 5 is an 
apparent outlier as, despite having higher uptake of drug than liver 2, liver 5 
had 1I3rd less receptor expression. Extremely interestingly, Huh7 cells did not 
detectably take up ribavirin despite expressing levels of ENTl higher than all 
but one of the primary hepatocytes tested. A non-parametric Spearman 
correlation test (rs) was done to assess any relationship between the two 
variables (A value of rs = 1 indicates perfect correlation and rs = 0 indicates 
that two variables do not vary together. p value less than 0.05 was considered 
to be significant). The correlation test gave a value of rs equal to 0.94 and a p 
value of 0.01 showing that there is a strong positive correlation between 
ribavirin uptake and ENTl receptor expression. 
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Figure 5.10 Correlation of ribavirin uptake and ENT1 expression 
_ RibcMrin 
_ ENr1 
Human hepatocytes from livers 1-6 and Huh7 cells were exposed to ribavirin 
and drug uptake and ENT] expression levels were quantified at 24 hour. 
Ribavirin concentration plotted on the left y-axis indicates ~ g g of drug over mg 
of total proteins in the sample. Total ENTl plotted on the right y-axis is the 
quantity in ng and is normalised to the house keeping gene HPRT. Bar graphs 
indicate the mean of three repeat experiments whereas error bars denote 
standard deviation. 
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5.3.6 Analysis of Huh7 ENT1 (SLC29A1) gene sequence 
The lack of ribavirin uptake by the Huh7 cell line despite relatively high levels 
of ENT! expression suggests either that the receptor itself is non-functional, or 
that other factors required for ribavirin uptake are not present in this cell line. 
In order to screen for the presence of any mutation, the Huh7 ENTI coding 
sequence was analysed by cloning into pCR® 2.1-TOPO® TA cloning 
vectorikit (Invitrogen) followed by direct sequencing. For this purpose, gene 
specific primers were designed and blast analysis of the primer pair was done 
to confirm specificity. Gradient PCR followed by agarose gel electrophoresis 
was performed to check efficiency and optimal annealing temperature. As 
shown in Figure 5.11 (A), there was a single product of the right size (1.3kb) 
without any non-specific bands. The resulting PCR product was filtered by 
column purification and used for cloning with the TOPO TA cloning kit 
(invitrogen) as elaborated in section 2.13. Plasmid analysis by direct 
sequencing revealed the SLC29Al gene sequence in Huh7 cells which was 
then blasted against the wild type sequence (Genebank). It was found that the 
ENTl gene expressed by the Huh7 cell line has the same coding sequence as 
the wild type. A representative chromatogram is shown in Figure 5.11 (C). 
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Figure 5.11 Aga rose gel analys is of peR product 
The E TI coding sequence was ampli fied using pecific primers and analysed 
b agaro e gel lectrophore i . A) Grad ient PCR to select optimal annealing 
t mperature (lan 1-10 and temperature range 60± I O°C). B) The temperature 
with the highe t amplification wa u ed fo r PCR amplifica tion and the 
r ulting product wa purified for cloning (lane 11 & 12) fo llowed by 
quencing CC). M = D marker, TC = non-template contro l 
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5.3.7 Effect of interferon-alpha on ribavirin uptake and 
ENT1 Expression 
In clinical practice, ribavirin is used in conjunction with interferon alpha 2a for 
the treatment of HeV infection. This combination significantly improves the 
treatment response rate from either of these agents administered alone. We 
therefore aimed to examine whether interferon modulates ENT 1 expression 
and ribavirin uptake in two sets of primary human hepatocytes. We found that 
in the case of liver 5, addition of interferon did result in a modest up-regulation 
of ENTl expression but this was not associated with increased ribavirin uptake 
(Figure 5.12). In the case of liver 6, the addition of interferon did not modulate 
either ribavirin uptake or ENTl expression. 
5.3.8 Effect of culture conditions on ribavirin uptake and 
ENT1 expression 
It is conceivable that the expression of ENT -1 may be modulated by the 
polarisation status of the hepatocytes, and that this may vary with culture 
conditions, particularly whether or not cells are in spheroids or 2D cultures. It 
follows that the variable degree of spheroid formation alone may simply be 
responsible for the variation of ribavirin uptake seen in different livers. In 
order to exclude this, we next wanted to see if using different culture systems 
could potentiate or knock down receptor expression and drug uptake. In our 
system, we found that culturing cells either on tissue culture plastic or collagen 
coated plates did not affect ribavirin uptake as seen in Figure 5.13. 
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Figure 5.12 Effect of interferon alpha on ribavirin uptake and ENTl 
expression 
Hepatocytes from human livers 5 and 6 were cultured on collagen coated plates. 
Ribavirin and interferon alpha 2 either alone or in combination were added to 
the culture medium and cells harvested at 24 hours. Ribavirin quantity (A) and 
ENTl expression levels (B) were compared in the presence and absence of 
interferon. (RV = ribavirin, IFN = interferon). Bar graphs indicate an average 
of three repeat experiments whereas error bars denote standard deviation. 
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Figure 5.13 Effect of culture condition on transporter expression 
Hepatocytes from human livers 5 and 6 were cultured either on tissue culture 
plastic or on collagen coated plates. Ribavirin quantity and ENTl expression 
were measured after 24 hours and compared between cell s grown on the two 
culture surfaces (TIC = tissue culture surface, cia = collagen coated surface). 
Bar graphs indicate an average of three repeat experiments whereas error bars 
denote standard deviation. 
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5.4 Discussion 
Studies have shown that the anti-Hey effects ofribavirin are dose related and 
response to treatment can be improved by increasing ribavirin delivery to 
hepatocytes (Levy et aI., 2006). Of the main nucleoside transporters, ENTl has 
been identified as a major ribavirin transporter (Govindarajan et aI., 2008, 
Jarvis et aI., 1998). Using a model system based on polio virus, Ibarra and 
Pfeiffer demonstrated that in all the cell lines tested, ribavirin uptake was 
mainly mediated by ENTl and resistance to ribavirin can be overcome by over 
expression of ENT! (Ibarra and Pfeiffer, 2009). A recent study using 
cryopreserved human hepatocytes suggested that ENTl may be the major 
transporter involved in ribavirin uptake and out of the three hepatocyte lines 
tested, one having the highest ENT! expression had the greatest drug uptake 
(Fukuchi et aI., 2010). However, none of the previous studies have explored 
expression of nucleoside transporters by sets of primary human hepatocytes 
isolated from human donors and cultured in vitro and their correlation with 
ribavirin uptake. 
Human hepatocytes are the most suitable tool to study function of cells inside 
the human body (Jigorel et aI., 2005). In this study, we have successfully 
isolated and cultured human hepatocytes validating a method described 
previously (Gottschalg et aI., 2006). Good cell viability was achieved and 
cultured cells maintained hepatocyte-like phenotype during the course of 
therapy. As shown in Figure 5.4(A), we isolated a highly homogenous 
population of healthy hepatocytes with no evidence of significant numbers of 
contaminating cells. We can therefore be confident that the differences in 
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ribavirin uptake among livers 1-6 are hepatocyte specific and not due to 
contamination and uptake by non-parenchymal cell types. Time course 
experiments demonstrated that hepatocytes continued to take up ribavirin, 
which itself is evidence that transport systems are intact in this in vitro culture 
model. Our principal finding is that ENTl expression varies by up to threefold 
in hepatocytes obtained from different donors and that there is a highly 
significant correlation between ribavirin uptake and the level of ENTl. We 
anticipate that this relationship may be very important in vivo where even a 
moderate increase in drug dosage correlates to better treatment outcome. Thus 
levels of ENT 1 expression may be an important predictor of treatment response 
in patients receiving combination therapy for HCV infection. In support of this 
concept, a recent study by Fujita et al implied that low ENTl expression levels 
is a predictor of poor response to Gemcitabine (a pyrimidine nucleoside 
analogue) in patients with pancreatic ductal carcinoma (Fujita et aI., 2010). 
In order to further explore mechanisms for the dramatic improvement in 
outcomes of combination therapy for HCV infection, we wished to see if the 
addition of interferon enhanced ribavirin uptake by an effect on ENTl 
expression. Based on data from two livers, we did not find any evidence that 
interferon modulated either ENTl expression or ribavirin uptake, suggesting 
that it is an unlikely mode of synergism between the two drugs. 
Within the liver, hepatocytes are arranged in a three dimensional framework in 
complex relationship with non-parenchymal cells, sinusoidal spaces and extra 
cellular matrix components (Figure 5.3). This arrangement maintains 
212 
hepatocytes in a polarised state which is lost in most culture models and this 
could be a factor determining transporter expression and function. In contrast 
to growth on tissue culture plastic, hepatocytes cultured on collagen coated 
surfaces form spheroids (Figure 5.3) which maintain the polarised state 
(Thomas et aI., 2006). To investigate whether differences in ENT! expression 
and ribavirin uptake could simply be a consequence of differences in the 
proportion of hepatocytes within spheroids, we compared ENT! expression 
and ribavirin uptake in hepatocytes from the same donor cultured on either 
tissue culture plastic or on collagen coated plates. No differences were 
observed in either transporter expression or drug uptake by primary 
hepatocytes in these different models. This indicated that differences in uptake 
levels are unlikely to be a direct consequence of the polarisation status of 
hepatocytes used in this study, but due to intrinsic variation in the levels of 
transporter expression. 
A fascinating observation in this study was that the Huh7 cell line, despite 
having ENT! expression levels which were at least as high as the majority of 
the livers tested, failed to take up any ribavirin. This interesting observation 
opens up new avenues to understand whether ENT! expression is sufficient for 
ribavirin uptake. Gene mutations could lead to defects in transporter function 
resulting in poor uptake of nucleosides and their analogues. Cytarabine (Ara-C) 
is a pyrimidine nucleoside analogue and is used for the treatment of acute 
myeloid leukaemia. A study by Zimmerman et al suggested that mutation in 
Glycine 24 in TMD ! of human ENT, a highly conserved amino acid among 
different ENT isoforms including ENT! and ENT2, abolished transporter 
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function without affecting gene expreSSIon and its plasma membrane 
localisation (Zimmerman et aI., 2009). This could explain resistance to Ara-C 
therapy in leukaemia patients. It was therefore important to explore the ENT! 
gene for the presence of any mutations which may provide an explanation for 
defect in ribavirin uptake by Huh7. Sequencing results, however, indicated that 
the ENT! gene had the wild type sequence in Huh7 cells and there was no 
mutation in the coding sequence. This might suggest that ENT! is necessary 
but may not be sufficient to mediate ribavirin uptake alone. On the other hand, 
factors affecting mRNA stability, promoter function and post-translational 
modification may play a role which needs further investigation. 
Alternative mRNA processing leads to formation of various splice variants 
which mayor may not code for the same protein. A number of splice variants 
have been reported for the ENTl gene. The study by Furihata et al also 
explored ENTl promotor region and showed that four different promoters give 
rise to at least 12 different ENTl isoforms (Fukuchi et aI., 2010). They also 
showed that expression levels of d I-d4 isoforms were higher in hepatocytes 
having higher drug uptake. However the primers used in the Furihata study 
were in fact non-specific and picked up ENTl variants other than dlld3 which 
they claimed were responsible for higher drug uptake. In view of the 
complexity of the splice variants of ENT 1 , we elected to exploit the 
relationship between ENTl and ribavirin uptake using a primer pair which 
captures all variants. It may be interesting in the future to explore presence of 
ENTl splice variants in primary human hepatocytes and Huh7 cells. 
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In summary, this study has successfully achieved: 
1. Validation of the method for human hepatocytes isolation 
2. Culture of human hepatocytes in vitro 
3. Development of robust HPLC methodology for the measurement ofribavirin 
4. Development of quantitative methodology for measurement of ENTl gene 
expressIOn 
5. Demonstration of a highly significant correlation between levels of ENTl 
expression and ribavirin uptake 
6. Demonstration that interferon does not modulate ENTl expression levels 
7. TheHuh7 cell line does not avidly take up ribavirin despite expressing wild 
type ENT!. 
Overall, our observations suggest that intrinsic differences in ENTI expression 
may determine uptake of ribavirin and have important consequences for the 
outcomes of current antiviral regimens for hepatitis C infection. 
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Chapter Six 
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6 Final discussion 
6.1 Project summary 
HCV infection is highly prevalent world wide and leads to life threatening liver 
diseases including cirrhosis and hepatocellular carcinoma. HCV is already the 
most common cause of liver transplantation in the USA and is a major and 
growing health burden in the UK. Despite its importance, present anti-viral 
drugs have inadequate and unpredictable therapeutic potency. Additionally, 
current therapies are associated with a wide range of side effects, and anaemia 
as a consequence of extra hepatic uptake of ribavirin is an important barrier to 
completion of therapy and viral eradication. It is therefore extremely important 
to study and devise measures to overcome these limitations. This could be 
achieved by both improving efficacy and reducing side effects of currently 
available drugs and identifying novel treatment targets. Furthermore, the highly 
variable response rate to current HCV drugs warrants independent 
investigation. The principal aims and outcomes of this study, set within the 
current framework of understanding ofHCV, are illustrated below. 
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6.2 Cardinal findings and future implications of the 
present study: 
6.2.1 Role of host protein in viral replication 
Previous studies have highlighted the importance of host genes involved in 
HeV replication (discussed in chapter 3). Using siRNA to dissect the virus-
host relationship is independently informative and provides a potential tool for 
inhibiting viral replication. The first challenge was to develop a subgenomic 
replicon model system to study the effects of our interventions on viral 
replication. Although this system is not new to people working in this field, it 
required considerable optimisations before an efficient replication system was 
established in our hands. We found that quality of in vitro transcribed JFHl 
RNA was the key factor in determining outcome. 
Several transfection methods are in use for in vitro delivery of nucleic acids. 
Most of these lipid based transfection reagents cause significant cell toxicity 
and have an unpredictable outcome. Additionally these methods are not 
suitable for delivering large molecules such as viral RNA. To overcome these 
issues, we used nucleofection as a transfection method with the aim of 
obtaining consistent and reproducible results for the co-transfection of both 
siRNA and viral RNA. We successfully developed a protocol for co-
transfection of replicon RNA and gene specific duplexes. In this system, V AP-
A and ST AT -3 proteins were found to positively regulate viral replication as 
specifically knocking down these genes resulted in significant reduction in 
viral replication. It was noted that the reduction in viral replication achieved 
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after knock down of both proteins, although statistically significant, was less 
than 1 log reduction. An effective therapeutic intervention for HCV would 
normally be expected to result in a reduction in replication of several logs. This 
factor may be less significant for the host genes we targeted as these 
interventions are likely to be used as an adjuvant to current therapy to enhance 
their therapeutic potency. Moreover, long term therapy may produce a more 
robust and sustained inhibition of viral replication. We were unable to validate 
our findings using a full length infectious virus as we did not have access to a 
category III facilities during the course of this study. However, the recent 
establishment of this resource, allowing us to use an infectious replicon system 
producing viral particles will be invaluable and will provide a more meaningful 
interrogation of the effects of these proteins on the full viral life cycle and 
infectability. This will not only help to validate currently identified targets in 
this or previous studies but will also enable screening for other proteins that 
will give us a deeper insight into the mechanism of virus replication and help in 
identification of novel anti-viral targets. An important practical requisite for 
using duplexes as therapeutic tools is the development of an efficient delivery 
vehicle. We therefore next wanted to assess feasibility of liposomal 
nanoparticles as carrier molecules. 
6.2.2 Liposomal nanoparticles as delivery vehicles 
Advances in nanotechnology have improved delivery of various therapeutic 
and imaging agents (Torchilin, 2007). This is particularly relevant for diseases 
like HCV affecting liver (Harivardhan Reddy and Couvreur, 2011), where 
targeting of therapeutic molecule to hepatic tissue is an important requisite. 
Testing liposomal formulations suitable for human use was the principal goal 
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of this project. It was done as part of collaboration with our industry partner 
(Lipoxen PLC ltd) to develop projects in translational research which could 
potentially have a great influence in the field of medicine. We note that, in 
addition to hepatitis C, other liver diseases like hepatic fibrosis and carcinoma 
will be optimally treated by a methodology which enhances the targeted 
accumulation of drug at the desired location with a consequent reduction in 
side effects. 
The results presented and discussed in chapter 4, however, demonstrate that the 
liposomal formulations containing siRNA used in this study were not effective. 
Initial testing suggested that siRNA containing liposomes were intrinsically 
unstable and unable to silence target gene expression irrespective of the 
liposomal formulation. In contrast, liposomal uptake and delivery of 
fluorescent label was subsequently boosted, both by changing the formulation's 
physical properties as well as modifying culture conditions. The difference 
between the two delivery vehicles is that fluorescent label is embedded within 
the lipid bilayer while siRNAs duplexes are enclosed in the hydrophilic centre. 
Further testing with more liposomal formulations is clearly required to develop 
an efficient and targeted drug delivery vehicle. This could be achieved by 
devising pH-sensitive liposomes which release their contents only when 
exposed to the appropriate pH. Previous reports have shown the feasibility and 
efficacy of pH-sensitive liposome for intra-cellular delivery of drugs to a 
specific cellular compartment like the endoplasmic reticulum (Ducat et aI., 
2011, D U z g i i n e ~ ~ and Nir, 1999). The practicability of such an approach for 
delivery of anti-virals needs to be further assessed. In contrast, our in-house 
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prepared polymeric nanoparticles were taken up effectively when exposed to 
cells. Their physical properties, such as charge and size were comparable to the 
liposomal preparations and such particles have potential as delivery vehicles 
for therapeutic interventions. Unlike liposomes, however, polymer based 
nanoparticles are untested in human trials and are therefore at a very early 
stage in development as clinical tools. 
6.2.3 Equilibrative nucleoside transporter 1 expression 
regulates ribavirin uptake by primary human 
hepatocytes 
Ribavirin addition to interferon alpha based anti-Hey regimens was an 
important breakthrough as it greatly improved the otherwise poor response rate 
associated with interferon monotherapy. Despite this advance, a significant 
proportion of treated individuals fail to respond. It is therefore important to 
identify the factors responsible for the limited cure rate in certain individuals. 
Being a nucleoside analogue, ribavirin requires a specific portal system as the 
hydrophilic nature of the drug prevents free penetration through the cell 
membrane. Of all the transporters, ENTl has been identified as the likely 
candidate ribavirin transporter. We therefore aimed to assess the relationship 
between ENTl expression and ribavirin uptake using an in vitro culture system 
based on primary human hepatocytes. The results obtained in this study suggest 
that ENT! expression varies up to threefold in primary hepatocytes derived 
from different sets of human livers and these inherent differences may 
determine ribavirin uptake. Our data strongly suggest that ENTl is the primary 
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ribavirin transporter but this requires further interrogation in vivo. It may also 
be useful to explore various ENTI isoforms in our patient populations and 
identify their contribution to ribavirin uptake. On the basis of these 
observations, we next planned to interrogate the correlation of ENT! single 
nucleotide polymorphisms and SVR rates in our patient populations. Further, it 
would be interesting to examine ENT! expression on PBMCs as a surrogate 
marker of hepatocyte expression. 
Another interesting finding of our study was that Huh7 cells, despite 
expressing ENT! to levels comparable to most of the liver samples, failed to 
take up any detectable ribavirin. Sequencing analysis of the ENT! coding 
sequence in Huh7 cells failed to show any mutation, suggesting a role for other 
factors in accounting for this discrepancy. It is known that hENT! protein is 
mainly localised to the cell membrane with some evidence of its presence on 
the mitochondrial membrane (Lai et aI., 2004). However, regulatory signals 
underlying processing, membrane targeting or activity of transporter protein 
are not understood completely. For a membrane protein like ENT!, correct 
folding as well as trafficking to plasma membrane is the key for transporter 
function and specific motifs in the N- and/or C- terminal of the protein have 
been shown to play a regulatory role in this process (Loo et aI., 2005, 
Williamson et aI., 2008). A study by Nivillac et al identified essential motifs in 
both the N- and C- terminals of human ENT! and showed that loss of these 
sequences prevents the plasma membrane localisation of the transporter and 
ER retention respectively (Nivillac et aI., 2009). This suggests that factors 
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responsible for proper protein folding and membrane localisation may be 
deficient in Hub7 cells and needs further investigation. 
6.3 Future work 
The outlook for anti-HCV therapy has been entirely transformed during the last 
three years since the start of this study. Directly acting anti-viral agents, such 
as protease inhibitors (Telaprevir and Boceprevir) have now entered clinical 
practice and are standard of care for the treatment ofHCV genotype I infection 
(Chapter 1). Additionally, other drugs like NS5A and polymerase inhibitors 
have also shown very high efficacy in recent clinical trials. PSI-7977, for 
example, is a highly potent uridine nucleotide analogue polymerase inhibitor. It 
has been shown to be associated with 100% SVR in genotype 1 infection, when 
used as combination therapy with pegylated interferon alpha 2a and ribavirin 
for 12 weeks. Recent data presented in AASLD (November, 2011) assessed 
optimal duration of interferon addition when PSI-7977 was used with ribavirin 
for 12 weeks (Edward J. Gane et aI., 2011). Remarkably, 12 weeks of 
combination therapy with PSI-7977 was associated with 100% SVR across 
viral genotypes 1-3, as assessed in robust Phase 2B trials. With the advent of 
these and other DAA based novel drug targets, the possibility of orally 
administered. interferon free, treatment regimens with 100% efficacy appears 
realistic and will transform the treatment algorithms for HCV infection. 
Nonetheless, these projected therapies all require a ribavirin backbone and are 
associated with an even more profound haemolytic anaemia than standard 
interferon and ribavirin. Moreover, the new therapies themselves also cause 
side effects, so the concept of using an efficient carrier molecule to specifically 
deliver drugs to hepatocytes remains valid. Further, the capacity to understand 
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factors responsible for variable ribavirin uptake could contribute to 
personalisation of drug regimens, and markers of ENTl expression may inform 
cost effective strategies for the administration of ribavirin. 
6.4 Conclusion 
In summary, the important observations/achievements presented in this thesis 
are: 
./ Establishment of an efficient subgenomic replicon system supporting 
HCV replication. It will be useful for screening other host genes 
required for viral replication and, once a suitable delivery vehicle is 
identified, testing anti-viral efficacy of these agents . 
./ Confirmation of V AP-A and STAT -3 as positive regulators of viral 
replication. Using specific drug delivery vehicle, effects of combination 
of ribavirin with these targets need to be assessed . 
./ That liposomes used in this study are not suitable delivery vehicles. 
Further testing with either new liposomal preparation or polymer based 
nanoparticles is required . 
./ Validation of an efficient method for isolation and culture of primary 
human hepatocytes. It can be used for any future studies requiring 
primary human cells, either hepatocytes or non-parenchymal cells like 
hepatic stellate cells . 
./ Ribavirin uptake in primary human hepatocytes strongly correlates with 
ENTl expression. Relationship between SNP in ENTl gene in patients 
need to be assessed with responsiveness of ribavirin based regimens. 
Additionally various ENTl isoforms need to be explored and correlated 
with ribavirin uptake. 
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8 Appendix 
8.1 Cell culture solutions 
A. Solution required for isolation of primary human hepatocytes 
1. 10x Hanks-HEPES buffer 
NaCl (, Fisher Scientific) 1.37M 
KCI (Sigma) 54 mM 
KH2P04 (Sigma) 4.4 mM 
Na2HP04.12H20 (Fluka) 3.6 mM 
HEPES Sigma) 200 mM 
NaOH (Sigma) 100mM 
Sterile distilled water 1000 ml 
• Syringe filtered and stored at 4°C 
• Diluted with autoclavedlsterile distilled water to make up 1 x 
2. EGTA solution (25mM) 
EGTA (Sigma, UK) 
Sterile 1 x Hanks HEPES 
(no bicarbonate/glucose) 
NaOH IM (Sigma, UK) 
0.48g 
25 ml 
2.5 ml 
• Made up to 50ml with sterile distilled water 
• Syringe filtered and aliquots stored at 4°C. 
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3) Calcium choloride (CaC12) solution (250mM) 
CaCh (Fluka) 1.84 g 
Sterile distilled water 50ml 
• Syringe filtered and stored at 4°C. 
4) Bicarbonate/glucose solution 
NaHC03 (Sigma) 
D-(+)-Glucose (Sigma) 
DL-Methionine (Sigma) 
Sterile distilled water 
0.74 M 
0.28 M 
0.1 M 
50 ml 
• Syringe filtered and stored in aliquots at -20°C. 
5) 90% Percoll 
Percoll (Sigma) 90 ml 
HBSS (I Ox) (GIBCO) 10 ml 
• Syringe filtered and stored at 4°C 
6) Diluted SoItran solution for transport and flushing of tissue 
Soltran (Baxter) 
Sterile distilled water 
500ml 
300ml 
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B. Isolation and growth media 
7) Primary human hepatocytes isolation medium 
Ingredient Volume Final concentration 
Dulbecco's modified Eagles Medium 500ml N/A 
(DMEM) (GibcoBRL, UK) 
L-glutamine (GIB CO) 5 ml 2mM 
Antibiotic (Hyclone Thermo Scientific) 5 ml 100 U penicillin 
100 ug streptomycin 
Foetal calf serum (Sigma, UK) 50 ml 10% 
8) Primary human hepatocytes plating medium 
Ingredient 
Williams medium E (GibcoBRL, UK) 
Antibiotic (Hyclone Thermo Scientific) 
Insulin solution (Sigma, 
Dexamethasone (Sigma, UK) 
L-glutamine (GIB CO) 
Volume Final concentration 
500 ml N/A 
5 ml 100 U penicillin 
100 J.lg streptomycin 
0.1 J.lM 
0.1 J.lM 
2mM 
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9) Primary human hepatocytes culture medium 
Ingredient Volume Final concentration 
Dulbecco's modified Eagles Medium 500ml N/A 
(DMEM) (GibcoBRL, UK) 
Antibiotics 5 ml 100 U penicillin 
(Hyclone Thermo Scientific) 100 f.lg streptomycin 
Insulin solution (Sigma, UK) 2 f.ll 0.1 IlM 
Dexamethasone (Sigma, UK) 500 III If.lM 
Foetal calf serum (Sigma, UK) 25 ml 5% 
10) Human hepatoma cell line (Huh7) culture medium 
Ingredient Volume Final concentration 
Dulbecco's modified Eagles Medium 500ml N/A 
(DMEM) (GibcoBRL, UK) 
L-glutamine (200 mM) 5 ml 2mM 
(GibcoBRL, UK) 
Antibiotic/antimycotic 5 ml 100 U penicillin 
(GibcoBRL, UK) 100 f.lg streptomycin 
250 ng amphotericin B 
Foetal calf serum (Sigma, UK) 50ml 10% 
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C. Preparation of buffers for human liver perfusion 
1) Buffer 1 (EGTAlChelating buffer) 
1 X Hanks Hepes buffer 
Bicarbonate/glucose solution 
EGTA solution 
2) Buffer 2 (No-EGT A buffer) 
1 X Hanks Hepes buffer 
Bicarbonate/glucose solution 
3) Buffer 3 (Collagenase buffer) 
1 X Hanks Hepes buffer 
Bicarbonate/glucose solution 
*Collagenase enzyme 
500mV1L 
10mV20ml 
10mV20ml 
500ml 
10m! 
500ml 
10ml 
65U 
. *Trypsin inhibitor(250mg, NB 4G proved 80mg 
Grade from Clostridium histolyticum, 
0.263 U/mg) 
• * Added only prior to use. 
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8.2 SDS Polyacrylamide gel electrophoresis 
A) Solutions: 
• Filtered all solutions and used the free base forms of Tris and glycine 
when making up solutions. HCL was used to adjust pH of Tris solutions. 
• 4x Gel Running Buffer (1.5M Tris-CI, pH 8.8) 
9.0g ofTris in 50ml of dH20 (PH 8.8). Stored up to 3 months at 4°C in dark. 
• 4x Gel Stacking Buffer (O.SM Tris-CI, pH 6.8) 
3.0g ofTris in SOml of dH20 (PH 6.8). Stored up to 3 months at 4°C in dark. 
• 10% SDS 
19 ofSDS to 10ml ofdH20. Stored up to 6 months at room temperature. 
• 2x Sample Buffer ( 100mM Tris, pH 6.8, 2% SDS, S% ~ ~
mercaptoethanol (BME), IS% glycerol, Bromophenol Blue to colour) 
Stored in a tightly sealed container to prevent the BME from going off. 
• Tris-glycine electrophoresis buffer (2SmM Iris base, 192mM glycine, 
0.1% SDS, pH 8.3) 
A Sx stock solution was prepared in SOOml by adding: 7.S6g Iris, 36g glycine, 
2.Sg SDS and dH20 to SOOml. Its pH is around 8.2-8.4 and is Stored at room 
temperature. 
• Transfer buffer: Prepare Ix solution of 10X TGS bugger with 20% 
Methanol in dH20. 
• 10X TGS buffer 
• 20% ethanol 
• water 
SOml 
100ml 
350 ml 
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B) Preparation of the SDS polyacrylamide gel: 
• Plates were cleaned with mild detergent and soft cloth and loaded onto 
mini gel apparatus (Biorad). Monomer solution for the running gel was 
prepared as per table below and was poured in the glass plate frame. 
Gel was allowed to polymerise at room temperature. 
Final gel concentration (l Oml, 2 each, 0.75mm thick 8£250 gels) 
10% 
Monomer solution (gel) ~ . 3 m l l
I4x Running Gel Buffer (l.5M Tris-HCL PH 8.8) \2.5ml 
10%SDS O.lml 
'riH20 14 ml 
~ P S · · ~ O O ,Ill 
TEMED ~ . 3 , 1 1 1 1
* 10% APS should be prepared first 
• While the gel is polymerising, prepare the stacking gel as per table 
below. 
O.75mm 
'Mono mer solution O.44ml 
~ x x Stacking Gel Buffer(O.5M Tris-HCI Ph 6.5) O.83ml 
10%SDS ~ 3 , 1 1 l l
dH20 2.03ml 
APS 16.7,111 
TEMED 1.7,111 
• Insert the gel into electrophoresis unit with the larger thicker plate to 
the outside. If not running two gels insert the clear plastic plate against 
the gasket and close the tabs. Mark the location of the well by a 
permanent marker. Add tris-glycine electrophoresis buffer (10% Tris-
glycine buffer). Remove the comb carefully. Make 4X loading buffer by 
adding 95pl o/Ioading buffer + 5pl ft- mercaptoethanol. 
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• Prepare the protein samples by adding 5 pi of loading buffer + 15 pi 
sample, then heat at 90°C for 5 minutes, and then keep in ice for 5 
minutes. 
• Load the samples onto the gel, and run the gel at 30mA per gel for 60-
90 minutes. Electrophoresis is complete when the dye reaches the 
bottom of the gel. Remaining procedure of western blotting is given in 
materials and methods. 
8.3 Solution and buffers used for HPLC: 
1) Ammonium Phosphate (NH4)H2P04) Buffer, 250mM 
Ammonium phosphate (Sigma) 7.2g 
Distilled water 250ml 
• pH adjusted to 8.5 using 10M sodium hydroxide and filtered through 
0.2 J.lm nylon filter membrane before use. 
2) Mobile phase (Ammonium Phosphate (NH4)H2P04) Buffer, 10mM 
Ammonium phosphate (Sigma) 1.15g 
Distilled water lL 
• pH adjusted to 6.5 using 10M sodium hydroxide and filtered through 
0.2 J.lm nylon filter membrane before use. 
3) 2.5% v/v formic acid in methanol 
Formic acid (Sigma) 2.5ml 
Methanol (Sigma) 97.5ml 
• Stored at room temperature. 
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